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Abstract
The t[(l 1; 19)(p22;q23)] translocation, which gives rise to the MLL-ENL fusion 
protein is commonly found in infant acute leukaemias of both the myeloid and 
lymphoid lineage. In order to study the molecular mechanism of haematopoietic 
progenitor cell (HPC) immortalisation by MLL-ENL, a conditional system of MLL- 
ENL expression was established in primary murine HPCs. This was achieved by 
delivering the Tet-Off inducible expression system to primary cells using two 
retroviral expression constructs. Several conditional immortalised myeloid cell lines 
were generated in vitro which were dependent on continued MLL-ENL expression 
for their survival and proliferation. The immortalised cells either terminally 
differentiated or died when MLL-ENL expression was turned off with doxycycline. 
Since several Hox genes are targets of MLL, the expression profile of all 39 murine 
Hox genes was analysed in the MLL-ENL immortalised cell lines by real-time 
quantitative PCR. Loss of MLL-ENL expression resulted in a decrease in the 
expression of multiple Hoxa genes. By comparing these changes with Hox gene 
expression in cells induced to differentiate with granulocyte-colony-stimulating 
factor, we found that reduced Hox expression was specific to loss of MLL-ENL 
expression and was not a consequence of differentiation. Affymetrix microarray 
analysis revealed that MLL-ENL may maintain or activate the expression of the 
transcription factor Sdccag33 and the serine / threonine kinase Pim-2, which 
confers protection from apoptosis. The analysis also demonstrated that MLL-ENL 
may repress the expression of apoptosis promoting genes such as Ddb2 and Aatk. In 
summary, MLL-ENL is required to initiate and maintain the immortalisation of 
myeloid progenitors and may contribute to immortalisation by aberrantly 
maintaining the expression of multiple Hoxa genes. The pathways regulated by 
multiple Hoxa genes and the MLL-ENL target genes identified by Affymetrix 
analysis represent new possibilities for therapies which may combat these 
aggressive leukaemias.
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Chapter 1 Introduction
1.1 Haematopoiesis
Haematopoiesis is the highly ordered process by which all mature blood cells are 
generated from a small subset of haematopoietic stem cells (HSCs). In the mouse, 
primitive haematopoiesis begins in the blood islands of the extraembryonic yolk sac 
on embryonic day 7 (E7) (Moore and Metcalf, 1970). The onset of circulation at 
around E8.5 coincides with the development of an intraembryonic site of 
haematopoiesis in the para-aortic splanchnopleura (P-Sp) which develops into the 
aorta-gonad-mesonephrous (AGM) region (Zon, 1995; Lensch and Daley, 2004). 
Definitive haematopoiesis commences at around E10 when embryonic HSCs 
migrate to and colonise the foetal liver (Johnson and Moore, 1975). However, it 
remains uncertain as to whether the definitive HSC precursors are derived from the 
yolk sac (Yoder et al., 1997) or the AGM (Muller et al., 1994; Medvinsky and 
Dzierzak, 1996). Late in gestation, definitive HSCs migrate from the foetal liver to 
the bone marrow where they remain throughout adult life (Keller et al., 1999).
HSCs possess the ability to self-renew and differentiate into all haematopoietic 
lineages. This differentiation programme involves the step-wise production of 
lineage-restricted progeny with progressively less potential to self-renew. Long­
term HSCs (LT-HSCs) give rise to short-term HSCs (ST-HSCs) with limited self­
renewal ability. Until recently, the earliest lineage restriction step was thought to 
involve the commitment of a ST-HSC to either the lymphoid or myeloid 
differentiation pathways resulting in the generation of either a common myeloid 
progenitor (CMP) or a common lymphoid progenitor (CLP). The CMP gives rise to 
either granulocyte-monocyte progenitors (GMPs) which in turn generate mature 
granulocytes and monocytes, or megakaryocyte-erythrocyte progenitors (MEPs) 
which give rise to erythrocytes and platelet-producing megakaryocytes (Akashi et 
al., 2000). The CLP predominantly gives rise to natural killer (NK) cells and both B 
and T lymphocytes (Kondo et al., 1997). This traditional model of haematopoiesis 
is summarised in Figure 1.1 A.
Foetal CMPs are not entirely restricted to the myeloid lineage since they also 
possess limited B cell differentiation potential (Traver et al., 2001). Likewise, foetal
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Figure 1.1 Maturation pathways of haematopoietic cells from HSCs. A) The
traditional model of haematopoiesis. Long term haematopoietic stem cells (LT- 
HSCs) with the potential to continuously self-renew, give rise to short-term HSCs 
(ST-HSCs) with limited self-renewal ability. ST-HSCs give rise to the common 
lymphoid progenitor (CLP) and the common myeloid progenitor (CMP) which in 
turn generate all mature cell types of the lymphoid and myeloid lineages 
respectively. CLPs exhibit limited monocytic differentiation potential shown by 
the dashed line. Foetal CMPs are not completely restricted to the myeloid lineage 
since they are also capable of generating B cells as shown by the red dashed line 
Adapted from Traver et al., 2001. B) The composite model of early 
haematopoiesis. In this model, ST-HSCs give rise to the lymphoid primed multi- 
potent progenitor (LMPP) and the CMP. LMPPs then give rise to CLPs and 
GMPs. The terminal differentiation pathways of the CLP, CMP, GMP and MEP 
progenitors are identical to that outlined in A. Pro-T: T cell progenitor, pro-B: B 
cell progenitor, NK: natural killer cell, GMP: granulocyte-monocyte progenitor, 
MEP: megakaryocyte-erythrocyte progenitor. Adapted from Adolfsson et al., 
2005.
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CLPs possess limited monocyte differentiation potential (Mebius et al., 2001). 
Therefore, foetal progenitors appear to retain a greater degree of plasticity than 
adult progenitors. Although a progenitor population that retains both B cell and 
macrophage differentiation potential has been identified in adult bone marrow 
(Montecino-Rodriguez et al., 2001), it remains to be determined whether this 
progenitor population is derived from an HSC or a CLP.
Recently an alternative model of haematopoiesis has been proposed. In this model 
the first lineage restriction step involves the commitment of a ST-HSC to either the 
myeloid / lymphoid or megakaryocytic / erythroid differentiation pathways 
resulting in the generation of either a lymphoid primed multipotent progenitor 
(LMPP) or an MEP (Adolfsson et al., 2005). This model was based on the 
identification of a population of progenitors which retained the ability to 
differentiate into lymphocytes, granulocytes and monocytes but lacked the potential 
to differentiate into megakaryocytes or erythrocytes. The authors describe a 
composite model of haematopoiesis which incorporates this finding into the 
traditional haematopoietic hierarchy. This composite model suggests that LMPPs 
co-exist with CMPs and that GMPs are derived from either the LMPP or the CMP 
(Figure 1.1B).
1.2 The role of transcription factors in haematopoiesis.
The mechanisms underlying the generation and self-renewal of HSCs and their 
commitment to various lineages are extremely complex. Gene targeting studies in 
mice have revealed specific roles for various transcription factors in the regulation 
of haematopoiesis. The Stem Cell Leukaemia haematopoietic transcription factor 
(SCL) and LIM domain only 2 (Lmo2) are essential for both primitive and 
definitive haematopoiesis (Warren et al., 1994; Robb et al., 1995; Shivdasani et al.,
1995). In contrast, Acute Myeloid Leukaemia 1 (AML-1) is dispensable for 
primitive haematopoiesis but is essential for definitive haematopoiesis (Okuda et 
al., 1996). Interestingly, a conditional gene targeting strategy revealed that while 
SCL was absolutely required for the generation of HSCs, it was not required for 
adult HSC function (Mikkola et al., 2003). A similar approach revealed that AML-1 
was also dispensable for adult HSC function (Ichikawa et al., 2004). Therefore, 
although these transcription factors are essential for the generation and localisation
15
of HSCs in the embryo (Cai et al., 2000), other factors regulate the functions of 
mature HSCs.
Other transcription factors such as GATA-1, C/EBPa and Pax5 are essential for the 
development of specific haematopoietic lineages. PU.l is essential for both myeloid 
and lymphoid development (Scott et al., 1994; McKercher et al., 1996). GATA-1 
and FOG-1 are required for the development of the erythrocyte and megakaryocyte 
lineages (Pevny et al., 1991; Shivdasani et al., 1997; Tsang et al., 1998) and 
C/EBPa is essential for the development of the neutrophil lineage (Zhang et al., 
1997). Pax5 and E2A are required for commitment to and development of the B cell 
lineage (Urbanek et al., 1994; Zhuang et a l, 1994; Nutt et al., 1999) and GATA-3 
is required for T cell development (Ting et al., 1996).
Multi-potent haematopoietic progenitors (MPPs) exhibit a promiscuous gene 
expression profile since they co-express low levels of lymphoid, myeloid and 
erythroid specific genes (Akashi et al., 2003). This finding suggests that these 
progenitors preserve their multipotent differentiation capacity by maintaining an 
open chromatin structure which allows transcriptional accessibility to multiple 
differentiation programmes (Cross and Enver, 1997; Akashi et al., 2003). Lineage 
commitment results in the amplification of the transcriptional programme specific 
to that lineage and the subsequent repression of transcriptional programmes , 
associated with other lineages (Enver and Greaves, 1998). For example, GATA-1 
and PU.l are co-expressed in CMPs. The commitment of a CMP to a GMP is 
associated with an increase in PU.l expression and a decrease in GATA-1 
expression (Zhu and Emerson, 2002). Interestingly, PU.l is able to bind directly to 
GATA-1 and this interaction results in an inhibition of DNA binding by GATA-1 
(Zhang et al., 1999; Zhang et al., 2000). Therefore, PU.l permits granulocyte / 
monocyte development by activating the expression of genes specific to these 
lineages and directly repressing the erythrocyte / megakaryocyte transcriptional 
programme by inhibiting GATA-1 function.
1.3 Human acute leukaemia
Acute leukaemia is characterised by a clonal expansion of myeloid blasts (acute 
myeloid leukaemia) or lymphoid blasts (acute lymphoblastic leukaemia) in the bone
16
marrow or blood (Downing and Shannon, 2002). Although carcinogenesis is 
usually a multi-step process in which multiple genetic aberrations culminate in 
tumour formation, leukaemogenesis may result from as little as two genetic changes 
(Knudson, 1992). One genetic change might even be sufficient for leukaemogenesis 
if the mutation affects multiple pathways. A current hypothesis is that a mutation 
which impairs or blocks differentiation, when combined with a mutation that 
promotes proliferation or blocks apoptosis, is sufficient for leukaemogenesis (Dash 
and Gilliland, 2001). The study of paediatric lymphoid leukaemias with the t(12;21) 
chromosomal translocation, which generates the TEL-AML 1 fusion protein, have 
revealed that this chromosomal translocation is the primary genetic event and that it 
generates a pre-leukaemic clone which is clinically covert. The acquisition of 
secondary genetic changes by the pre-leukaemic clone such as loss of the remaining 
TEL allele may then result in leukaemogenesis (Greaves, 1999).
Chromosomal translocations involving genes encoding transcription factors are 
observed in as many as 65% of cases of acute leukaemia (Look, 1997). 
Chromosomal translocations de-regulate normal expression of the transcription 
factor by one of two mechanisms. The transcription factor gene can undergo 
translocation into regions of genes that are highly transcriptionally active, e.g. 
translocation of the myc gene into the immunoglobulin locus of B cell progenitors is 
associated with B-cell leukaemia and Burkitt’s lymphoma. Alternatively, the 
transcription factor undergoes a non-random reciprocal chromosomal translocation 
with a particular partner gene to generate a novel in-frame chimeric fusion gene 
with altered properties. Examples include TEL-AML and E2A-HLF, both of which 
are associated with lymphoid leukaemia (Look, 1997).
1.4 MZJL-translocations in acute leukaemia
Translocations involving the MLL (Mixed Lineage Leukaemia) gene on 
chromosome band 1 lq23 are associated with leukaemias of both the myeloid and 
lymphoid lineage. MLL re-arrangements are present in approximately 7-10% of 
cases of acute lymphoblastic leukaemia (ALL) and 5-6% of cases of acute myeloid 
leukaemia (AML) (Erfurth et al., 2004). They are most common in infant 
leukaemia where they comprise 80% of ALL cases and 60% of AML cases (Pui et 
al., 1995). They are also prevalent in treatment-related secondary leukaemias
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(Felix, 1998). Tandem duplications of the MLL gene or deletions of MLL exon 8 are 
found in a small subset of leukaemias (Schichman et al., 1995; Caligiuri et al.,
1996). However, in the vast majority of cases, MLL is joined to a partner gene 
resulting in the creation of an in-frame chimeric fusion gene. Over 40 fusion 
partners of MLL have now been identified, of which the most common are AF4,
ENL and AF9 (Scandura et al., 2002). The [t(4; 11 )(q21 ;q23)] translocation, which 
generates the MLL-AF4 fusion gene, is prevalent in infant pro-B ALL and is 
associated with a particularly poor prognosis (Heerema et al., 1999). The 
[t(9;l I)(p22;q23)] translocation, which generates the MLL-AF9 fusion gene, is 
predominantly associated with AML and the [t(l 1 ;19)(q23;pl3.3)] translocation, 
which generates the MLL-ENL fusion gene, is associated with both AML and ALL 
(Rubnitz et al., 1996). The ALL cases associated with MLL-ENL and MLL-AF4 
fusion genes usually exhibit a mixed lineage phenotype. The mixed lineage 
leukaemias are classified as ALL since the blasts are morphologically lymphoid. 
However, the blasts usually lack expression of the B cell marker CD 10 and express 
myeloid antigens (Pui et al., 1991).
1.5 The generation of MLL translocations
Reciprocal translocations involving the MLL gene result in the fusion of 5’ 
sequences of the MLL gene to 3’ sequences of its partner gene. The generation of an 
MLI-translocation involves the cleavage of MLL in a localised 8.3 kb region 
spanning exons 5 to 11 known as the breakpoint-cluster-region (BCR) (Gu et al.,
1994). This region of MLL is thought to be susceptible to DNA double strand 
cleavage in response to topoisomerase II (topo II) inhibitors and apoptotic nucleases 
(Stanulla et al., 1997; Strissel et al., 1998). A current hypothesis is that apoptotic 
nucleases, which are activated upon the initiation of the apoptotic programme, 
generate double strand breaks in the MLL gene and its prospective partner gene.
The two genes are then subsequently joined together by the error-prone non- 
homologous end joining (NHEJ) DNA repair pathway, resulting in the formation of 
an MLI-translocation (Reichel et al., 1998; Gillert et al., 1999; Betti et al., 2001). 
While it is generally accepted that the NHEJ pathway plays a role in MLL-fusion 
gene formation, the hypothesis that apoptotic nucleases are responsible for the 
double strand breaks is controversial since it assumes that cells committed to
18
undergo apoptosis can somehow circumvent this programme and survive (Betti et 
al., 2003).
An alternative hypothesis is that topo II inhibitors are responsible for the double 
strand breaks which lead to the formation of MLZ-fusion genes. This hypothesis is 
supported by the finding that patients who develop therapy related AML (t-AML) 
following treatment of a primary malignancy with topo II inhibitors such as 
etoposide, often display MLL-translocations (Super et al., 1993). Interestingly, the 
MLL breakpoints of infant ALL patients with t(4:l 1) translocations and of t-AML 
patients are usually clustered toward the telomeric 3’ half of the BCR. In contrast, 
the majority of MLL breakpoints of non-infant ALL patients with the t(4; 11) 
translocation and other de novo leukaemias with MLL-rearrangements, are clustered 
towards the cetromeric 5’ half of the BCR (Broeker et al., 1996; Cimino et al.,
1997; Reichel et al., 2001). This observation suggests that the mechanism 
underlying MLL rearrangements is similar for both infant leukaemias and therapy 
related leukaemias (Mitterbauer-Hohendanner and Mannhalter, 2004). The high 
concordance of leukaemia in identical infant twins has led to the theory that the 
MLL-translocation occurs in utero (Greaves, 1999). Hence, exposure of the mother 
to naturally occurring topo II inhibitors such as dietary bioflavonoids may result in 
the formation of an MLZ-translocation in the foetus which would then be 
predisposed to develop leukaemia (Ross et al., 1994; Strick et al., 2000).
1.6 The cell of origin in MLL-rearranged leukaemias
Different MLL fusion proteins are associated with leukaemias of different lineages, 
for example, MLL-AF9 is predominantly associated with myeloid leukaemias 
whereas MLL-AF4 is found almost exclusively in lymphoid leukaemias. Two 
models have been proposed which may account for this observation. The instructive 
model proposes that the MLL-translocation occurs in an HSC or uncommitted 
progenitor and that the MLL fusion partner dictates the lineage of the resultant 
leukaemia. The non-instructive model is based on the hypothesis that certain 
translocations are only permissive in particular progenitors. For example, the 
chromatin configuration of the AF9 gene may differ between B-cell and myeloid 
progenitors such that an MLL-AF9 translocation cannot occur in B cell progenitors 
but can occur in myeloid progenitors (Daser and Rabbitts, 2004). Alternatively, the
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action of the fusion protein may only be permissive in particular lineages. For 
example the MLL-AF9 fusion protein may only be oncogenic in myeloid 
progenitors and the MLL-AF4 fusion protein may only be oncogenic in lymphoid 
progenitors.
There is accumulating evidence which suggests that HSCs are the targets of 
transformation in AML. The vast majority of human AML cells lack any detectable 
self-renewal or proliferative capacity (Moore et al., 1973; Buick et al., 1979) and 
only a very small proportion of these cells were able to engraft and regenerate the 
leukaemia in NOD/SCID mice (Bonnet and Dick, 1997). This small population of 
AML cells that were able to regenerate leukaemia in mice were termed leukaemic 
stem cells (LSCs). LSCs were isolated based on their CD34+ CD38' 
immunophenotype, which is shared by normal HSCs (Bonnet and Dick, 1997). 
Further studies revealed that LSCs, like normal HSCs, are functionally 
heterogeneous with some possessing extensive self-renewal ability (LT-LSC) and 
others possessing limited self-renewal ability (ST-LSC) (Hope et al., 2004). The 
fact that the leukaemias initiated by the LSCs in the NOD/SCID mice were mostly 
composed of blasts with limited self-renewal and proliferative capacity suggests 
that AML is arranged as a hierarchy. As with normal HSCs, LSCs can self-renew 
and give rise to myeloid progeny. However, the myeloid progeny either inherit or 
acquire mutations that render them unable to terminally differentiate (Warner et al., 
2004).
While the studies outlined above provide compelling evidence that HSCs are the 
targets of transformation in AML, there is also evidence that more committed 
progenitors such as the CMP and GMP may be targets of transformation in some 
cases. The retroviral transduction of purified populations of murine HSCs, CMPs 
and GMPs with MLL-ENL yielded immortalised cell lines (Cozzio et al., 2003). 
Furthermore, MLL-ENL transduced HSC, CMP and GMP induced leukaemia in 
recipient mice with similar phenotypes and latencies. However, limiting dilution 
analysis revealed that MLL-ENL transformed HSCs more efficiently that CMPs or 
GMPs (Cozzio et al., 2003). Although MLL-ENL translocations are associated with 
myeloid and lymphoid leukaemias in patients, MLL-ENL was not able to transform 
a purified population of CLPs (Cozzio et al., 2003). The same was true for MLL-
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GAS7 which gave rise to biphenotypic, myeloid or lymphoid leukaemias upon the 
transduction of a purified HSC population (So et al., 2003a). Therefore, the cell of 
origin in biphenotypic or mixed lineage leukaemias is most likely an HSC or a bi­
potential B/macrophage progenitor.
Similar experiments revealed that although the fusion proteins MOZ-TIF2 and 
BCR-ABL were both able to transform HSCs, only MOZ-TIF2 was able to 
transform the CMP and GMP progenitor populations (Huntly et al., 2004). Since 
MLL-ENL and MOZ-TIF2 are able to transform CMPs and GMPs which lack 
inherent self-renewal capacity, these fusion proteins must confer self-renewal 
capability to these progenitors. MLL-ENL and MOZ-TIF2 are both associated with 
acute myeloid leukaemia in patients whereas BCR-ABL is associated with chronic 
myeloid leukaemia (CML) and to a lesser extent acute lymphoid leukaemia. Further 
experiments are required in order to ascertain whether the acute and chronic phases 
of myeloid leukaemia are distinguished by the ability of the leukaemia associated 
oncogene to promote aberrant self-renewal activity (Jamieson et al., 2004).
1.7 The function of MLL
MLL is the human homologue of the Drosophila trithorax (TRX) gene (Tkachuk et 
al., 1992). TRX positively regulates homeotic (HOM-C) gene expression during 
development since TRX mutants exhibit either loss or abnormal patterns of HOM-C 
gene expression resulting in segment identity defects (Breen and Harte, 1993). 
Importantly, TRX is responsible for the maintenance but not the initiation of HOM- 
C gene expression. The actions of TRX are opposed by the polycomb-group (Pc-G) 
proteins, which repress homeotic gene expression. TRX and Pc-G proteins are 
components of large complexes, which associate with chromatin and regulate 
homeotic gene expression through epigenetic mechanisms which remain poorly 
understood (Pirrotta, 1998; Canaani et al., 2004).
The normal function of MLL has been studied in mice using various gene-targeting 
approaches. One strategy was the targeted disruption of exon 3B using a LacZ 
reporter (Yu et al., 1995). An alternative strategy was the replacement of exons 12- 
14 with a PGK-neo cassette (Yagi et al., 1998). Homozygous mutant mice died 
before birth at E l0.5 in the former study and between El 1.5 and E l4.5 in the latter
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study. Heterozygous mutant mice possessed homeotic transformations of the axial 
skeleton and exhibited haematological abnormalities such as anaemia and 
thrombocytopenia (Yu et al., 1995). Analysis of Hox (the mammalian homologues 
of the Drosophila HOM-C genes) gene expression in heterozygous mutant embryos 
revealed a one-segment posterior shift in Hoxc8 gene expression (Hanson et al., 
1999). Interestingly, embryos deficient for Bmi-1 (the mammalian homologue of 
the Pc-G gene Drosophila Posterior Sex combs) exhibited a one-segment anterior 
shift in Hoxc8 expression. The fact that MLL+/' Bmi-1'A double mutant mice exhibit 
normal patterns of Hoxc8 expression suggest that like the TRX and Pc-G proteins 
of Drosophila, MLL and Bmi-1 reciprocally regulate the expression of some Hox 
genes (Hanson et al., 1999). Although MLL deficient embryos exhibited normal 
patterns of Hoxc8 and Hoxa7 expression prior to E9 (Yu et al., 1998), expression of 
these genes were not observed after this time-point. Therefore, MLL functions in a 
similar way to TRX in that it is required to maintain but not initiate the expression 
of particular Hox genes. Subsequent studies have revealed that in addition to Hoxc8 
and Hoxa7, MLL maintains the expression of Hoxa9, Hoxa 10, Hoxb4, Hoxb5, 
Hoxb6, Hoxb8, Hoxc6 and Hoxc9 (Hanson et al., 1999; Ernst et al., 2004b).
Haematopoietic progenitors isolated from both the yolk sac (Hess et al., 1997) and 
foetal liver (Yagi et al., 1998) of MLL deficient mice demonstrated a reduced 
clonogenic capacity in vitro. The number and size of colony forming unit 
macrophages (CFU-M), colony forming unit granulocytes-macrophages (CFU- 
GM), colony forming unit granulocytes-erythrocytes-macrophages-megakaryocytes 
(CFU-GEMM) and burst forming unit erythrocytes (BFU-E) were markedly 
reduced in MLL'1' embryos. However, the cells present in these colonies were 
identical to those generated from MLL+/+ and MLL+I' embryos. These results are 
consistent with a role for MLL in the haematopoietic progenitor, possibly in 
proliferation or lineage determination but not in later stages of differentiation (Hess 
etal., 1997).
MLL deficient mice displayed many defects in non-haematopoietic tissues (Yu et 
al., 1995; Yu et al., 1998; Yagi et al., 1998). This is because MLL is not only 
expressed in haematopoietic cells but also in a wide variety of other tissues (Butler 
et al., 1997; Kawagoe et al., 1999). In order to investigate the haematopoiesis
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specific functions of MLL, blastocysts were reconstituted with A/LZ-deficient or 
heterozygous ES cells (Ernst et al., 2004a). Analysis of El 4 foetal livers from 
MLL+/' and MLL'1' chimeras revealed that MLZ-deficient cells did not contribute to 
the c-Kit+ lin" progenitor population. Although normal numbers of c-Kit+ cells were 
present in the AGM of MLL'f' embryos, these cells exhibited reduced expression of 
many other HSC markers including CD34, CD45 and PECAM. Furthermore El 1.5 
AGM cells derived from MLL'1' mice failed to reconstitute RAGyC1' recipients. 
Surprisingly, detectable donor contribution was only observed in 2 out of 9 
recipients engrafted with MLL+I‘ AGM cells. This data shows that MLL is essential 
for definitive haematopoiesis. Either MLL is required to generate normal HSCs in 
the AGM or it is required for HSCs to migrate from the AGM and seed the foetal 
liver (Ernst et al., 2004a).
Analysis of embryoid bodies which were formed from MLL'f' ES cells revealed that 
MLL was not required for the development of the hemangioblast (the common 
mesodermal precursor of HSCs and endothelial cells) (Ernst et al., 2004b). MLL'f' 
embryoid bodies were able to generate definitive c-Kit+ CD41+ haematopoietic cells 
efficiently. However, these cells were unable to produce haematopoietic colonies 
(Ernst et al., 2004b). Therefore, although MLL is not required for the commitment 
of mesodermal cells to the haematopoietic lineage, it is absolutely required for the 
proliferation and subsequent differentiation of haematopoietic cells (Ernst et al., 
2004a; Ernst et al., 2004b).
1.8 The role of Hox genes in haematopoiesis
The under-expression of a subset of Hox genes in MLL deficient mice may 
contribute to their severe haematopoietic defect. Mammalian Hox (Homeobox) 
genes are a family of transcription factors characterised by the presence of a highly 
conserved 183 nucleotide sequence termed the homeobox which encodes a helix- 
tum-helix DNA binding domain (Gehring et al., 1994). Mammals possess 39 Hox 
genes, which are organised into four clusters (A, B, C and D), on four different 
chromosomes (Boncinelli et al., 1989). Each cluster contains between 9 and 11 Hox 
genes which have been assigned to 13 paralog groups. For example, paralog group 
1 consists of Hoxal, Hoxbl and Hoxdl. The genomic organisation of the Hox genes 
is summarized in Figure 1.2.
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Figure 1.2 The organisation and conservation of the HOM-C and HOX  gene 
families. In mammals, the four HOX gene clusters (A, B C and D) which are 
organised on four different chromosomes, are thought to have arisen by 
duplication and divergence. Each cluster contains between 9 and 11 HOX genes 
which have been assigned to 13 paralog groups. During embryogenesis, HOX 
genes specify positional identity along the anterior-posterior axis. Their expression 
is spatially and temporally regulated such that the 3’ HOX genes such as HOXA1 
are expressed earlier and in a more anterior position in the embryo than the 5’ 
HOX genes such as HOXA13. Reproduced from Grier et al., 2005.
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Hox proteins are key regulators of the mammalian body plan and play important 
roles in regulating axial-skeleton, hind-brain and limb development during 
embryogenesis (Boncinelli et al., 1989; Lawrence and Largman, 1992; Kmita and 
Duboule, 2003; Grier et al., 2005). In addition to their role in specifying cell fate 
during embryogenesis, these proteins are also important regulators of 
haematopoiesis. Multiple members of the HOXA, HOXB and HOXC clusters are 
expressed in primary haematopoietic cells (Giampaolo et al., 1994; Moretti et al., 
1994; Sauvageau et al., 1994) and several HOXA and HOXB genes are expressed in 
the most primitive progenitor populations of human bone marrow (Sauvageau et al.,
1994). The level of expression of these genes is highest in the stem cell and 
committed progenitor populations and is down-regulated as these cells differentiate 
(Kawagoe et al., 1999). The VHOX  genes such as HOXB3 and HOXB4 are down 
regulated prior to lineage commitment. However, the 5’HOX genes, such as 
HOXA9 and HOXA 10, are down regulated during later stages of differentiation 
(Sauvageau et al., 1994).
Further evidence for the role of Hox genes in haematopoiesis has come from gene 
targeting studies in mice. Hoxa9~'' mice have decreased numbers of myeloid and 
pre-B cell progenitors (Lawrence et al., 1997) and it has been reported that Hoxa9 
deficient HSCs fail to compete efficiently in bone marrow transplantation chimeras 
(Lawrence et al., 1998). Mice deficient in Hoxb3 and Hoxb4 displayed reductions 
in foetal HSC numbers and an impairment in HSC proliferation and repopulating 
ability (Bjomsson et al., 2003). Interestingly, mice with a deficiency in Hoxb4 
alone have similar albeit less pronounced defects (Brun et al., 2004). Therefore, the 
combined deficiency of Hoxb4 and Hoxb3 enhances these defects, without altering 
the phenotype, in a dose-dependent manner.
Mice engineered to over-express certain Hox genes by retroviral transduction, 
followed by bone marrow transplantation, have provided further insight into the 
role of these genes in haematopoiesis. Mice over-expressing Hoxa9 displayed an 
expansion of HSCs and myeloid progenitor cells (Thorsteinsdottir et al., 2002) and 
eventually developed AML (Kroon et al., 1998). Over-expression of HoxalO 
conferred a proliferative advantage to myeloid progenitors (Bjomsson et al., 2001), 
promoted megakaryocytic differentiation at the expense of macrophage
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differentiation and induced AML (Thorsteinsdottir et al., 1997). Over-expression of 
HoxalO, like Hoxa9, caused a block in B cell development at the pre-B cell 
progenitor stage suggesting that down-regulation of these genes is required for 
normal B cell development (Thorsteinsdottir et al., 1997; Thorsteinsdottir et al., 
2002). Over-expression of Hoxb3 caused a block in both B cell and T cell 
development and induced a myeloproliferative disorder which progressed to AML 
(Sauvageau et al., 1997). In contrast, over-expression of Hoxb4 enhanced HSC 
proliferation and self-renewal without altering differentiation or promoting 
leukaemic development (Sauvageau et al., 1995). Interestingly, Hoxa9, HoxalO or 
Hoxb4 were able to rescue haematopoietic colony formation from MLL'1 embryoid 
bodies, although the subsequent differentiation of the colonies varied according to 
the particular Hox gene expressed (Ernst et al., 2004b). This finding suggests that 
although Hoxa9, HoxalO and Hoxb4 promote the development of different 
haematopoietic lineages, they are functionally redundant in their ability to promote 
the proliferation of immature haematopoietic cells (Ernst et al., 2004b).
1.9 The functional domains of MLL
The MLL gene spans 90 kb, possesses 37 exons and encodes a 431 kDa protein, 
which is proteolytically cleaved into two fragments. MLL is cleaved at two 
conserved sites by a novel protease called Taspase 1 (Hsieh et al., 2003b). This 
cleavage yields an N-terminal 320 kDa fragment and a C-terminal 180 kDa 
fragment. These two fragments heterodimerise and their interaction confers stability 
and correct subnuclear localisation of the protein (Yokoyama et al., 2002; Hsieh et 
al., 2003a; Hsieh et al., 2003b). Several domains of MLL are now well 
characterised. These include the AT hooks, the DNA methyltransferase homology 
domain and the SET domain. The domain structure of the full-length MLL protein, 
the proteolysis and subsequent interaction of the N and C-terminal fragments are 
depicted in Figure 1.3.
Sub-nuclear localisation domains
The sub-nuclear localisation domains (SNL1 and SNL2) are responsible for 
determining the punctate expression pattern of MLL in the nucleus (Yano et al.,
1997).
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Figure 1.3 Structure of the wild-type MLL protein. MLL is proteolytically 
cleaved by taspase (a threonine aspartase) at two conserved sites near its C- 
terminus. Cleavage results in the generation of a large N-terminal peptide of 
300kDa (p300) and a smaller C-terminal peptide of 180kDa (pi 80) which 
interact in vivo via the FYRN domain of p300 and the FYRC domain of p i80. 
AT 1-3: AT hooks, SNL1-2: sub-nuclear localisation domains, MT:
methyltransferase homology domain, PHD 1-3: PHD fingers, TA: transactivation 
domain. Adapted from Eguchi et al., 2003.
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AT hooks
MLL contains three closely spaced AT hooks which enable MLL to bind to AT-rich 
regions of DNA in the minor groove. However, they recognise DNA structure 
(intrinsically bent or cruciform DNA) rather than specific sequences (Aravind and 
Landsman, 1998).
DNA methyltransferase homology domain
The DNA methyltransferase (MT) domain possesses homology to DNA 
methyltransferase I (Ma et al., 1993). This domain also confers DNA binding 
ability to MLL and enables it to selectively bind to unmethylated CpG sequences 
(Birke et al., 2002). The methylation of CpG sequences in promoters or enhancers 
is associated with transcriptional silencing (Bird and Wolffe, 1999; Siegfried et al., 
1999). Although MLL is not reported to methylate DNA, the region of MLL 
encompassing the MT domain has transcriptional repression activity in reporter 
assays which is partially mediated through interactions with histone deacetylases 
(HDACs) and the polycomb group proteins HPC2 and Bmi-1 (Zeleznik-Le et al., 
1994; Xia et al., 2003). The ability of MLL to bind specifically to unmethylated 
CpG sequences may contribute to the mechanism whereby MLL binds to 
transcriptionally active target genes and modifies chromatin such that their 
expression is maintained.
PHD domain
The PHD (plant homeodomain) domain of MLL is composed of four zinc fingers 
which are highly conserved with TRX. PHD fingers are present in many proteins 
that are involved in chromatin-associated transcriptional regulation (Aasland et al.,
1995). Therefore, it is considered that the PHD domain of MLL may play an 
important role in regulating the expression of MLL target genes. The PHD zinc 
fingers of MLL can homodimerise and the third zinc finger is able to bind to the 
nuclear cyclophilin Cyp33 (Fair et al., 2001). Interestingly, the binding of Cyp33 to 
the PHD domain increased the binding of HD AC 1 to the repression domain of 
MLL (Xia et al., 2003). Furthermore, the over-expression of Cyp33 in cells 
containing wild-type MLL resulted in the down-regulation of the MLL target genes 
HOXC8 and HOXC9 (Fair et al., 2001). This down-regulation was dependent upon 
the cis / trans prolyl-isomerase activity of Cyp33, since it was not observed in the
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presence of the cis / trans prolyl-isomerase inhibitor cyclosporine (Fair et al., 2001). 
This data suggests that the cis / trans prolyl-isomerase activity of Cyp33 alters the 
conformation of MLL to allow HDAC1 binding and the subsequent repression of 
MLL target genes (Xia et al., 2003).
Transactivation domain
In addition to the repression domain, a transactivation domain exists between the 
PHD and SET domains of MLL (Prasad et al., 1995). This transactivation domain 
facilitates the binding of MLL to the transcriptional co-activator CBP (c AMP 
binding protein), which promotes its interaction with CREB (cAMP response 
element binding) and thus enhances transcriptional activation (Ernst et al., 2001). 
Cleavage of MLL by Taspase 1 at a conserved proteolytic site between the PHD 
and transactivation domains results in the generation of two peptides, with opposite 
transcriptional properties. The N-terminal peptide contains the repression domain of 
MLL whereas the C-terminal peptide contains the transactivation domain of MLL 
(Figure 1.3). The post-translational processing of MLL by Taspase 1 is therefore a 
potential mechanism whereby the transcriptional activity of MLL is regulated 
(Yokoyama et al., 2002).
SET domain
The SET (Su(var)3-9, enhancer of zeste and trithorax) domain of MLL is the most 
highly conserved domain between MLL and TRX. Previous studies have shown 
that this domain possesses histone H3 lysine 4-specific methyltransferase activity, 
which is stimulated by H3 peptides that are acetylated on lysine 9 or lysine 14 
(Milne et al., 2002; Nakamura et al., 2002). Since H3-K4 histone methylation is 
associated with transcriptional activation (Nakamura et al., 2002), it is likely that 
the SET domain plays an important role in regulating MLL target gene expression. 
Accordingly, the SET domain of MLL was required for the transcriptional 
activation of Hoxc8 upon the re-expression of MLL in MLL null fibroblasts (Milne 
et al., 2002). This was mediated by direct binding of MLL to the Hoxc8 promoter 
and subsequent H3-K4 methylation of the Hoxc8 promoter and 5’ enhancer. MLL 
was also able to methylate the promoters of Hoxa7 and Hoxa9 (Milne et al., 2002) 
suggesting that H3-K4 methylation of MLL target gene promoters is likely to be a 
common mechanism of transcriptional activation by MLL. The re-expression of
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MLL in MLL null cells also resulted in H3 and H4 acetylation of the 5’ and 3’ 
enhancers of Hoxc8 (Milne et al., 2002). This suggests that MLL also promotes 
histone acetylation of its target genes. In accordance with this, a recent study 
demonstrated that MLL was able to interact with the H4-K16 specific histone 
acetyltransferase MOF (Dou et al., 2005). Importantly, both H3-K4 methylation 
and H4-K16 acetylation of the Hoxa9 locus were required for optimal Hoxa9 
expression (Dou et al., 2005). Therefore, MLL recruits coactivators to its target 
gene promoters, which cooperate with MLL to maintain the expression of MLL 
target genes.
1.10 MLL is a component of a multi-protein super complex.
It is now understood that MLL is a component of a super-complex which consists 
of more than 29 proteins, which acetylate, deacetylate and methylate histones 
(Nakamura et al., 2002). Many of the proteins associated with MLL are 
components of transcription complexes. These include components of the TFIID 
complex (which is required for the assembly of the transcriptional preinitiation 
complex), the SWI/SNF chromatin remodelling complex and the NuRD and Sin3A 
histone deacetylases complexes. Many of these components were identified at the 
promoter of HOXA 9 which suggests that these components are required by MLL to 
remodel the chromatin of MLL target genes and thus maintain their expression 
(Nakamura et al., 2002).
Recently, another complex of MLL was identified whose components included 
HCF-2, ASH2L1, menin, RBBP5 and WDR5 (Yokoyama et al., 2004). Of these 
components only menin, which was originally identified as a product of the MEN 1 
tumour suppressor gene, was found to be crucial for the maintenance of HOXA 9 
expression. Loss of menin expression resulted in a similar decrease in HOXA9 
expression as loss of MLL expression (Yokoyama et al., 2004). Therefore, menin 
plays an important role in regulating the expression of MLL target genes. This was 
highlighted by the finding that menin promoted the binding of MLL to target gene 
promoters (Milne et al., 2005). Although many of the components of this new 
complex are similar to that of the yeast and human SET1 histone methyltransferase 
complexes (Miller et al., 2001; Roguev et al., 2001; Nagy et al., 2002; Wysocka et 
al., 2003), only WDR5 and RBBP5 were present in the previously identified MLL
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super-complex (Nakamura et al., 2002). The authors speculated that the 
composition of the complex may vary with different cellular conditions and this 
may account for the lack of common components between the two MLL complexes 
(Yokoyama et al., 2004).
1.11 MLL domains retained in fusion proteins
The AT hooks, sub-nuclear localisation domains and MT homology domain of 
MLL are consistently retained in the MLL fusion protein whereas the PHD, 
transactivation and SET domains of MLL are replaced by sequences of the partner 
protein (Figure 1.4). The MLL fusion protein also lacks the Taspase 1 proteolytic 
cleavage site and the FYRN domain required for interaction with the p i80 C- 
terminal MLL fragment. Since the binding of Cyp33 to the PHD domain represses 
MLL target genes, the loss of the PHD domain may convert MLL to a constitutive 
activator (Fair et al., 2001).
MLL is thought to maintain appropriate expression levels of its target genes, which 
are required for normal haematopoietic differentiation, through the H3-K4 
methyltransferase activity of its SET domain. Since MLL-fusion proteins lack this 
domain, it is likely that they will not be able to maintain appropriate expression 
levels of MLL target genes. The stability and transcriptional activity of the MLL 
fusion protein is expected to differ from the wild-type MLL protein since the fusion 
protein is not processed by Taspase 1 (Hsieh et al., 2003a). It is likely that the 
composition of the MLL-fusion protein super complex will also vary from that of 
wild-type MLL. In support of this, MLL-fusion proteins retain the ability to interact 
with menin but not other components of the MLL/HCF super complex (Yokoyama 
et al., 2004).
1.12 Functions of the MLL fusion partners
Some of the MLL fusion partners share homology, for example AF4/AF5q31/LAF4, 
ENL/AF9 and AF10/AF17 are members of common gene families (Nakamura et al., 
1993; Chaplin et al., 1995; Nilson et al., 1997; Taki et al., 1999). However, most of 
the fusion partners share no homology or common functional domains. Therefore, 
they have generally been divided into two categories, signalling molecules that 
localise to the cytoplasm, or nuclear factors involved in transcriptional regulation
31
Wild-type MLL
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Figure 1.4 Structure of wild-type MLL and a typical MLL-fusion protein. In
all MLL-fusion genes examined, MLL is cleaved within an intron in a conserved 
region known as the breakpoint-cluster-region (BCR) which spans exons 5-8. 
Once MLL is cleaved, it is joined to the 3’ sequences of one of its many partner 
genes resulting in the generating an in-frame chimeric fusion protein. The AT 
hooks (AT 1-3), sub-nuclear localisation domains (SNL1 and 2) and the 
methyltransferase homology (MT) domain of MLL are retained in the fusion 
protein. In contrast, the plant homeodomain (PHD 1-3), the FYRN and FYRC 
domains which mediate the interactions of the p300 and pi 80 MLL fragments and 
the SET domain are replaced by the C-terminal sequences of the partner protein.
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(Eguchi et al., 2003). The function of each MLL partner protein and its cellular 
localisation is summarised in Table 1.1.
AF4, AF9 and ENL are the most common MLL fusion partners and all three 
possess transcriptional activation function in reporter assays (Rubnitz et al., 1994; 
Prasad et al., 1995; Morrissey et al., 1997). Like MLL, AF9 is required for embryo 
patterning and normal Hox gene expression since AF9 null mice possess axial 
skeletal defects and abnormal patterns of Hoxd4 expression (Collins et al., 2002). 
Although, AF9 is normally expressed in the megakaryocyte and erythroid lineage, 
normal haematopoiesis was observed in AF9 null mice (Collins et al., 2002). In 
contrast, AF4 null mice exhibited defects in lymphoid development, with reduced 
numbers of CD4/CD8 double positive T cells, pre-B and mature B cells (Isnard et 
al., 2000).
AF9, ENL and GAS41 share homology to TGF3/ANC1 which binds to the yeast 
chromatin re-modelling complex SWI/SNF through its interactions with SNF5 
(Cairns et al., 1996). Although GAS41 is not a direct fusion partner of MLL, it is 
able to interact with the MLL fusion partner AF10 (Debemardi et al., 2002). A role 
for ENL in chromatin remodelling is supported by the finding that it is a component 
of a novel human SWI/SNF chromatin remodelling complex (Nie et al., 2003).
Since ENL and AF9 share significant homology and both interact with the 
Polycomb 3 (hPc3) protein (Garcia-Cuellar et al., 2001), it is likely that AF9 is also 
a component of a chromatin remodelling complex. Interestingly, GAS41 has been 
shown to interact with INI1 (the human homologue of the yeast SWI/SNF 
component SNF5) and may therefore act as a bridging factor between AF10 and 
SWI/SNF complexes. More recently, AF10 has been shown to interact with 
hDOTIL which possesses H3-K79 histone methyltransferase activity (Okada et al., 
2005). Hence, like MLL, many of the MLL fusion partners may be either directly or 
indirectly involved in chromatin remodelling.
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Table 1.1 Cloned MLL-partner genes and chromosomal abnormalities involving 
the MLL gene on chromosome llq23.
Gene Cytogeneticabnormality Function Localisation
ABI-1 t(10;l l)(pl 1.2;q23) Regulator of endocytosis? / cell motility C
AFlp t(l;ll)(p32;q23) Regulator of endocytosis C, N
AFlq t(l;ll)(q21;q23) NK NK
AF3p21 t(3; 11 )(p21 ;q23) NK N
AF4 t(4;ll)(q21;q23) Transcriptional activator N
AF5q31
AF6
AF9
t(5; 11 )(q31 ;q23) 
t(6;ll)(q27;q23) 
t(9;ll)(q22;q23)
Homology to AF4, 
transcriptional activator? 
Maintenance of cell-cell 
junctions and cell polarity 
Homology to ENL, 
transcriptional activator
N?
C
N
AF9q34 t(9;ll)(q34;q23) Ras GTPase-activating protein C
AF10 t(10;ll)(pl2;q23) Transcription factor N
AF15ql4 t( 11; 15)(q23 ;q 14) NK NK
AF17 t( 11; 17)(q23 ;q21) Transcription factor N
AFX t(X;ll)(ql3;q23) Forkhead transcription factor N
CALM
CBL
CBP
inv(ll)(ql4;q23) 
del(ll) 
t(l 1 ;16)(q23;pl3)
Regulator of endocytosis, 
clathrin assembly protein 
Negative regulator of receptor 
tyrosine kinases 
Transcriptional co-activator, 
Histone acetylase
C, N 
C 
N
EEN t( 11; 19(p 13 ;q23) Regulator of endocytosis? C?
ELL t(l 1; 19)(q23;pl3.1) Transcriptional activator* N
ENL t(ll;19)(q23;pl3.3) Transcriptional activator N
FBP17 ins(l 1 ;9)(q23;q34) inv(ll)(ql3)(q23) NK C
FKHRL1 t(6;ll)(q21;q23) Forkhead transcription factor N
GAS7 t(l 1 ;17(q23;pl3) Growth-arrest specific gene C
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GMPS
GPHN
t(3;l I)(q25;q23) 
t(ll;14)(q23;q24)
Guanosine monophosphate 
synthetase 
Gly and GABA receptor 
assembly
C
C
GRAF t(5;ll)(q31;q23) Negative regulator of RhoA c
hCDCrel t(l 1 ;22)(q23;ql 1.2) Septin family c
LAF4 t(2;l l)(ql 1.2- 12;q23)
Homology to AF4, 
transcriptional activator N
LARG del(ll) Activator of Rho GTPases c
LASPI t(l 1; 17)(q23;q21) NK c
LCX t(10;ll)(q22;q23) NK NK
LPP t(3;ll)(q28;q23) Regulator of cell motility and focal adhesion C,N
MPFYVE t(ll;15)(Q23;ql4) NK NK
MSF t(l I;17)(q23;q25) Septin family C
p300 t(l 1 ;22)(q23;ql3) Transcriptional co-activator, histone acetylase N
Septin6 ins(X;l I)(q24;q23) Septin family C
The most common MLL partner genes are highlighted in bold. N indicates nuclear 
localisation, C indicates cytoplasmic localisation and NK means not known. * 
indicates that the transcriptional activation activity is indirect and is mediated 
through binding to EAF1 (Luo et al., 2001). Adapted from Eguchi et a l, 2003 and 
Mitterbauer-Hohendanner and Mannhalter, 2004.
Many of the fusion partner proteins interact with each other such as AF4 and AF9 
(Erfurth et al., 2004) and ENL and ABI1 (Garcia-Cuellar et al., 2000). More 
recently ENL was found to interact with AF4 and AF5q31 (Zeisig et al., 2005). 
These interactions have led to the proposal of the ‘MLL web hypothesis’ which 
suggests that although the partner proteins do not share homology or a common 
function they may all be part of a large complex network which is disrupted by the 
formation of an MLL-fusion protein (Erfurth et al., 2004).
1.13 Models of MLL leukaemias
Various in vitro and in vivo models have been established in order to investigate 
whether MLL-fusion proteins are leukaemogenic.
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In vitro models
Prior to the development of animal models, the properties of MLL fusion proteins 
were examined by over-expressing them in haematopoietic cell lines. The murine 
32Dcl3 myeloid cell line is IL-3 responsive and normally undergoes terminal 
neutrophil differentiation in response to G-CSF. The over-expression of an N- 
terminal MLL protein, which was truncated at the BCR, inhibited the differentiation 
of 32Dcl3 cells in response to G-CSF. However, cells over-expressing full-length 
MLL differentiated normally in response to G-CSF (Joh et al., 1996). This finding 
suggests that MLL fusion proteins may act in a dominant negative fashion by 
disrupting the normal function of MLL (Joh et al., 1999). Attempts at generating 
stable 32Dcl3 cell lines over-expressing the MLL-AF9 or MLL-ENL fusion genes 
failed. Therefore, inducible systems of fusion protein expression were generated. 
Wild-type 32Dcl3 cells or a stable 32Dcl3 cell line expressing full-length MLL 
displayed an up-regulation of Hoxa7, Hoxb7 and Hoxc9 expression upon G-CSF 
treatment (Joh et al., 1999). However, the induction of expression of MLL-AF9 or 
N-terminal truncated MLL inhibited the up-regulation of these Hox genes in 
response to G-CSF (Joh et al., 1999). Truncated MLL may therefore block G-CSF 
induced differentiation of 32Dcl3 cells by disrupting Hox gene expression. It was 
not reported whether MLL-AF9 also blocked the G-CSF induced differentiation of 
32Dcl3 cells.
The induction of MLL-AF9 expression in the U937 human monoblastic cell line 
induced growth arrest, macrophage differentiation and apoptosis of these cells 
(Caslini et al., 2000). Deletion mutagenesis revealed that the N-terminus of MLL 
spanning the AT hooks was responsible for the induction of growth arrest and 
differentiation. A more detailed study found that graded expression of MLL-AF9, 
which was achieved using different concentrations of tetracycline, always resulted 
in a higher percentage of cells in S-phase than cells which expressed only the N- 
terminus of MLL (Caslini et al., 2004). This finding suggests that MLL-AF9 may 
confer a proliferative advantage to the cells even though MLL-AF9 expression is 
ultimately not compatible with survival in this cell line (Caslini et al., 2004). The 
induction of MLL-AF4 expression in U937 cells resulted in a decrease in growth 
rate and partial macrophage differentiation (Caslini et al., 2004). Interestingly, cells 
expressing MLL-AF4 exhibited an increased survival in response to highly
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cytotoxic doses of etoposide. This finding is consistent with the observation that 
cell lines derived from patients with t(4; 11) translocations proliferate more slowly 
than non-t(4;l 1) derived cell lines and are resistant to apoptosis induced by serum 
deprivation (Kersey et al., 1998). The apparent difficulty in generating stable cell 
lines over-expressing certain MLL-fusion proteins is probably due to the fusion 
protein being expressed at greater than physiological levels. This highlights the 
need to examine the role of these fusion proteins in a more relevant cell type such 
as primary haematopoietic progenitor cells.
In vivo models
Three different strategies have been employed to generate murine models of MLL 
leukaemias. These include the knock-in of the fusion partner into the endogenous 
MLL gene, over expression of the fusion gene by retroviral transduction of 
haematopoietic progenitor cells (HPCs) and the de novo creation of the 
translocation by engineering interchromosomal recombination between the MLL 
and partner gene loci.
The knock-in approach
The first model of MLL leukaemia was the development of an MLL-AF9 ‘knock­
in’ mouse (Corral et al., 1996). Homologous recombination in ES cells was used to 
fuse the 3’-terminal human AF9 sequence with exon 8 of MLL such that MLL-AF9 
expression was under the control of the endogenous murine MLL promoter. 
Chimeric mice were generated which developed AML between 4 and 9 months of 
age while mice with an MLL-myc-tag translocation (where the myc-tag was fused to 
exon 8 of MLL) failed to develop AML (Corral et al., 1996). This finding suggests 
that truncation of MLL alone is not sufficient for leukaemogenesis and that the 
partner protein AF9 confers a gain of function upon MLL. A more detailed analysis 
over a longer observation period revealed that while the majority of the chimeric 
mice developed AML, a small percentage developed ALL (Dobson et al., 1999). 
Although the MLL-AF9 translocation is predominantly associated with AML in 
humans, it is observed in a small percentage of ALL cases. Therefore, the MLL- 
AF9 knock-in model mimics the incidence of acute leukaemias found in patients 
with this translocation.
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The retroviral transduction approach
The transduction of murine HPCs with retroviral MLL-fusion gene expression 
constructs is a more common method of generating murine models of MLL 
leukaemias. Haematopoietic progenitors enriched in HSCs were transduced with 
MLL-ENL and cultured in methylcellulose. The transduced cells were able to 
serially replate in methylcellulose and establish immortalised myeloid cell lines in 
liquid culture (Lavau et al., 1997). However, HPCs transduced with a truncated 
MLL construct (containing only MLL sequence that is present in the translocation) 
or wild-type ENL, failed to replate beyond the second round (Lavau et al., 1997). 
Importantly, the immortalised MLL-ENL cell lines induced AML (with a latency of 
3-4 months) when transferred into syngeneic recipients (Lavau et al., 1997). 
Subsequent studies have demonstrated that the fusion of MLL with ELL, AF10, 
AFX, FKHRL1 and CBP can immortalise HPCs and induce myeloid leukaemia 
when transferred into mice, although with differing latencies (Lavau et al., 2000a; 
Lavau et al., 2000b; DiMartino et al., 2002; So and Cleary, 2002; So and Cleary, 
2003). An overview of the retroviral transduction method is presented in Figure 1.5.
A model of acute biphenotypic leukaemia (ABL) which mimics the mixed-lineage 
phenotype of many of the human leukaemias associated with MLL-fusion proteins 
has been developed. Transduction of HPCs with MLL-ENL followed by culture in 
methylcellulose supplemented with cytokines that support B cell development . 
yielded B220+ CD 19' immortalised cell lines (Zeisig et al., 2003a). Transfer of 
these cell lines into syngeneic recipients resulted in the development of ABL within 
3-4 months. The leukaemic cells possessed a B220+ CD 19' Mac-lint mixed lineage 
immunophenotype and were of a monocytoid morphology. In addition to their 
mixed-lineage immunophenotype, the cells co-expressed lymphoid specific and 
myeloid specific genes (Zeisig et al., 2003a). Interestingly, MLL-GAS7 is the only 
MLL-fusion protein examined thus far that can induce AML, ALL or ABL in 
syngeneic recipients transplanted with freshly transduced HSCs (So et al., 2003a).
The interchromosomal recombination approach
An interchromosomal recombination model has recently been developed which 
more accurately mimics the human MLL translocation than any of the 
aforementioned murine models. In this model the de novo translocation of MLL and
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Figure 1.5 Experimental strategy of haematopoietic progenitor cell
retroviral transduction. Lin' (lineage depleted) haematopoietic progenitor cells 
(HPCs) were isolated from the bone marrow of mice, 5 days after the injection of 
5-fluorouracil (5-FU). Purified HPCs were transduced with an MLL-fusion gene 
retroviral expression construct and then serially replated in methylcellulose. 
Following the third replating, immortalised cells were maintained in liquid 
culture. The leukaemogenicity of the immortalised cells was measured by 
transfer into sub-lethally irradiated recipients. Adapted from Eguchi et al., 2003.
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ENL loci occurs specifically in haematopoietic cells and results in the generation of 
both reciprocal translocation products, which previous models have failed to 
recapitulate. This was achieved by engineering loxP sites into the murine MLL and 
ENL loci using homologous recombination in ES cells. Mice were generated using 
the mutant ES cells and inter-bred with cre-expressing mice (where ere was under 
the control of the Lmo2 promoter) to generate translocator mice (Forster et al.,
2003). Translocator mice expressed the MLL-ENL fusion gene and succumbed to 
AML rapidly, within 4 months of birth. Although the MLL-ENL fusion gene is 
associated with both myeloid and lymphoid leukaemias in humans, none of the 
translocator mice developed ALL or ABL. The reasons for this are presently 
unclear but it is possible that in mice, MLL-ENL preferentially transforms the 
myeloid lineage (So et al., 2003b).
1.14 Are secondary mutations required for MLL leukaemogenesis?
The short latency of the leukaemias which arose in the MLL-ENL translocator mice 
led the authors to speculate that the MLL-ENL translocation might be the only 
mutation required for leukaemogenesis (Forster et al., 2003). The very short latency 
of infant leukaemias with MLL-translocations and the high concordance rate in 
identical twins has also fuelled speculation that secondary mutations are not 
required (Greaves, 1999). However, most cancers are the result of multiple genetic 
aberrations. The hypothesis that an MLL-translocation alone is sufficient for 
leukaemogenesis is therefore controversial. In the case of infant leukaemias, it is 
possible that the genotoxic agent that initiated the MLL-translocation in utero was 
also able to mutate other genes, which co-operated with the MLL-fusion protein to 
induce leukaemia (Eguchi et al., 2003). It is also possible that the infant inherited 
particular mutations, which predisposed it to leukaemia. Alternatively, the MLL- 
fusion protein itself may directly influence the acquisition of secondary mutations 
(So and Cleary, 2002). Interestingly, it has recently been suggested that the de­
regulated expression of the MLL target gene Hoxa9 induces cytogenetic aberrations 
(Jordan and Guzman, 2004). Therefore, MLL-fusion proteins may promote 
genomic instability by de-regulating the expression of MLL target genes. Murine 
models of MLL leukaemias have demonstrated that particular MLL-fusion proteins 
induce leukaemia with substantially different latencies. For example, MLL-ENL, 
MLL-AF9, MLL-GAS7, MLL-AFlp and MLL-AF10 transduced cells required
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between 3 and 5 months to give rise to leukaemia in syngeneic recipients 
(DiMartino et al., 2002; Cozzio et al., 2003; Martin et al., 2003; So et al., 2003a;
So et al., 2003b). In contrast, MLL-ELL, MLL-AFX, MLL-FKHRL1 and MLL- 
CBP transduced cells gave rise to leukaemia after a much longer latency (Lavau et 
al., 2000a; Lavau et al., 2000b; So and Cleary, 2003). These studies suggest that 
MLL-fusion proteins differ in their oncogenecity or their requirement for secondary 
mutations.
If secondary mutations are required for MLL leukaemias, it is possible that the 
leukaemic cells would no longer be dependent on the MLL-fusion protein for their 
survival. Conditional systems of MLL-fusion protein expression have been 
developed in order to investigate whether immortalised cells are dependent on 
continued expression of the MLL-fusion protein. HPCs immortalised using an 
oestrogen regulated conditional MLL-ENL fusion protein were dependent on the 
continued presence of tamoxifen for their survival and proliferation (Zeisig et al.,
2004). The withdrawal of tamoxifen and subsequent inactivation of MLL-ENL 
resulted in the terminal differentiation of the immortalised cells into neutrophils. 
Therefore, MLL-ENL is required to maintain the immortalised phenotype in vitro. 
However, it remains to be determined whether MLL-ENL is required to maintain 
leukaemia in vivo.
Several studies have examined the effect of targeting the expression of the MLL- 
fusion genes in cell lines derived from patient material. The targeted down- 
regulation of the MLL-AF9 transcript in the THP-1 cell line was achieved using 
antisense oligonucleotides and resulted in reduced HOXA7 and HOXA 10 
expression, reduced proliferation and some apoptosis (Kawagoe et al., 2001). 
Similar results were obtained following the down-regulation of MLL-ENL 
transcript expression in the KOCL33 cell line (Akao et al., 1998). The inhibition of 
THP-1 cell growth was not accompanied by terminal differentiation and the down- 
regulation of MLL-AF9 did not restore the ability of the cells to differentiate in 
response to G-CSF or M-CSF (Pession et al., 2003). Hence, although MLL-AF9 
promotes the proliferation of leukaemic cells and protects them from apoptosis, it 
does not block their differentiation. It is likely that mutations other than MLL-AF9
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contribute to a block in differentiation of these leukaemic cells (Pession et al.,
2003).
1.15 The mechanism of action of MLL fusion proteins
The models of MLL leukaemias described above have provided important insights 
into the mechanism of action of MLL fusion proteins. Knock-in mice which were 
engineered to express an MLL-myc tag only possess one functional copy of MLL 
yet they do not develop leukaemia (Corral et al., 1996; Dobson et al., 1999). 
Therefore, it is unlikely that MLL haploinsufficiency promotes leukaemogenesis. 
Furthermore, MLL-fusion proteins can immortalise HPCs in the presence of two 
copies of MLL (Lavau et al., 1997). The simple truncation of MLL or the over­
expression of ENL is not sufficient to immortalise HPCs suggesting that the partner 
protein confers a gain of function to MLL (Lavau et al., 1997).
A possible dominant negative effect of MLL-fusion proteins on normal MLL 
function has been inferred from the finding that the over-expression of an N- 
terminal truncated MLL protein, but not full-length MLL, can block G-CSF 
induced differentiation of 32Dcl3 cells (Joh et al., 1996). However, MLL-AF9 
knock-in mice, which possess one translocated MLL allele and one wild-type MLL 
allele, are viable (Dobson et al., 1999). Since the MLL null mutation is embryonic 
lethal (Yu et al., 1995; Yagi et al., 1998), the production of viable MLL-AF9 
heterozygote mice suggests that MLL fusion proteins do not act as dominant 
negative inhibitors of normal MLL function (Ayton and Cleary, 2001). However, 
there is evidence to suggest that MLL fusion proteins can act as dominant negative 
inhibitors of partner protein function. For example, fusion of MLL to the forkhead 
transcription factor AFX suppressed the ability of the wild-type forkhead protein 
FKHRL1 to induce the apoptosis of Ba/F3 cells (So and Cleary, 2002).
Furthermore, the C-terminus of AFX was able to enhance the self-renewal of HPCs, 
although not to the same extent as MLL-AFX. The fact that the MLL-AFX fusion 
protein and the C-terminus of AFX lack an intact forkhead DNA binding domain 
suggests that they may compete with wild-type forkhead proteins for essential 
cofactors (So and Cleary, 2002). Therefore, MLL-AFX and MLL- FKHRL1 may 
disrupt the activity of the AFX and FKHRL1 forkhead proteins, which normally 
function to suppress cell growth. The MLL partner proteins GAS7, Abi-1, AF6 and
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AFlp also function to suppress cell growth, suggesting that fusion with MLL may 
disrupt their activity and promote leukaemogenesis (So and Cleary, 2002; So et al., 
2003b).
Taken together, the knock-in model and the retroviral transduction model have 
demonstrated that the MLL fusion partner confers critical effector domains to MLL, 
which are required for leukaemogenesis. These studies therefore support a gain of 
function model as the mechanism of action of MLL fusion proteins. In addition, the 
MLL-fusion protein may act as a dominant negative inhibitor of the normal 
function of the partner protein in some cases, which may also contribute to 
leukaemogenesis.
1.16 The transcriptional transactivation domains of nuclear MLL fusion 
partners are essential for leukaemogenesis
Deletion mutagenesis studies of various MLL-fusion genes have been performed in 
order to gain insight into the mechanism of HPC immortalisation. Deletion of 
various sections of MLL-ENL revealed that the AT hooks and the MT domain of 
MLL and the transcriptional transactivation domain of ENL were essential for 
immortalisation (Slany et al., 1998). A more comprehensive study revealed that the 
AT hooks were dispensable but the MT domain, as well as a novel domain with 
unknown function in the N-terminus and an uncharacterised central region of MLL, 
were required for immortalisation by MLL-ENL (Ayton et al., 2004). Interestingly, 
the ability of MLL-ENL to immortalise HPCs was strictly dependent on an intact 
CXXC domain, which mediates the binding of MLL to unmethylated CpG 
sequences (Ayton et al., 2004).
The region of ENL encompassing the transcriptional transactivation domain 
encodes two helical structures, which are highly conserved in AF9. The ability of 
the C-terminus of ENL to act as a transcriptional activator was confirmed in 
reporter gene assays. The C-terminus of MLL-ENL and the MT domain of MLL 
were required in order for MLL-ENL to transactivate the minimal SV40 and Hoxa7 
promoters (Schreiner et al., 1999). Therefore, although the MT domain of MLL is a 
transcriptional repressor (Zeleznik-Le et al., 1994), fusion with ENL results in the 
generation of a potent transcriptional activator (Schreiner et al., 1999).
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The fusion of MLL with a variety of transactivator and repressor domains, 
confirmed that transactivator properties donated by the fusion partner are required 
for the oncogenic effects of some MLL-fusion proteins. Interestingly, a perfect 
correlation between the transactivation capacity and the transformation ability of 
each fusion gene was observed. The MLL-VP16 fusion protein, in which MLL was 
fused to the complete Herpes simplex VP 16 activation domain, transactivated the 
minimal SV40 and Hoxa7 promoters and immortalised HPCs (Zeisig et al., 2003b). 
However, MLL-VP16 did not transactivate these promoters as well as the authentic 
MLL-ENL fusion protein and the MLL-VP16 immortalised cells grew more slowly 
and exhibited a phenotype which was more mature than that of MLL-ENL 
immortalised cells. Fusion of MLL with the GAL4 activation domain, the acidic 
transactivator sequence AD42 or the KRAB repressor domain failed to transactivate 
the SV40 and Hoxa7 promoters as well as MLL-VP16 and failed to immortalise 
HPCs (Zeisig et al, 2003b). This data and the fact that most, if not all, nuclear 
fusion partners of MLL possess transactivation domains or domains that enable 
their interaction with transcriptional activators, suggests that the fusion partner 
confers novel transcriptional regulatory activity on MLL, resulting in de-regulation 
of wild-type MLL target genes and thus leukaemogenesis.
1.17 The dimerisation domains of cytoplasmic MLL fusion partners are 
essential for leukaemogenesis.
The observation that many of the MLL fusion partners are cytoplasmic with no 
known roles in transcription, suggests that these partner proteins confer a different 
activity to MLL. Some of the cytoplasmic MLL fusion partners such as AFlp and 
GAS7 contain coiled-coil dimerisation motifs (Cupers et al., 1997; She et al.,
2002). A current hypothesis is that these dimerisation motifs contribute to the 
leukaemogenic activity of the MLL fusion protein. This hypothesis was based on 
the finding that a significant number of mice engineered to express an artificial 
MLL-fi-galactosidase (LacZ) fusion gene developed leukaemia, yet mice expressing 
an MLL-myc-tag did not succumb to the disease (Dobson et al., 2000). While the 
phenotype of the leukaemia was similar to that of the MLL-AF9 knock-in mice 
(Corral et al., 1996), the latency and penetrance of the disease was very different. 
Whereas the majority of the MLL-AF9 chimeric mice had succumbed to the disease 
by 12 months, only 35% of the MLL-LacZ chimeric mice had developed leukaemia
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by 20 months (Corral et al., 1996; Dobson et al., 2000). The P-galactosidase 
enzyme normally functions as a tetramer which suggests that the MLL-p- 
galactosidase fusion protein may also exist as a tetramer (Dobson et al., 2000). 
Hence, p-galactosidase may confer dimerisation motifs to MLL which alters its 
activity and results in leukaemogenesis.
The dimerisation hypothesis is also supported by several other studies. A 
conditional MLL construct, which could be induced to dimerise by a 
pharmacological agent, was created by fusing N-terminal truncated MLL with the 
FK506 binding protein (FKBP). The ability of this construct to activate 
transcription and immortalise HPCs was strictly dependent on the presence of the 
dimerising agent (Martin et al., 2003). Internal N-terminal partial tandem 
duplications of MLL are found in a subset of patients with AML (Caligiuri et al.,
1998). Interestingly, an MLL construct in which the N-terminal sequences spanning 
the AT hook and MT domains were duplicated, activated reporter gene expression 
to the same extent as dimerised MLL-FKBP (Martin et al., 2003). Therefore, exon 
duplicated MLL and dimerised MLL may function in a similar way. The dimerised 
form of MLL and exon duplicated MLL should have twice as many DNA binding 
motifs as the undimerised form. For example, the dimerised protein will have two 
AT hook domains and two MT domains. Dimerised MLL may therefore possess a 
greater affinity for target gene promoters or accessory co-factors than wild-type • 
MLL, which may explain its enhanced transcriptional activity. The observation that 
MLL-FKBP binding to the Hoxa9 promoter was increased in the presence of 
dimeriser is in agreement with this hypothesis (Martin et al., 2003).
The coiled-coil domains of the MLL fusion partners AFlp, GAS7 and SEPTIN6 
facilitate their homo-dimerisation and are essential for MLL-AFlp, MLL-GAS7 
and MLL-SEPT6 mediated transformation (So et al., 2003b; Ono et al., 2005). 
Although truncated MLL, AFlp and GAS7 possessed little transcriptional 
transactivation ability themselves, the MLL-AFlp and MLL-GAS7 fusion proteins 
were potent transcriptional activators, capable of transactivating the Hoxa7 
promoter over 50-fold (So et al., 2003b). Hence, the role of both the nuclear and 
cytoplasmic MLL fusion partners may be to convert MLL into a constitutive 
transcriptional activator (Figure 1.6). In agreement with this hypothesis, MLL-
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Figure 1.6 Mechanisms of Hox gene regulation by MLL fusion proteins. A)
Wild-type MLL is cleaved at the proteolytic cleavage site by Taspase 1 into bl­
and C-terminal peptides. Following chromosomal translocation, the N-terminus of 
MLL is fused to the C-terminus of either nuclear or cytoplasmic fusion partners. 
AT 1-3: AT hooks, SNL1 and 2: sub-nuclear localisation domains, CxxC: cysteine 
rich methyltransferase homology domain, PHD 1-3: PHD domain. B) Gene 
regulation by wild-type MLL. The processed N- and C-terminal peptides of MLL 
interact in a multi-protein super-complex which remodels the chromatin of Hox 
genes such that their expression is maintained in haematopoietic progenitors (grey 
circles: unmethylated histones, yellow circles: methylated histones). During 
haematopoietic differentiation, polycomb group proteins may antagonise the 
function of MLL such that Hox gene expression is no longer maintained. C) MLL- 
fusion proteins may act as monomers to constitutively activate Hox gene 
expression if the fusion-partner possesses transactivation properties. D) 
Alternatively, MLL-fusion proteins may act as dimers to constitutively activate 
Hox gene expression if the fusion partner possesses dimerisation motifs. 
Reproduced from Hsu and Look, 2003.
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GAS7 and MLL-ENL immortalised cells exhibited very similar patterns of Hoxa7, 
Hoxa9, HoxalO and Meis-1 expression (So et al., 2003b). Therefore, MLL-fusion 
proteins may aberrantly maintain the expression of a subset of Hox genes which 
may contribute to leukaemogenesis.
1.18 The role of Hox genes in leukaemogenesis
A fundamental role for HOX genes in leukaemogenesis is supported by the 
observation that multiple HOXA and HOXB genes are frequently over-expressed in 
patients with AML and that several HOXC genes are over-expressed in patients 
with lymphoid leukaemias (Celetti et al., 1993; Bijl et al., 1996; Drabkin et al., 
2002). High levels of HOX gene expression are associated with a poor prognosis in 
AML (Drabkin et al., 2002) and HOXA9 expression in particular is highly 
correlated with treatment failure (Golub et al., 1999).
The involvement of HOX genes in leukaemogenesis was supported by the 
identification of chromosomal translocations involving the NUP98 gene and several 
HOX genes in a subset of AML patients. NUP98 fusion partners include HOXA9, 
HOXA11, HOXA13, HOXC11, HOXC13 and HOXD13 (Pineault et al., 2004).
These translocations generate chimeric fusion proteins in which the homeodomain 
of the Hox protein is always retained. NUP98-Hoxa9 and NUP98-Hoxdl3 induce a 
myeloproliferative disease and eventually AML when over-expressed in a murine 
transplant model (Kroon et al., 2001; Pineault et al., 2003). Interestingly, novel 
NUP98-Hox fusion proteins, which are not found in patients such as NUP98- 
HoxalO and NUP98-Hoxb3, are also leukaemogenic in mouse models (Pineault et 
al., 2004). However, the NUP98-Hoxb4 fusion protein is not. This finding is 
consistent with previous studies in which HoxalO and Hoxb3 but not Hoxb4 are 
leukaemogenic when over-expressed in a murine transplant model (Sauvageau et 
al., 1995; Sauvageau et al., 1997; Thorsteinsdottir et al., 1997). Collectively these 
data suggest that many, but not all, Hox genes are potentially leukaemogenic.
NUP98-Hox fusion proteins induce AML after a long latency which is usually 
monoclonal and preceded by a myeloproliferative disorder. This suggests that 
secondary mutations are required for disease progression. Interestingly, the latency 
of AML onset is dramatically reduced by the co-expression of Meis-1 (Pineault et
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al., 2004). Meis-1 (myeloid ecotropic viral insertion site 1) is a non-Hox 
homeodomain containing transcription factor that acts as a co-factor for Hox 
proteins. It was originally identified as a common site of retroviral integration in 
BXH-2 myeloid leukaemias (Moskow et al, 1995). BXH-2 mice carry an ecotropic 
murine leukaemia virus that acts as an insertional mutagen. Therefore, these mice 
can be used to identify genes which co-operate to induce leukaemia (Moskow et al., 
1995). Retroviral integrations at the Meis-1 locus occurred in approximately 15% of 
BXH-2 leukaemias, of which 95% also contained activating retroviral integrations 
in the Hoxa7 or Hoxa9 genes (Nakamura et al., 1996a). This finding implied that 
Meis-1 co-operates with Hoxa9 or Hoxa7 to induce leukaemia. Indeed, Meis-1 is a 
common collaborator in leukaemogenesis. Although, Meis-1 over-expression alone 
is not sufficient for leukaemogenesis, the over-expression of Meis-1 in concert with 
Hoxa9, HoxalO, Hoxb3, Hoxb4 or Hoxb6 induces AML with a much shorter 
latency than over-expression of these Hox genes alone (Thorsteinsdottir et al.,
1997; Kroon et al., 1998; Thorsteinsdottir et al., 2001; Pineault et al., 2004; 
Fischbach et al., 2005). Meis-1 is required for normal haematopoietic development 
and is thought to play a role in regulating the proliferation or self-renewal of the 
HSC (Hisa et al, 2004).
Since Hox gene over-expression blocks the differentiation of haematopoietic 
progenitor cells (Calvo et al., 2000; Pineault et al, 2004), a current hypothesis is 
that Meis-1 co-operates with this differentiation block by increasing the 
proliferative or self-renewal capacity of these immortalised cells (Pineault et al.,
2005). Consistent with this hypothesis, a recent study found that the over­
expression of Meis-1 in Hoxa9 immortalised progenitor cells activated the 
expression of HSC specific genes such as Flt-3 and CD34 (Wang et al., 2005). This 
finding implies that the over-expression of Meis-1 can convert immortalised 
progenitor cells into leukaemic stem cells. Another study found that the over­
expression of Hoxa9 and Meis-1 protected several myeloid and lymphoid cell lines 
from pro-apoptotic stimuli (Wermuth and Buchberg, 2005). Therefore, Hoxa9 and 
Meis-1 may cooperate to confer a protection from apoptosis which may provide a 
strong selective advantage to cells and ultimately promote leukaemogenesis.
48
1.19 Identification of MLL-fusion protein target genes
Much emphasis has been placed on the role of Hox genes in MLL leukaemias. This 
is because MLL-fusion proteins are thought to de-regulate the expression of wild- 
type MLL target genes and the only known targets of MLL to date are a subset of 
Hox genes.
Gene expression profiling of patient samples
Gene expression profiling of patient material has revealed that leukaemias with 
MLL translocations possess a unique gene expression profile which can distinguish 
them from other myeloid or lymphoid leukaemias lacking MLL translocations 
(Armstrong et al., 2002). High levels of HOXA4, HOXA5, HOXA9, HOXAIO, 
HOXC6, MEIS-1 and PBX-3 expression were observed in MLL rearranged B- 
precursor ALL but not in B-precursor ALL lacking MLL rearrangement (Armstrong 
et al., 2002; Andersson et al., 2005). In addition, HOXA9, HOXAIO, HOXC6 and 
MEIS-1 were differentially expressed in T-lineage ALL with MLL rearrangements 
(Ferrando et al., 2003). High levels of HOXA4, HOXA5, HOXA9, HOXAIO, MEIS- 
1 and PBX-3 have also been reported in MLL rearranged myeloid leukaemias 
(Debemardi et al., 2003; Ross et al., 2004). Therefore, a popular hypothesis is that 
MLL-fusion proteins establish a HOX transcriptional programme, which contributes 
to leukaemogenesis (Armstrong et al., 2003). However, HOXA9 and MEIS-1 are 
frequently co-expressed in AML and are not specific to AML with MLL 
rearrangements. Instead co-activation of HOXA9 and MEIS-1 is a common event in 
AML (Lawrence et al., 1999).
Inducible systems of MLL-fusion gene expression
Although common gene expression signatures can be identified by analysing 
patient samples, it is not possible to discriminate between genes which are targets 
of the MLL-fusion protein and those which are up-regulated as the leukaemic cells 
acquire subsequent mutations. Conditional systems of MLL-fusion protein 
expression are more useful in this respect. The gene expression profile of HPCs 
immortalised by an oestrogen-regulated conditional MLL-ENL fusion protein was 
examined by microarray analysis following treatment with or without tamoxifen 
(Zeisig et al., 2004). Some of the genes down-regulated after the withdrawal of 
tamoxifen (when MLL-ENL was inactivated) were over-expressed in patients with
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MZZ-rearrangements. These included Flt-3, Meis-1, Hoxa9 and Lmo2. Further 
analysis using real-time PCR revealed that Hoxa7 was also expressed in the 
immortalised cell lines and down-regulated when MLL-ENL was inactivated 
(Zeisig et al., 2004). The authors concluded that the genes down-regulated upon 
inactivation of MLL-ENL were targets of MLL-ENL. However, an alternative 
explanation is that the over-expression of Hoxa9 and Meis-1 in MLL-ENL 
immortalised cell lines is a function of the stage of differentiation of the 
immortalised cell. Hence, it is possible that the expression of these genes decreased 
upon the withdrawal of tamoxifen because the immortalised cells differentiated 
upon loss of MLL-ENL expression. Therefore, Hoxa9 and Meis-1 may not 
necessarily be direct targets of MLL-ENL. Similar experiments using HPCs 
immortalised by a conditional MLL dimerisation construct revealed that expression 
of Hoxa7, Hoxa9 and Meis-1 decreased following the withdrawal of dimeriser. 
However, the re-addition of dimeriser resulted in the up-regulation of these genes, 
which suggests that these genes are targets of dimerised MLL (Martin et al., 2003).
In order to determine if Hoxa9 and Meis-1 were targets of MLL-ENL, these genes 
were over-expressed in MLL-ENL immortalised cells and then MLL-ENL was 
inactivated by the withdrawal of tamoxifen (Zeisig et al., 2004). The authors 
proposed that if these genes were targets of MLL-ENL then they should be able to 
substitute for MLL-ENL expression when MLL-ENL was inactivated. The over­
expression of Hoxa9, Hoxa7 or Meis-1 alone was not able to prevent the terminal 
differentiation observed when MLL-ENL was inactivated. In contrast, the co­
expression of Hoxa9 and Meis-1 was sufficient to maintain the immortalised 
phenotype when MLL-ENL was inactivated (Zeisig et al., 2004). Therefore, the 
authors concluded that Hoxa9 and Meis-1 were targets of MLL-ENL. However, 
they failed to account for the fact that the immortalised cell line ‘rescued’ by the 
over-expression of Hoxa9 and Meis-1, possessed a more mature phenotype than 
that of the parental cell line originally immortalised by MLL-ENL. Previous studies 
have shown that the co-expression of Hoxa9 and Meis-1 can immortalise HPCs in 
vitro and in vivo (Calvo et al., 2001; Thorsteinsdottir et al., 2001). Therefore, it is 
possible that alleviation of the differentiation block imposed by MLL-ENL by the 
withdrawal of tamoxifen, allowed the cells to differentiate up to a point at which 
they were susceptible to the differentiation block imposed by Hoxa9 and Meis-1
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and effectively re-immortalised. In this case, over-expression of Hoxa9 and Meis-1 
would not necessarily be substituting for MLL-ENL expression. Similar studies 
have shown that the over-expression of AML1-ETO, PML-RARa, NUP98-Hoxa9, 
Hoxa9, Hoxb8 or Hoxa7 prevented the terminal differentiation of conditional E2A- 
PBX1 myeloid immortalised cell lines upon the withdrawal of tamoxifen (Sykes 
and Kamps, 2001). Importantly, the differentiation block imposed by each 
oncogene was unique and different to that originally imposed by E2A-PBX1 (Sykes 
and Kamps, 2001), which suggests that these oncogenes were not substituting for 
E2A-PBX1 expression.
Aims
The aim of my project was to establish the molecular mechanism by which MLL- 
ENL induces leukaemia. I used retroviral delivery in combination with the Tet-Off 
conditional expression system. I immortalised murine HPCs with MLL-ENL and 
then turned off expression of the fusion protein by the addition of doxycycline 
(dox). This system allowed me to determine whether continued expression of MLL- 
ENL was required to maintain immortalisation in vitro. It also allowed me to 
investigate whether continued expression of MLL-ENL was required to maintain 
the leukaemia in vivo. This was achieved by transferring the immortalised cells into 
mice and administering dox once the mice displayed signs of leukaemia. Finally, 
this system enabled me to identify targets of MLL-ENL and thus establish its 
oncogenic mechanism.
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Chapter 2 Materials and Methods 
Table 2.1 Buffers used in this study.
Buffer Components
Erythrocyte lysis 
buffer 
Stain buffer (flow 
cytometry)
RIP A lysis buffer
NP40 lysis buffer
5 x protein sample 
buffer
1 x running buffer 
1 x transfer buffer 
1 x stripping buffer 
TNES
Denaturing solution
Neutralising 
solution 
5 x probe labelling 
buffer 
Pre-hybridisation 
solution
TE (pH 8.0)
17 mM Tris (pH 7.2); 0.144 M NH4C1
PBS; 0.5% BSA; 0.05% sodium azide
150 mM NaCl; 1% Triton X-100; 0.5% sodium 
deoxycholate; 0.1% SDS; 50 mM Tris (pH 8.0); 5 mM
EDTA
150mM NaCl; 0.5% NP40; 50mM Tris (pH 8.0)
500 mM DTT; 10% SDS; 312.5 mM Tris (pH 6.8); 0.05% 
Bromophenol Blue; 25% Glycerol
0.192 M glycine; 25 mM Tris; 0.1% SDS
9.5 mM CAPS (pH 11.0)
62.5 mM Tris (pH 6.8); 1% SDS; 50 mM 2-mercaptoethanol 
TE (pH 8.0); 0.1 mM NaCl; 1% SDS
1.5 M NaCl; 0.5MNaOH
1 M Tris (pH 7.4); 1.5 M NaCl
0.5 M Na2HP04; 0.5 M NaH2P 0 4; 0.5% 2-ME; 1 mM of 
dATP, dGTP and dTTP 
5 x SSC; 0.5% SDS; 0.1 g/ml dextran sulphate; 5 x 
Denhardt’s solution
10 mM Tris (pH 8.0); 1 mM EDTA (pH 8.0)
2.1 Retroviral constructs
Diagrams of all the constructs described in this section are shown in Figures 2.1 and 
2.2. All of the MLL-fusions were sequenced prior to sub-cloning by Dr. Dale 
Moulding and Dr. Inusha de Silva of the Molecular Haematology and Cancer 
Biology (MHCB) unit. Comprehensive restriction digests of the constructs were 
performed and DNA sequencing around the cloning sites of the MLL-fusion 
constructs confirmed that errors had not been introduced during the sub-cloning 
process.
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pMSCV-tT A-IRES-EGFP
k z ^ z :
5’LTR T + | tTA-l-E
EcoR1 Sail
3’LTR Ampr
pMSCV-neo-mod-tT A-IRES-EGFP
HZZH
5’LTR y + I tTA-l-E I PGK Neor 3’LTR Ampr 
EcoR1 Sail
pREV-TRE-hCD2t (sense orientation)
5’LTR Hygr ITREI hCD2t I 3’LTR Ampr
Xho1 BamH1 C\a1
pREV-TRE-hCD2t (reverse orientation)
—CZHU
5’LTR T + Hygr I hCD2t 'TRE' 3’LTR 
D te l BamHI Xttctl
Ampr
pMSCV-tTS-IRES-EGFP
HZZHU
5’LTR VP+ I tTS-l-E
EcoR1 S t e f
3’LTR Ampr
Figure 2.1 A diagram of the retroviral reporter constructs used in this study.
Restriction sites that are crossed out indicate that the site was destroyed by filling 
in the over-hang with Klenow and by performing a blunt-end ligation. tTA-I-E: 
tTA- (tetracycline transactivator) IRES- (internal ribosome entry site), EGFP- 
(enhanced green fluorescent protein), tTS-I-E: tTS- (tetracycline suppressor)- 
IRES-EGFP, hCD2t: human CD2 tail-less gene, TRE: tetracycline response 
element, LTR: long terminal repeat, 4^: viral packaging signal, PGK: 
phosphoglycerate kinase promoter, Neor: neomycin resistance gene, Hygr: 
hygromycin resistance gene, Ampr: ampicillin resistance gene.
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pREV-TRE-myc-MLL-ENL Cla1
5’LTR V+ Hygr TRE I MLL-ENL I 3’LTR Ampr 
Xho1 BamH1 X b t f l
pMSCV-neo-TRE-myc-MLL-ENL
5’LTR PGK Neor TRE I MLL-ENL I 3’LTR Ampr
XkcrT BamH1 Cla1
pMSCV-neo-mod-myc-MLL-ENL
5’LTR y + I MLL-ENL I PGK Neor 3’LTR Ampr 
EcoR1 Xho1
pMSCV-neo-mod-FLAG-MLL-ENL
5’LTR 4>+ MLL-ENL PGK Neor 3’LTR Ampr
pMSCV-neo-mod-FLAG-MLL-AF4
5’LTR MLL-AF4 PGK Neor 3’LTR Ampr
pMSCV-mod-FLAG-MLL-AF4
5’LTR y + MLL-AF4 3’LTR Ampr
pMSCV-neo-TRE
5’LTR V+ PGK Neor TRE 3’LTR Ampr
Figure 2.2 A diagram of the MLL-fusion gene retroviral constructs used in 
this study. Restriction sites that are crossed out indicate that the site was 
destroyed by filling in the over-hang with Klenow and by performing a blunt-end 
ligation. TRE: tetracycline response element, LTR: long terminal repeat, 'F+: viral 
packaging signal, PGK: phosphoglycerate kinase promoter, Neor: neomycin 
resistance gene, Hygr: hygromycin resistance gene, Ampr: ampicillin resistance 
gene.
54
pMSCV-tTA-IRES-EGFP
pUHT 61-1 (Clontech) was digested with BamHI and EcoRI to release the 0.76 kb 
tetracycline transactivator (tTA) fragment. pMSCV-F5a-IRES-EGFP (constructed 
by Dr. Owen Williams of the MHCB unit) was also digested with these enzymes. 
The tTA cDNA was then sub-cloned directionally into pMSCV-F5a-IRES-EGFP, 
immediately upstream of the F5a T-cell receptor (TCR) cDNA. The F5a cDNA 
was removed from the construct by digesting with BamHI and Notl. The over-hangs 
were filled in with Klenow (Roche) and the vector was re-ligated.
pMSCV-neo-mod-tT A-IRES-EGFP
pMSCV-tTA-IRES-EGFP was digested with EcoRI and Sail to excise the 2.1 kb 
fragment encoding tTA-IRES-EGFP. pMSCV-neo-mod was also digested with 
these enzymes and then the tTA-IRES-EGFP fragment was sub-cloned upstream of 
the phosphoglycerate kinase promoter (PGK) and the neomycin resistance gene 
(Neor). pMSCV-neo-mod is a derivative of pMSCV-neo (Clontech) that contains an 
altered multiple cloning site (MCS). It was constructed by Dr. Inusha de Silva of 
the MHCB unit.
pREV-TRE-hCD2t (sense orientation)
The cDNA of the human tail-less CD2 gene (hCD2t) was amplified by polymerase 
chain reaction (PCR) using pMI-IRES-hCD2t as the template which was the kind 
gift of Dr. M.J Bevan (Department of Immunology, Seattle). An 800 bp fragment 
encoding the hCD2t gene was amplified using a forward primer which incorporated 
a BamHI site and a reverse primer which incorporated a Clal site.
Forward primer: 5 ’-CGGGATCCATGGGCTTTCCATGTAAATTTG-3 ’
Reverse primer: 5 ’-C ATCGATGGCCGCTTAGGAAGTTGCTGG-3 ’. 
Incorporated restriction sites are highlighted in bold. The pREV-TRE vector 
(Clontech) was digested with BamHI and Clal and then the 0.8 kb hCD2t PCR 
product was sub-cloned immediately downstream of the tetracycline response 
element (TRE).
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pREV-TRE-hCD2t (reverse orientation)
pREV-TRE-hCD2t (sense) was digested with Clal. The Clal over-hangs were filled 
in with Klenow and then the vector was digested with^Y/io/to release the 1.2 kb 
fragment encoding TRE-hCD2t. Meanwhile, the pREV-TRE vector was digested 
with Xhol, filled in with Klenow and then digested with Sail. This digestion 
removed TRE and allowed the directional sub-cloning of the 1.2 kb TRE-hCD2t 
fragment downstream of the hygromycin resistance gene (hygr).
pMSCV-tTS-IRES-EGFP
pTet-tTS (Clontech) was digested with Clal. The over-hangs were filled in with 
Klenow and the 0.86 kb tetracycline suppressor (tTS) fragment was excised by 
digestion with EcoRI. Meanwhile, the pMSCV-F5a-IRES-EGFP construct was 
digested with Notl, filled in with Klenow and then digested with EcoRI. This 
digestion removed the F5a cDNA and allowed the directional sub-cloning of tTS 
upstream of the internal ribosome entry site (IRES) and the gene encoding 
enhanced green fluorescent protein (EGFP).
pREV-TRE-myc-MLL-ENL
The pCSARQ2 construct containing the MLL-ENL cDNA (aa 27-1444 of MLL and 
aa 5-559 of ENL) was a gift from D. C. Tkachuk (Princess Margaret Hospital, 
Toronto, Canada (Adler et al., 1997)]. This construct contains 6 myc tags at the 5’ 
end of MLL-ENL and 1 HA tag at the 3’ end. In order to sub-clone MLL-ENL into 
pREV-TRE, pCSARQ2 was digested with Clal and the overhangs were filled in 
with Klenow. The 6.24 kb fragment encoding MLL-ENL was then excised by 
digestion with Xhol. Meanwhile, pREV-TRE was digested with BamHI, filled in 
with Klenow and then digested with Sail. MLL-ENL was then sub-cloned 
directionally into pREV-TRE, immediately downstream of the TRE. The BamHI 
site still exists at the start of MLL-ENL since ligation of a blunted BamHI to a 
blunted Clal site recreated the BamHI site.
pMSCV-neo-TRE-myc-MLL-ENL
pREV-TRE-myc-MLL-ENL was digested with Xhol and Clal to release the 6.7 kb 
TRE-MLL-ENL fragment. pMSCV-neo was digested with Sail and Clal and then 
the TRE-MLL-ENL fragment was sub-cloned downstream of the PGK-Neor.
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pMSCV-neo-mod-myc-MLL-ENL
pCS ARQ2 was digested with Clal and the over-hangs were filled in with Klenow. 
The 6.24 kb MLL-ENL cDNA fragment was then excised by digestion with Xhol. 
pMSCV-neo-mod was digested with EcoRI, filled in with Klenow and then 
digested with Xhol. The MLL-ENL cDNA was then sub-cloned into pMSCV-neo- 
mod upstream of the PGK-Neor. The EcoRI site still exists at the start of MLL-ENL 
since ligation of a blunted EcoRI site to a blunted Clal site recreated the EcoRI site. 
The pMSCV-neo-FLAG-MLL-ENL, pMSCV-neo-FLAG-MLL-AF4 and pMSCV- 
FLAG-MLL-AF4 constructs were made by Dr. Inusha de Silva of the MHCB unit. 
All three of these constructs contained 1 FLAG tag at the 5’ end of MLL-fusion.
The pMSCV-neo-TRE construct was made by Dr. Michelle Morrow of the MHCB 
unit.
2.2 Culture of LinXE and NIH3T3 fibroblast cell lines
The LinXE ecotropic retrovirus packaging cell line, 293T and NIH3T3 cell lines 
were cultured in complete medium (Dulbecco’s Modified Eagle’s medium 
[DMEM, Invitrogen] supplemented with 10% foetal calf serum [FCS] and 2 mM L- 
glutamine). The LinXE cells were maintained in 7.5 pg/ml hygromycin (Cayla) to 
select for the presence of the gag, pol and env genes.
2.3 Transfection of LinXE cells
LinXE cells were seeded at a density of 0.75 x 106 per 10cm plate 3 days prior to 
transfection. Cells were transfected with 8 pg retroviral plasmid DNA using 40 pi 
Lipofectamine (Invitrogen) in a total volume of 8 ml optimum (Invitrogen) 
according to the manufacturer’s instructions.
2.4 Retroviral transduction of NIH3T3 cells
NIH3T3 cells were seeded the day before transduction at a density of 2 x 105 per 
6cm plate. Retroviral supernatant, which was harvested from LinXE cells 48 hours 
after transfection, was cleared of cell debris using a 0.45pm filter. NIH3T3 cells 
were transduced by replacing their media with cleared retroviral supernatant diluted 
1:4 in complete medium supplemented with 5 pg/ml polybrene (Sigma-Aldrich). 
The NIH3T3 cells were then returned to culture overnight. For the co-transductions,
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equal volumes of the two retroviral supernatants were mixed and diluted 1:2 in 
complete medium. After 24 hours the media was changed. The cells were analysed 
for viral protein expression by flow cytometry or western blot 48 hours after 
transduction.
2.5 Determination of viral titre by titration on NIH3T3 cells
NIH3T3 cells were seeded the day before transduction at a density of 5 x 104 cells 
per well of a 6-well plate. Viral supernatant was harvested from LinXE cells as 
previously described and diluted 1:10, 1:1000 or 1:100000 in complete medium. 
NIH3T3 cells were transduced with 2 ml of each virus dilution in the presence of 5 
pg/ml polybrene. The cells were passaged after 24 hours and were reseeded at a 
1:20 dilution into 10cm plates. Antibiotic selection was added to the cells 48 hours 
after transduction. 1 mg/ml G418 (Invitrogen) was used to select for cells 
transduced with pMSCV-neo and 250 pg/ml hygromycin (Cayla) was used to select 
for cells transduced with pREV-TRE. Fresh media and selection was added to the 
plates 5 days after selection was initiated. The number of colonies on each plate 
was counted 12 days after transduction. In order to count the colonies, the plates 
were washed in PBS and the colonies were visualised by staining with 1.7 mg/ml 
methylene blue (Sigma-Aldrich) in Methanol. The viral titre was calculated using 
the following formula:
Viral titre (infectious particles / ml) = number of colonies x dilution factor
2
2.6 Isolation of haematopoietic progenitor cells (HPCs)
HPCs were isolated from mice which were maintained in the animal facilities of the 
National Institute for Medical Research. All experiments were performed according 
to institutional guidelines and Home Office regulations.
i) Foetal HPCs
c-Kit+ Ter-119' or c-Kit+ Sca-1+ HPCs were purified by Dr. Owen Williams from
embryonic day 12 (E l2) foetal liver of C57BL/10 mice by fluorescence activated
cell sorting (FACS) using a MoFlo sorter (DakoCytomation) and monoclonal 
antibodies (mAh) specific to c-Kit and Ter-119 or Sca-1 (Table 2.2).
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ii) Adult HPCs
Bone marrow was extracted by Dr. Owen Williams from 4-6 week old C57BL/10 
or C57BL/6 mice 5 days after the injection of 150 mg/kg of 5-fluorouracil (5-FU) 
into the lateral tail vein. A single cell suspension was made from the marrow of the 
femur and tibia and the red cells were lysed in 2 ml of erythrocyte lysis buffer for 
10 minutes at room temperature. In some experiments HPCs were purified by 
magnetic activated cell sorting (MACS) using MACS separation columns (Miltenyi 
Biotech) and monoclonal antibodies specific to c-Kit (Table 2.2). In other cases, 
lineage depleted cells were isolated by MACS using a lineage panel kit which 
consisted of a CD3 (145-2C11), a Mac-1 (Ml/70), a B220 (RA3-6B2), a Gr-1 
(RB6-8C5), a Ter-119 (BD Pharmingen).
Foetal HPCs were seeded at a density of 2 x 105/ml and unsorted adult HPCs were 
seeded at a density of 1 x 106/ml. HPCs were stimulated overnight in complete 
medium supplemented with 50 pM 2-mercaptoethanol (2-ME) (BDH), 100 ng/ml 
stem cell factor (SCF), 10 ng/ml interleukin-6 (IL-6) and 10 ng/ml interleukin-3 
(IL-3). In some experiments the complete medium was supplemented with 20 ng/ml 
interleukin-7 (IL-7) and 10 ng/ml fins-like tyrosine kinase-3 ligand (Flt-3L), instead 
of IL-3 and IL-6. All recombinant murine growth factors were supplied by 
Peprotech EC.
2.7 Transduction of haematopoietic progenitor cells
Retroviral supernatant was harvested as described previously. HPCs were 
transduced on two consecutive days. Complete medium was added to the LinXE 
cells after the first virus harvest and fresh virus was collected from the same culture 
the following day. The retroviral supernatant was concentrated 10-fold in some 
experiments. The supernatant was cleared of cell debris by 2 rounds of 
centrifugation at 580g for 5 minutes. Cleared virus was then aliquotted into 1.5ml 
eppendorf tubes and concentrated by centrifugation for 1 hour at 16,000g. HPCs 
were transduced at a density of 104 cells per well of a 96-well flat-bottomed plate.
A total of 6 wells were set up for each condition and 6 x 104 HPCs were transduced 
with a total of 600 pi virus unless otherwise stated. The viral supernatant was 
supplemented with 20% FCS, 50 pM 2-ME, 5 pg/ml polybrene, 100 ng/ml SCF, 10
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ng/ml IL-3 and 10 ng/ml IL-6. In some experiments the cells were stimulated prior 
to transduction with SCF, IL-7 and Flt-3L (section 2.6). In these experiments, the 
viral supernatant was supplemented with 50 pM 2-ME, 5 pg/ml polybrene, 100 
ng/ml SCF, 20 ng/ml IL-7 and 10 ng/ml Flt-3L. The cells were transduced by 
spinoculation (centrifugation at 700 g, 25°C, 45 minutes) and then returned to 
culture. The transduction was repeated after 24 hours, 60 pi of medium was 
removed from each well and replaced with 100 pi of fresh viral supernatant and 
growth factors. After culture overnight, the transduced HPCs were used for colony 
forming assays.
2.8 Colony forming cell assays
Approximately 24 hours after the second transduction, the 6 wells of transduced 
cells were pooled, washed in 5 ml Minimal Essential-Alpha Media (MEM) 
(Invitrogen) and resuspended in 100 pi MEM. For the myeloid assays the cells were 
added to 3 ml of methylcellulose (M3434) (Stem cell Technologies Inc.), 
containing IL-3, IL-6 and SCF which was supplemented with 10 ng/ml GM-CSF 
(Peprotech). For the B cell assays, the cells were added to 2.4 ml methylcellulose 
(M3231) (Stem cell Technologies Inc.) which was supplemented with 100 ng/ml 
SCF, 20 ng/ml IL-7 and 10 ng/ml Flt-3L. Selection was employed in the first round 
of methylcellulose plating. 1 mg/ml G418 (Invitrogen) was used to select for cells 
transduced with pMSCV-neo constructs and 1.5 mg/ml hygromycin (Cayla) was 
used to select for cells transduced with pREV-TRE constructs. The volume of 
methylcellulose containing the cells, antibiotic and growth factors was made up to 
3.3 ml with MEM. The components were then mixed thoroughly and 1.1 ml was 
aliquotted into duplicate 35mm plates according to the manufacturer’s instructions. 
Duplicate methylcellulose cultures were placed in 10cm plates and cultured for 6- 
10 days alongside a 35mm plate containing PBS to humidify the cultures.
After 6-10 days, colonies containing 50 cells or more were scored. The cells were 
harvested from the methylcellulose by the addition of 1 ml MEM to each plate, 
followed by gentle pipetting to create a single cell suspension. The cells from 
duplicate methylcellulose cultures were pooled and washed in 10 ml MEM 
containing 2% FCS. The cells were counted and 1 x 104 cells were replated into
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secondary assays under identical conditions but in the absence of antibiotic 
selection. This process was repeated every 7-10 days. In some cases 2 pg/ml 
doxycycline (BDH) was added in subsequent rounds. Colonies were stained with 1 
mg/ml p-iodonitrotetrazolium (INT) (Sigma-Aldrich) in PBS.
2.9 Generation of cell lines in liquid culture
Cells harvested from the fourth round of the myeloid colony forming assays were 
seeded at a density of 1 x 105 cells/ml in RPMI-1640 (Invitrogen) with 10% FCS, 2 
mM L-glutamine and 50 pM 2-ME supplemented with 100 ng/ml SCF, 10 ng/ml 
IL-6 and 10 ng/ml IL-3. Cells harvested from the fourth round of the B cell colony 
forming assays were seeded at a density of 1 x 105 cells/ml in RPMI-1640 with 
10% FCS, 2 mM L-glutamine and 50 pM 2-ME supplemented with 100 ng/ml SCF, 
20 ng/ml IL-7 and 10 ng/ml Flt-3L.
2.10 Flow cytometry
Cells were washed in PBS / 0.05% sodium azide and pre-incubated with 100 pi 
stain buffer containing unlabelled anti-Fcy III/II Receptor mAb for 15-30 minutes. 
Following this blocking step, the cells were washed and each subsequent stain was 
performed for 30 minutes in a total volume of 100 pi stain buffer containing the 
appropriate antibody. For the reporter gene experiments, NIH3T3 cells or HPCs 
were stained with biotin-conjugated mAb specific for CD2. In other experiments, 
HPCs were stained with phycoerythrin (PE)-, allophycocyanin (APC)-, biotin- or 
fluorescein isothiocyanate (FITC)- conjugated mAbs specific for various markers of 
cellular differentiation (Table 2.2). Biotin-conjugated mAb were visualised using 
Streptavidin-PE or Streptavidin-Tricolour (Streptavidin-TC). Flow-cytometry was 
performed using either a Beckman Coulter Epics XL analyser and EXP03 software 
(Beckman Coulter) or a Cyan ADP analyser and Summit 4.1 software 
(DakoCytomation).
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Table 2.2 Flow cytometry antibodies used in this study.
Antibody Clone Isotype Supplier Workingdilution
Anti- Fey III/II 2.4G2 I§G2b k BD Pharmingen 1:100
Anti-CD2 Bio LFA2 IgG2b X BD Pharmingen 1:100
Anti-cKit PE 2B8 IgG2b k BD Pharmingen 1:100
Anti-cKit FITC 2B8 IgG2b k BD Pharmingen 1:100
Anti-Sea-1 PE D7 IgG2a k BD Pharmingen 1:100
Anti-Mac-1 PE Ml/70 IgG2b K BD Pharmingen 1:100
Anti-Mac-1 FITC Ml/70 IgG2bK eBioscience 1:100
Anti-Gr-1 PE RB6-8CS IgG2b K BD Pharmingen 1:200
Anti-Gr-1 APC RB6-8CS IgG2bK eBioscience 1:100
Anti-CD43 PE S7 lgG2a k BD Pharmingen 1:500
Anti-Terl 19 PE T erll9 IgG2b k BD Pharmingen 1:100
Anti-F4/80 PE F4/80 IgG2a k Caltag 1:100
Anti-B220 PE RA3-6B2 IgG2a k BD Pharmingen 1:100
Anti-CD 19 PE 1D3 lgG2a k BD Pharmingen 1:100
Anti-BP 1 Bio 6C3 IgG2a k eBioscience 1:100
Anti-CD45.2 Bio 104 IgG2a k eBioscience 1:100
Anti-IgG2A PE G155-178 IgG2a k BD Pharmingen 1:100
Anti-IgG2B PE MPC-11 IgG2b K BD Pharmingen 1:100
Streptavidin PE N/A N/A BD Pharmingen 1:250
Streptavidin TC N/A N/A Caltag 1:100
2.11 In vivo leukaemogenicity assays
NOD/SCID mice were maintained in the animal facilities of the Institute of Child 
Health and all experiments were performed according to institutional guidelines and 
Home Office regulations. 106 immortalised cells were resuspended in 300 pi of 
Hanks balanced saline solution (HBSS) (Invitrogen) buffered with 10 mM Hepes 
(Invitrogen). The cells were then injected into the intraperitoneal cavity of 6-8 week 
old NOD/SCID mice by Dr. Owen Williams. The peripheral blood of these mice 
was analysed for the presence of leukaemic cells at regular intervals two months
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after transfer. Approximately 100 pi of peripheral blood was collected by Dr. Owen 
Williams from the lateral tail vein following a small incision and mixed 
immediately with 20 USP units/ml of Heparin (Sigma Aldrich) to prevent it from 
clotting. The red cells were lysed in erythrocyte lysis buffer, washed with PBS / 
0.05% sodium azide and stained with the Mac-1-PE-conjugated mAb (Table 2.2). 
Mice were sacrificed when they showed more than two moderate symptoms of 
illness such as weight-loss, marked piloerection, subdued behaviour or hunched 
posture. Single cell suspensions were then made from their bone marrow, spleen
A 7and lymph nodes. In some cases, 2 x 1 0  to 10 splenocytes were resuspended in 
200 pi HBSS /10  mM Hepes and injected into the intraperitoneal cavity of 
secondary recipients. Approximately 500 pg of dox was injected into the 
intraperitoneal cavity of some of the primary recipient mice by Dr. Owen Williams. 
The following day these mice were administered 2 mg/ml dox and 2.5% sucrose in 
the drinking water.
2.12 Cytokine induced differentiation of the cell lines
Differentiation of the cell lines was performed in RPMI-1640 with 10% FCS, 2 mM 
L-glutamine and 50 pM 2-ME supplemented with either 10 ng/ml granulocyte 
colony-stimulating factor (G-CSF) or 10 ng/ml macrophage colony-stimulating 
factor (M-CSF).
2.13 Cytopsin analysis of cellular morphology
Approximately 3 x 104 cells were washed in PBS and resuspended in 100 pi PBS. 
Cells were centrifuged onto slides at 35g for 5 minutes at low deceleration using a 
cytospin 3 machine (Shandon). The slides were then fixed and stained with May- 
Grunwald-Giemsa (MGG) using a Shandon varistain 24-4 automated staining 
machine in the Haematology department at Great Ormond Street Hospital.
2.14 Histological analysis of murine tissue
The liver and kidney from moribund mice were fixed in formalin (Sigma Aldrich). 
These tissues were then sectioned and stained with hematoxylin and eosin by Dr. 
Neil Sebire of the histopathology department at Great Ormond Street Hospital.
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2.15 MTS assay
Cells were seeded at a density of between 103 to 104 cells per well of a flat- 
bottomed 96-well plate depending on the rate of proliferation of the cell line. The 
cells were cultured in RPMI-1640 with 10% FCS, 2 mM L-glutamine and 50 pM 2- 
ME supplemented with various combinations of cytokines. These included 100 
ng/ml SCF, 10 ng/ml IL-3, 10 ng/ml IL-6, 10 ng/ml GM-CSF, 10 ng/ml G-CSF, 10 
ng/ml M-CSF, 20 ng/ml IL-7 and 10 ng/ml Flt-3L. After a specified period of 
culture, CellTiter 96® A q ue0us One Solution Reagent (Promega) was added to each 
well according to the manufacturer’s instructions. The plates were wrapped in foil 
and returned to culture for 4 hours. After this time the cell viability was measured 
by reading the absorbance at 490nm using a 550 Biorad plate-reader.
2.16 Preparation of cellular extracts for Western blot
Adherent cells from confluent 6cm plates and 1-5 x 106 immortalised cells were 
washed in PBS and then lysed on ice for 10 minutes. Adherent cells were lysed 
using either 240 pi RIP A buffer containing 10 pg/ml Aprotinin, 250 pg/ml PMSF, 
10 pg/ml Leupeptin and 10 pg/ml Pepstatin A or 240 pi NP40 buffer containing 1 x 
complete protease inhibitor tablets (Roche). Immortalised cells were lysed using 60 
pi NP40 buffer containing 1 x protease inhibitor tablets. DNA was pelleted by 
centrifugation at 16000g for 10 minutes at 4°C. The supernatant containing the 
protein extract was mixed with 1 x sample buffer and then the lysate was snap- 
frozen and stored at -20°C until it was analysed by Western blot.
2.17 Western blot analysis of protein expression
Lysates were boiled at 100°C for 5 minutes and then 20pl was loaded onto 6 % 
SDS-polyacrylamide gels along with 10 pi Rainbow™ molecular weight marker 
(Amersham Pharmacia). The 6% resolving gel and 4% stacking gel were prepared 
according to standard protocols. Electrophoresis was performed for 16 hours at 40V 
in 1 x running buffer. Protein was then transferred to a PVDF membrane 
(Immobilon-P, Millipore) for 5 hours at 0.5A in 1 x transfer buffer. Membranes 
were blocked in PBS with 5% non-fat milk and 0.2% tween-20. MLL-ENL fusion 
proteins were visualised by staining with anti-myc, anti-HA, anti-FLAG or anti- 
MLL antibodies (Table 2.3). Proteins were detected using the appropriate
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secondary horse radish peroxidase (HRP)-conjugated antibody (Table 2.3), and a 
chemiluminescent Reagent (ECL, Amersham Biosciences) according to the 
manufacturer’s instructions. Membranes were stripped in 1 x stripping buffer, the 
blocking step was repeated and the membranes were re-probed with anti-alpha 
tubulin as a loading control.
2.18 Isolation of genomic DNA from cells
5-10 x 106 cells were washed in PBS and lysed overnight in 400 pi TNES 
containing 0.5 mg/ml proteinase K (Roche) at 37°C. Genomic DNA was extracted 
using Phenol-Chloroform-Isoamylalcohol (Sigma-Aldrich). The lysate was mixed 
with 0.5 ml of Phenol-Chloroform-Isoamylalcohol (25:24:1) by shaking vigorously 
for 1 minute. The phases were separated by centrifugation at 16000g for 5 minutes 
and the supernatant was transferred to a tube containing 1 ml ethanol:3M NaOAc 
(25:1). The DNA was precipitated by freezing on dry ice for 2 hours, pelleted by 
centrifugation at 16000g for 10 minutes and then washed in 70% ethanol. The DNA 
was vacuum dried and dissolved in 100 pi TE (pH 8.0).
Table 2.3 Western antibodies used in this study.
Antibody Clone Supplier Workingdilution
Mouse anti-Myc 9E10 Roche 1:400
Mouse anti-Myc 9B11 Cell signalling technologies 1:1000
Mouse anti-Flag M2 Sigma Aldrich 1:800
Rat anti-HA 3F10 Roche 1:500
Mouse anti-MLL N4.4 Dr. M.L Cleary, Stanford. 1:3
Rat anti-tubulin YL1/2 Serotec 1:1000
Sheep anti-mouse HRP N/A Amersham Biosciences 1:2000
Sheep anti-rat HRP N/A Serotec 1:2000
2.19 Southern blot analysis of DNA
Southern blotting was performed according to standard protocols. Briefly, 10 pg of 
genomic DNA was digested with 44 units EcoRI in the presence of 40 pg/ml BSA
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and 10 pg RNase overnight. Digested DNA was resolved on a 0.8% agarose gel for 
16 hours at 35V. The DNA was denatured by soaking the gel in denaturing solution 
for 45 minutes. Following this, the gel was washed in water, soaked in neutralising 
solution for 40 minutes and then washed in 10 x SSC (National Diagnostics). DNA 
was transferred onto a nylon-based membrane (genescreen, NEN Lifescience) 
overnight by capillary transfer according to standard wet-blotting protocols. The 
membrane was then baked for 2 hours at 80°C in order to fix the DNA onto the 
membrane.
A hybridization probe was prepared by digesting pCSARQ2 with Hindlll. This 
digest released a 2.1 kb cDNA fragment which contains N-terminal MLL sequence. 
This fragment was isolated and gel purified for use in probing the membrane. The 
probe (100 ng) was denatured at 94°C for 10 minutes and then labelled with [ P] 
a-dCTP using random primer labelling. The components of the labelling reaction 
were 1 x labelling buffer, 100 ng hexanucleotide primers (Sigma-Aldrich), 0.4 
mg/ml BSA, 20 mM MgCE, 5 units Klenow (Promega), 100 ng denatured probe 
and 1.11 MBq 32P dCTP. The labelling reaction was carried out at 37°C for 2 hours 
and then stopped by the addition of 0.1% SDS in TE. The probe was purified using 
Sephadex G50 columns equilibrated with 0.1 M EDTA. The probe was eluted from 
the column by centrifugation at 390g for 3 minutes into 1 M NaOH to denature the 
probe. The probe was then neutralised by the addition of 2 M Tris (pH 8.5).
The membrane was blocked prior to hybridisation by incubation with pre­
hybridisation solution containing 0.5 mg/ml salmon sperm DNA (Sigma-Aldrich) 
for 2 hours at 65°C. After this time, the probe was added and allowed to hybridise 
to the membrane overnight at 65°C. The membrane was then washed twice in 2 x 
SSC / 0.1% SDS at 55°C and bands were visualised using a Typhoon 
phosphorimager (Amersham Biosciences).
2.20 Isolation of total RNA from cells
3-6 x 106 cells were lysed in 1 ml of Trizol (Invitrogen). The lysate was mixed with 
0.2 ml chloroform by shaking vigorously for 15 seconds and then incubated at room 
temperature for 15 minutes. Phases were separated by centrifugation at 12000g for
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15 minutes at 4°C. The upper aqueous phase was isolated, mixed with 0.5 ml 
isopropanol and incubated at room temperature for 10 minutes. The RNA was 
precipitated by centrifugation at 12000g for 10 minutes at 4°C and washed in 70% 
ethanol. The RNA was then air-dried and re-suspended in 30 pi diethyl 
polycarbonate (DEPC) treated H2O (Invitrogen).
2.21 cDNA synthesis
4 - 10 fig of RNA was treated with 2 units of DNase I (Invitrogen) for 15 minutes at 
22°C to degrade genomic DNA. The DNase was then neutralised using 2.5mM 
EDTA (Invitrogen) and heat inactivated at 65°C for 5 minutes. Reverse 
transcription was performed using Moloney murine leukaemia virus reverse 
transcriptase (MMLV-RT) at a concentration of 105 U/mL, in the presence of 0.5 
mM dNTP, 5 x 103 U/mL RNase Inhibitor and 50 pM random hexamer primers (all 
Invitrogen) at 37°C for two hours. Negative controls contained equimolar quantities 
of all the reactants except the MMLV-RT enzyme.
2.22 Polymerase Chain Reaction (PCR)
The MLL-ENL transcript was detected by PCR amplification of cDNA using 
primers that span the MLL-ENL breakpoint. Two MLL primers and 1 ENL primer 
were designed:
MLL forward primer 1:5’ CAGAATCTACAATGGATGCC 3’
MLL forward primer 2: 5’ CCGCCAAGAAAAGAAGTTCCC 3’
ENL reverse primer: 5’ GGACAAACACCATCCAGTCG 3’.
The first MLL primer and the ENL primer generate a PCR product of 846 bp.
These primers were used in chapter 4. The second MLL primer and the ENL primer 
generate a PCR product of 490 bp. These primers were used in chapter 5.
Other primers used were:
GM-CSFR forward primer: 5’ GGAGACCCGCCTCGCCTTCC 3’
GM-CSFR reverse primer: 5’ ACTCGCACGTCGTCGGACAC 3’
G-CSFR forward primer: 5’ ACAGGAGTGTGAACTTCGCT 3’
G-CSFR reverse primer: 5’ TTGCTTCTTCTGACACCACG 3’
M-CSFR forward primer: 5’ ATGAGTCCCTCTTCACTCCG 3’
M-CSFR reverse primer: 5’ ACCTTCAGCACTGCATCTTC 3’
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PCR was performed using 250 ng cDNA, 0.625 units Taq DNA polymerase (AB 
gene), 0.2 mM dNTPs (Ammersham Pharmacia), 1.5 mM MgCb and 25 pmol of 
each primer. The reaction was comprised of 35 cycles. An initial denaturation step 
was performed at 94°C for 5 minutes. Each cycle was composed of three steps: a 
denaturation step at 94°C for 30 seconds, an annealing step at 50°C for 1 minute 
and an elongation step at 72°C for 1 minute.
2.23 Real-time Quantitative PCR (Q-PCR)
Q-PCR was carried out using TaqMan™ probe-based chemistry (Applied 
Biosystems). This chemistry utilizes a fluorogenic oligonucleotide probe consisting 
of a 5’ reporter and a 3’ quencher that anneals specifically between the forward and 
reverse primers. Global Hox gene expression profiling was carried out by D. Grier, 
G. McGonigle, A. Thompson and T. Lappin, Queen’s University, Belfast. This 
analysis allowed the absolute Hox gene copy number to be determined. In other 
experiments, pre-designed probe and primer sets (Applied Biosystems) were used 
to examine the relative expression levels of the Hox co-factor genes and Flt-3. All 
data was normalised to 18S rRNA expression. Quadruplicate Q-PCR reactions were 
carried out in 96-well plates in a total volume of 20 pi using 5 ng cDNA, 1 x 
TaqMan fast universal PCR mastermix (Applied Biosystems) and 1 x probe / 
primer set. An initial incubation at 95 °C for 20 seconds activated the Amplitaq 
Gold™ DNA polymerase. The amplification reaction consisted of 40 cycles and 
each cycle was composed of 2 steps, a denaturation step at 95°C for 1 second and 
an annealing / extension step at 60°C for 20 seconds. The amplifications were 
performed using an ABI Prism 7900HT fast Sequence Detection System (Applied 
Biosystems) and data was analysed using Sequence Detector v 2.2.2 software 
(Applied Biosystems).
2.24 The design of a Q-PCR assay to determine MLL-ENL transcript 
expression
In order to measure MLL-ENL transcript expression by Q-PCR, two primers and a 
probe were designed using Primer express software (Applied Biosystems). The 
primers flanked the MLL-ENL breakpoint and the probe was designed such that it 
spanned the breakpoint:
Forward primer: 5’ CAGGGTGGTTTGCTTTCTCTGT 3’
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Reverse primer: 5’ GCGATGCCCCAGCTCTAA 3’
Probe: 5’ TGGACGGTGCACTCTACATGCCCACTA 3’
These sequences were submitted to Applied Biosystems who then synthesised the 
primers and probe. The 5’ reporter of the probe was 6-carboxyfluorescein (FAM) 
and the 3’ quencher was 6-carboxy-tetramethylrhodamine (TAMRA). In order to 
determine the optimum concentration of each primer, Q-PCR reactions were set up 
using various combinations of concentrations of the two primers (50 nM to 900 
nM). The reactions were carried out using 50 ng cDNA (prepared from total RNA 
isolated from TRE-ME2), 50 nM of probe and 1 x TaqMan universal PCR 
mastermix. An initial incubation step at 50°C allowed uracil-N-glycosylase (UNG) 
to remove contaminating PCR products. This was followed by incubation at 95°C 
for 10 minutes to inactivate the UNG enzyme and activate the Amplitaq Gold™ 
DNA polymerase. The amplification reaction consisted of 40 cycles and each cycle 
was composed of 2 steps, a denaturation step at 95°C for 15 seconds and an 
annealing / extension step at 60°C for 1 minute. All optimisation reactions were 
carried out in quadruplicate using the ABI 7000 Sequence Detection System and 
associated software (version 1.2) (Applied Biosystems). The results of this 
optimisation step are shown in the appendix (Figure A.l A). During the exponential 
phase of the amplification, a fluorescence signal threshold is set at which point all 
the reactions can be compared. The threshold cycle (Cj) value is the number of 
PCR cycles required to generate sufficient fluorescent signal to reach this threshold 
(Ginzinger, 2002). The fluorescent signal (Rn) value is greatest at the end of the 
exponential phase of the amplification. Hence, the longer the exponential phase of 
the reaction, the greater the accumulation of fluorescent signal and the higher the 
Rn value. The optimum primer concentrations were 900 nM of the forward primer 
(900f) and 300 nM of the reverse primer (300r). This combination was optimal 
since it produced the lowest C j value (Figure A.l A) and the highest Rn value (data 
not shown).
Having optimised the primer concentrations, the optimum probe concentration was 
determined by setting up Q-PCR reactions using different concentrations of probe 
(25 nM to 225 nM). The reactions were carried out using 50 ng cDNA, 900 nM of 
the forward primer, 300 nM of the reverse primer and 1 x TaqMan universal PCR 
mastermix. The results of this optimisation step are shown in the appendix (Figure
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A. IB). The optimum concentration of probe was 150 nM since this was the lowest 
concentration used which did not affect the Ct value.
In order to examine whether the Q-PCR reaction was efficient at low and high 
cDNA concentrations, a standard curve was generated. Q-PCR reactions were set 
up using various concentrations of cDNA (3.125 ng to 100 ng) in the presence of 
900 nM of the forward primer, 300 nM of the reverse primer, 150 nM probe and 1 x 
TaqMan universal PCR mastermix. In order to analyse the MLL-ENL Q-PCR data 
using the 2'AACT relative quantitation method (Livak and Schmittgen, 2001), it is 
important to ensure that the MLL-ENL and GAPDH (endogenous control) Q-PCR 
reactions are equally efficient. Therefore, a standard curve was also generated for 
GAPDH. Reactions were set up using various concentrations of cDNA (3.125 ng to 
100 ng), 1 x GAPDH probe and primer set (optimised by the manufacturer [Applied 
Biosystems]) and 1 x Taqman universal PCR mastermix. The MLL-ENL and 
GAPDH standard curves are shown in the appendix (Figure A.2). The correlation 
co-efficients of the MLL-ENL and GAPDH standard curves were 0.9969 and 
0.9961, respectively. Therefore, the MLL-ENL and GAPDH Q-PCR assays are 
reproducible at high and low cDNA concentrations. The efficiency of each reaction 
was calculated using the formula:
PCR efficiency = (10(1/'s))-l (Ginzinger et al, 2002), where s is the gradient of the 
standard curve. The efficiency of the MLL-ENL reaction was 103% and that of 
GAPDH was 109%. Since the efficiencies were comparable, the 2‘AACT relative 
quantitation method was used to determine the relative level of MLL-ENL 
expression.
2.25 Affymetrix gene chip arrays
RNA was prepared from 3 conditional cell lines and 1 constitutive cell line 
following treatment with or without dox. The integrity of the RNA was determined 
using the Agilent 2100 Bioanalyser (Agilent Technologies) according to the 
manufacturer’s instructions. The ratio of 28S:18S ribosomal RNA in each sample 
was between 1.6 and 2. This indicates that the RNA was not degraded and was of a 
high quality. A representative electopherogram and densitometry plot is shown in 
Figure A.3. The concentration and purity of the RNA were determined using the 
ND-1000 spectrophotometer (Nanodrop). The A26o'A28o ratio of each RNA sample 
was between 1.8 and 1.9. Therefore, the RNA samples were of a sufficiently high
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quality and purity to proceed with the cDNA synthesis reaction. cDNA was 
synthesised using the Roche Microarray cDNA synthesis kit according to the 
manufacturer’s instructions. All subsequent steps were performed using Affymetrix 
reagents according to the instructions in the Affymetrix expression analysis 
technical manual. Briefly, 5 pg of RNA was reverse transcribed using a T7- 
Oligo(dT) promoter primer in the first-strand cDNA synthesis reaction. The second 
strand cDNA synthesis reaction was then carried out following the removal of 
hybridised RNA using RNase H. The double-stranded cDNA product was purified 
and used as a template for the in vitro transcription (IVT) reaction. Biotinylated 
complimentary RNA (cRNA) was amplified in the IVT reaction using T7 RNA 
polymerase and a biotinylated ribonucleotide analogue mix. The biotinylated cRNA 
was then purified, fragmented and hybridised to GeneChip® Mouse Genome 430 
(version 2) arrays (Affymetrix). Following hybridisation, the arrays were washed 
and stained with streptavidin phycoerythrin using a Fluidics Station (FS450) 
(Affymetrix). The fluorescence was amplified by adding a biotinylated anti- 
streptavidin antibody and more streptavidin phycoerythrin. The arrays were then 
scanned following excitation at 570 nm using a GeneChip Scanner (GCS3000) 
(Affymetrix). This process is summarised in Figure 2.3.
Affymetrix microarray suite 5 (MAS5) was used to quantitate expression levels for 
each gene. The arrays are designed such that for every probe on the array, there is 
also a mismatch probe that differs from the perfect match probe by one nucleotide. 
By comparing the level of hybridisation of the perfect match and the corresponding 
mismatch probes to the target sequence, it was possible to assign a detection call of 
present or absent for each gene. Since there are multiple probe pairs within each 
probe set, a detection algorithm was used to generate a detection p value which 
reflects the confidence of the detection call for that probe set. A signal value was 
then determined for each gene after correction for non-specific signal by subtraction 
of the mismatch probe value. In order to compare gene signals across multiple 
arrays, a scaling factor was determined for each array. The total signal of each array 
was averaged and the scaling factor required to adjust the average signal of each 
array to an arbitrary target of 100 was calculated. The signal values of each array 
were then multiplied by the appropriate scaling factor. The scaling factor of each 
array was within 3 standard deviations of the mean. Therefore, gene signals across
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Figure 2.3 Overview of the steps undertaken to analyse gene expression by 
microarray. Adapted from the Affymetrix expression analysis technical manual.
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each array could be directly compared. The data was analysed using GeneSpring 
version 7.2 software (Agilent Technologies). The 6 conditional arrays were 
normalised to each other by normalising the median total signal of each array (per 
chip normalisation) and the median signal of each gene (per gene normalisation). 
The three conditional cell lines were grouped as replicates so that pairwise 
comparisons of the samples treated with or without dox could be made to identify 
differentially expressed genes. The data was filtered by selecting for genes which 
were present with a detection p-value (calculated using the detection algorithm by 
MAS5) of less than 0.1 in all 6 arrays. The data was filtered further by selecting for 
genes whose expression level changed more than 1.3-fold upon treatment with dox. 
A Welch t-test was then used to identify genes which were changed significantly in 
the conditional cell lines upon dox treatment. In order to compare the fold changes 
in gene expression of the constitutive and conditional cell lines, the per chip and per 
gene normalisations were repeated so that the 2 constitutive arrays could be 
normalised to the 6 conditional arrays. The fold change in expression of every gene 
that was significantly changed upon dox treatment in the conditional cell lines 
could then be determined in the constitutive cell line.
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Chapter 3 Delivery of two retroviral constructs that enable 
conditional protein expression in target cells.
The Tet-Off conditional expression system is comprised of two components. The 
first component is the tetracycline transactivator (tTA) which is a fusion of the Tet 
repressor (TetR) and the activation domain of the herpes simplex virus VP 16 
protein. The second component is the tetracycline response element (TRE) which is 
upstream of the gene to be over-expressed. The TRE contains seven direct repeats 
of the tetracycline resistance operon (TetO), upstream of a minimal CMV promoter 
which can be bound by the tTA (Gossen and Bujard, 1992).
In order to assess the efficacy of using two retroviral vectors to deliver this 
expression system to target cells, pMSCV-tTA-IRES-EGFP and pREV-TRE-hCD2t 
retroviral reporter constructs were made. The internal ribosome entry site (IRES) 
allows the translation of two proteins from a bicistronic mRNA. Since tTA is linked 
via an IRES to the enhanced green fluorescent protein (EGFP), target cells 
successfully transduced with the tTA expression vector can be identified based on 
their EGFP expression profile. In the absence of doxycycline (dox), tTA binds to 
the TRE and activates transcription of the human tail-less CD2 (hCD2t) gene 
(Figure 3.1). In the presence of dox, the antibiotic binds to tTA and causes a 
conformational change such that tTA is no longer able to bind to the TRE and 
activate transcription of the CD2 gene. These reporters were used to optimise dual 
transduction of NIH3T3 fibroblast cells and ultimately haematopoietic progenitor 
cells (HPCs), the target cells for transformation with MLL-ENL expression 
constructs.
3.1 Optimisation of NIH3T3 cell transduction with two retroviral constructs.
A series of NIH3T3 transductions were performed in order to determine the 
optimum conditions for dual transduction with two retroviral reporter constructs. 
NIH3T3 cells were transduced with pMSCV-tTA-IRES-EGFP and then at various 
time points after the initial transduction (6 hours, 19 hours and 29 hours), with 
pREV-TRE-hCD2t. In addition, cells were simultaneously co-transduced with both 
retroviral constructs. The optimum transduction conditions were determined by
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pMSCV-tTA-IRES-EGFP
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5’LTR ¥ + tTA
IRES-EGFP
O'3’LTR Ampr
5’LTR T + Hygr TRE hC D2t 3’LTR Ampr
pREV-TRE-hCD2t
Figure 3.1 The use of two retroviral reporter constructs to deliver the Tet- 
Off system to target cells. In the absence of doxycycline (dox) tTA binds to the 
TRE and activates expression of the CD2 gene. In the presence of dox tTA 
undergoes a conformational change such that it is no longer able to bind to the 
TRE and therefore CD2 is not expressed. LTR: long terminal repeat, v|/+: viral 
packaging signal, tTA: tetracycline transactivator, Ampr: ampicillin resistance 
gene, Hygr: hygromycin resistance gene, IRES: internal ribosome entry site, 
EGFP: enhanced green fluorescent protein, hCD2t: human tail-less CD2.
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measuring EGFP and CD2 expression approximately 48 hours after the second 
transduction was performed, by flow cytometry. Maximum co-expression of EGFP 
and CD2 was obtained when the cells were simultaneously transduced with both 
retroviral constructs (data not shown).
3.2 Conditional reporter gene expression can be achieved following retroviral 
delivery of the Tet-Off system to NIH3T3 cells and haematopoietic 
progenitors,
i) NIH3T3 cells
In order to determine whether the Tet-Off system enabled conditional reporter gene 
expression, NIH3T3 cells were co-transduced with pMSCV-tTA-IRES-EGFP and 
pREV-TRE-hCD2t. Single transductions were also performed with either pMSCV- 
tTA-IRES-EGFP or pREV-TRE-hCD2t. The transduced cells were passaged after 
three days and co-transduced cells were maintained with or without dox for a 
further 5 days. The EGFP and CD2 expression profiles of the transduced cells were 
then analysed by flow cytometry. Following single transductions, approximately 
30% of the cells were transduced with pMSCV-tTA-IRES-EGFP as determined by 
their EGFP expression profile (Figure 3.2A.i). Unexpectedly, cells transduced with 
pREV-TRE-hCD2t alone expressed CD2 (Figure 3.2A.ii). This was surprising since 
CD2 should not be expressed in the absence of tTA binding to the TRE. As this 
result was reproducible we concluded that the TRE drove a low level of constitutive 
CD2 expression in the absence of tTA binding to the TRE.
Following co-transduction of NIH3T3 cells with pREV-TRE-hCD2t and pMSCV- 
tTA-IRES-EGFP, 23% of cells maintained in the absence of dox expressed both 
EGFP and CD2 (Figure 3.2A.iii). Interestingly, the mean fluorescence intensity 
(MFI) of CD2 expression was much higher in this EGFP+ CD2+ population than the 
MFI of the CD2+ population observed following transduction with the CD2 
construct alone. Therefore, tTA binding to the TRE elevated the expression levels 
of CD2. Following co-transduction, two distinct populations of CD2 expressing 
cells were present within the EGFP’ CD2+ population (Figure 3.2A.iii). One 
population of cells expressed low levels of CD2 with an MFI similar to that 
observed following transduction with the CD2 construct alone. The other 
population expressed much higher levels of CD2 with an MFI similar to that
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Figure 3.2 The Tet-Off system allows conditional reporter gene expression in 
both NIH3T3 cells and haematopoietic progenitor cells. A) NIH3T3 cells 
were transduced with either pREV-TRJE-hCD2t (CD2 only) or pMSCV-tTA- 
IRES-EGFP (tTA only) or both of these constructs (CD2 / tTA). Co-transduced 
cells were maintained with or without dox for 5 days and then analysed by flow 
cytometry. B) The overlay plot shows the CD2 expression profile of NIH3T3 
cells co-transduced with pREV-TRE-hCD2t and pMSCV-tTA-IRES-EGFP 
maintained in the presence (thick red line) or absence (grey line) of dox. The 
plots were gated on EGFP+ cells. C) Haematopoietic progenitor cells (HPCs) 
were transduced with the same constructs as detailed in A. The cells were 
analysed 48 hours after transduction by flow cytometry.
iii) CD2 / tTA - dox
10°  101 102 1 03 1 04
CD2 I tTA + dox
10°  101 102 103 104
77
observed in the EGFP+ CD2+ population in which tTA was inducing elevated levels 
of CD2 expression. Therefore, it is possible that despite the presence of the IRES in 
the pMSCV-tTA-IRES-EGFP construct, some cells transduced with this construct 
expressed tTA but not EGFP.
The co-transduced cells maintained in the presence of dox expressed low levels of 
CD2 with a MFI similar to that observed following transduction with the CD2 
construct alone (Figure 3.2A.iv). The population of high CD2 expressing cells that 
was observed following culture of the co-transduced cells in the absence of dox was 
not observed in the presence of dox (Figure 3.2B). Therefore, dox was effective at 
abrogating the induction of CD2 expression by tTA.
ii) Haematopoietic progenitors
Since conditional reporter gene expression was achieved in NIH3T3 cells, the 
ability of the Tet-Off system to induce conditional reporter gene expression in 
HPCs was examined. c-Kit+ Terl 19' HPCs isolated from embryonic day 12 (E l2) 
mouse foetal liver were co-transduced with pMSCV-tTA-IRES-EGFP and pREV- 
TRE-hCD2t. Single transductions were also performed with either pMSCV-tTA- 
IRES-EGFP or pREV-TRE-hCD2t. After 48 hours the cells were analysed by flow 
cytometry. A single transduction with pMSCV-tTA-IRES-EGFP yielded 44% 
EGFP+ cells (Figure 3.2C.i). As observed withNIH3T3 cells, HPCs transduced 
with pREV-TRE-hCD2t expressed CD2 in the absence of tTA binding to the TRE 
(Figure 3.2C.ii). Therefore, the low level of constitutive CD2 expression observed 
in the absence of tTA binding to the TRE is not unique to NIH3T3 cells.
Following co-transduction of HPCs with pREV-TRE-hCD2t and pMSCV-tTA- 
IRES-EGFP, 20% of the cells co-expressed EGFP and CD2 (Figure 3.2C.iii). The 
MFI of CD2 expression in this EGFP+ CD2+ population was over an order of 
magnitude higher than that observed following transduction with the CD2 construct 
alone. Therefore, tTA was able to induce elevated levels of CD2 expression in 
HPCs. The ability of dox to abrogate this induction was not investigated in this 
experiment.
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3.3 The Tet-suppressor abolishes low levels of constitutive tTA independent 
CD2 expression in NIH3T3 cells.
As described in section 3.2, a low level of constitutive CD2 expression was 
observed in the absence of tTA binding to the TRE. The hygromycin resistance 
gene, which is situated between the 5’LTR and the TRE, should prevent 
translational read-through of the messenger RNA (mRNA) expressed from the 
promoter elements of the 5’LTR. Either this was not the case here, or enhancer 
elements in the 5’LTR were acting on the minimal CMV promoter in the TRE 
resulting in low levels of constitutive CD2 expression. Strict regulatable reporter 
gene expression has been obtained when the TRE-reporter gene is in the anti-sense 
orientation with respect to the 5’LTR of the retroviral vector (Unsinger et al., 
2001). In order to test whether an anti-sense CD2 expression construct expressed 
lower levels of constitutive CD2, TRE-hCD2t was sub-cloned in the anti-sense 
orientation with respect to the 5’LTR of the pREV vector (Figure 2.1). This ‘anti­
sense’ reporter expressed 2-fold lower levels of constitutive CD2 than the sense 
reporter in which TRE-hCD2t was in the sense orientation with respect to the 
5’LTR (data not shown). The fact that constitutive CD2 expression was still 
observed using an anti-sense CD2 reporter implies that enhancer elements in the 
5’LTR, which can act on the TRE regardless of its orientation, are responsible for 
the low levels of constitutive CD2 expression. Although the level of constitutive 
CD2 expression was substantially reduced using the anti-sense orientation • 
construct, it was not completely abrogated. Therefore, the ability of the Tet 
suppressor (tTS) to abrogate the low level of constitutive tTA independent CD2 
expression was investigated.
The Tet suppressor is a fusion of the TetR and the KRAB-AB silencing domain of 
the Kid-1 protein (Freundlieb et al., 1999). tTS can bind to the TRE in the absence 
of dox. In doing so it may prevent enhancer elements in the 5’LTR from acting on 
the minimal CMV promoter in the TRE. In the presence of dox, tTS undergoes a 
conformational change such that it is inactivated and therefore no longer able to 
bind to the TRE (Figure 3.3). In order to test the ability of tTS to abrogate tTA 
independent constitutive CD2 expression, a bulk population of NIH3T3 cells that 
had been cultured for approximately 2 months following transduction with pREV- 
TRE-hCD2t were transduced with pMSCV-tTS-IRES-EGFP. The transduced cells
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Figure 3.3 The function of the tetracycline suppressor. The tetracycline 
suppressor (tTS) binds to the same site in the TRE as tTA and may prevent 
enhancer elements in the 5’LTR from acting on the TRE, thereby preventing tTA 
independent CD2 expression. In the presence of dox, tTS is inactivated such that it 
cannot bind the TRE and can no longer suppress low levels of constitutive CD2 
expression. LTR: long terminal repeat, \|/+: viral packaging signal, tTS: 
tetracycline suppressor, IRES: internal ribosome entry site, EGFP: enhanced green 
fluorescent protein, Ampr: ampicillin resistance gene, Hygr: hygromycin 
resistance gene, TRE: tetracycline response element, hCD2t: human CD2 tail-less.
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were passaged after 4 days and maintained with or without dox for a further 5 days. 
The EGFP and CD2 expression profiles of the transduced cells were then analysed 
by flow cytometry. EGFP+ cells, expressing tTS were almost completely CD2 
negative (Figure 3.4A.ii). However, almost half of these cells were transduced with 
the CD2 expression construct since following the addition of dox, and tTS 
inactivation, they re-expressed CD2 (Figure 3.4A.iii). This data shows that tTS 
functioned as anticipated in abrogating the low levels of constitutive CD2 
expression observed in the absence of tTA binding to the TRE (Figure 3.4B).
3.4 Conditional MLL-ENL expression can be achieved in NIH3T3 cells.
Having optimised the Tet-Off system using reporter constructs, it was necessary to 
examine if conditional MLL-ENL expression could be achieved. This was first 
tested by transient transfection of the human embryonic kidney epithelial 293T cell 
line. Cells were co-transfected with pREV-TRE-MLL-ENL (or the empty pREV- 
TRE vector) and pMSCV-tTA-IRES-EGFP. Cells co-transfected with the Tet-On 
inducible MLL-ENL expression construct pCS-TRE-MLL-ENL and the pTet-On 
vector encoding the rtTA (reverse tetracycline transactivator) were used as a 
positive control. Cells co-transfected with these constructs will express MLL-ENL 
in the presence of dox since the rtTA, in contrast to the tTA, binds the TRE and 
initiates MLL-ENL expression in the presence of dox. These constructs were kindly 
provided by Dr. D. Moulding of the MHCB unit.
Co-transfected cells were maintained in the presence or absence of dox for 24 hours * 
and then lysed for Western blot analysis. Since MLL-ENL was myc-tagged at the 
5’ end in both the pREV-TRE-MLL-ENL and pCS-TRE-MLL-ENL constructs, the 
anti-myc antibody (clone 9E10) or the higher affinity anti-myc antibody (clone 
9B11) were used to detect MLL-ENL protein expression. As expected a 220 kD 
band corresponding to full-length MLL-ENL was detected in pCS-TRE-MLL-ENL 
and rtTA co-transfected cells maintained in the presence of dox (the positive 
control) (Figure 3.5A). The full-length MLL-ENL protein was also detected in 
pREV-TRE-MLL-ENL and pMSCV-tTA-IRES-EGFP co-transfected cells 
maintained in the absence of dox (Figure 3.5 A). However, it was not detected in co-
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Figure 3.4 The tetracycline suppressor prevents tTA independent CD2 
expression. A) A bulk culture of pREV-TRE-hCD2t transduced NIH3T3 cells 
that had been cultured for 2 months were transduced with pMSCV-tTS-IRES- 
EGFP. The co-transduced cells were maintained with or without dox for 5 days 
and then analysed by flow cytometry. B) The overlay plot shows the CD2 
expression profile of NIH3T3 cells co-transduced with pREV-TRE-hCD2t and 
pMSCV-tTS-IRES-EGFP maintained in the presence (thick red line) or absence 
(grey line) of dox. Plots were gated on EGFP+ cells.
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Figure 3.5 Conditional MLL-ENL expression can be achieved following 
transient transfection of 293T cells and transduction of NIH3T3 cells. A)
293T cells were co-transfected with pREV-TRE-MLL-ENL (pREV-TRE-M/E) or 
the empty vector (pREV-TRE) and pMSCV-tTA-IRES-EGFP (pMSCV-tTA). As 
a positive control, cells were co-transfected with the Tet-On expression constructs 
pCS-TRE-MLL-ENL (pCS-TRE-M/E) and the reverse tetracycline transactivator 
(rtTA). Co-transfected cells were maintained with or without dox for 24 hours 
and then lysed for Western blot analysis. MLL-ENL protein was detected with 
the anti-myc antibody (clone 9E10). B) NIH3T3 cells were co-transduced with 
pREV-TRE-M/E and pMSCV-tTA or C) pMSCV-TRE-M/E and pMSCV-tTA. 
Cells were also transduced with the constitutive MLL-ENL expression construct 
pMSCV-M/E. Untransduced NIH3T3 cells or empty vector (pMSCV-TRE) 
transduced cells served as a negative control. Co-transduced cells were 
maintained with or without dox for 24 hours and then lysed. The blot in C was 
probed with the high affinity anti-myc antibody (clone 9B11). Each blot was 
stripped and re-probed with an anti-tubulin antibody.
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transfected cells maintained in the presence of dox. Therefore, regulatable MLL- 
ENL expression was obtained following transient transfection of 293T cells.
In addition to the band corresponding to full-length MLL-ENL, many other bands 
were detected using the anti-myc antibody (Figure 3.5A). However, since these 
bands were not present in the lanes corresponding to pREV-TRE and pMSCV-tTA- 
IRES-EGFP co-transfected cells, they probably represent degradation products of 
the full-length MLL-ENL fusion protein which contains several PEST motifs and is 
inherently unstable.
Since conditional MLL-ENL expression was obtained following transient 
transfection of 293T cells, MLL-ENL expression was examined following 
transduction of NIH3T3 cells. NIH3T3 cells were co-transduced with pREV-TRE- 
MLL-ENL and pMSCV-tTA-IRES-EGFP. Transduced cells were maintained in the 
presence or absence of dox for 24 hours and then lysed for Western blot analysis. 
Untransduced NIH3T3 cells were used as a negative control. Full-length MLL-ENL 
was detected following maintenance of the co-transduced cells in the absence of 
dox but not after 24 hours in the presence of dox (Figure 3.5B). This data shows 
that conditional MLL-ENL expression was achieved following integration of both 
the pMSCV-tTA-IRES-EGFP and pREV-TRE-MLL-ENL pro virus into the genome 
of target cells.
Full-length MLL-ENL expression could not be detected in NIH3T3 cells 
transduced with a flag-tagged constitutive MLL-ENL expression construct using 
either anti-flag or anti-MLL antibodies. Therefore, a myc-tagged constitutive MLL- 
ENL expression construct was made so that the level of MLL-ENL protein 
expression could be directly compared in NIH3T3 cells transduced with either the 
constitutive or conditional MLL-ENL expression constructs. Full-length MLL-ENL 
was detected in cells transduced with the myc-tagged constitutive MLL-ENL 
expression construct (Figure 3.5C). Furthermore the amount of full-length MLL- 
ENL protein expressed was similar to that in cells co-transduced with pMSCV-tTA- 
IRES-EGFP and pMSCV-TRE-MLL-ENL (a new conditional MLL-ENL 
expression construct that produced a viral titre comparable to the constitutive 
construct). This new conditional MLL-ENL expression construct (Figure 2.2),
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which is capable of producing higher titre retrovirus is discussed in more detail in 
chapter 4.
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Discussion
Very few studies have employed two retroviral constructs to express a reporter that 
is strictly regulatable by tTA. Regulatable reporter gene expression has been 
obtained using a self-inactivating (SIN) retroviral vector containing a single 
autoregulatory cassette encoding both the tTA and the TRE-reporter gene 
(Hofmann et al., 1996). SIN vectors contain deletions in the enhancer and promoter 
elements of the 3’ LTR. These deletions are then transferred to the 5’LTR during 
reverse transcription, which results in transcriptional inactivation of the provirus. 
The inactivation of the enhancer and promoter elements in the 5’LTR is 
advantageous since it prevents their interference with the tTA regulated minimal 
CMV promoter within the TRE (Hofmann et al., 1996). It was not possible to use a 
single autoregulatory expression construct to express MLL-ENL in a conditional 
manner since the MLL-ENL cDNA is 6.2 kb. A retrovirus encoding both MLL- 
ENL and tTA would not be packaged effectively since the size of the viral RNA 
would exceed the upper packaging constraint limit of 10 kb. Therefore, the efficacy 
of using two retroviral constructs to deliver the Tet-Off system to target cells was 
examined using reporter constructs.
A low level of constitutive reporter gene expression was observed in NIH3T3 cells 
and HPCs which were not transduced with the tTA expression construct. However, 
binding of tTA to the TRE did induce elevated reporter gene expression, which 
could be abrogated by dox. The low levels of constitutive, tTA independent, 
reporter gene expression posed a potential problem since low levels of constitutive 
MLL-ENL expression may be sufficient to immortalise HPCs. If this is the case 
dox would not turn off MLL-ENL expression, since expression would be 
independent of tTA binding to the TRE. Therefore, ways of shutting off the low 
levels of constitutive, tTA independent, reporter gene expression were investigated.
Strict regulatable reporter gene expression has been obtained in other studies when 
the TRE-reporter gene was in the anti-sense orientation with respect to the 5’LTR 
(Unsinger et al., 2001). However, in this study low levels of constitutive CD2 
expression were still observed using an anti-sense orientation TRE-hCD2t reporter. 
We hypothesised that the low levels of constitutive, tTA independent, reporter gene 
expression were caused by enhancer elements in the 5’ LTR acting on the minimal
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CMV promoter in the TRE. This is because enhancer elements are able to activate 
gene expression regardless of the orientation of the gene. If this was the case, it was 
possible that the Tet-suppressor, when bound to the TRE, might prevent enhancer 
elements in the 5’LTR from acting on the minimal CMV promoter of the TRE and 
therefore prevent tTA independent CD2 expression. This was found to be the case. 
Furthermore, in the presence of dox, tTS was no longer able to bind to the TRE and 
was not able to prevent tTA independent, CD2 expression. These experiments 
suggest that even in the event that a low level of constitutive MLL-ENL expression 
is sufficient to immortalise HPCs, transduction of the immortalised cell line with 
pMSCV-tTS should abrogate MLL-ENL expression and this may be regulated by 
dox.
The reporter constructs enabled us to optimise the delivery of the Tet-Off system to 
target cells and determine the efficacy with which the system allowed conditional 
gene expression in both NIH3T3 cells and HPCs. Having confirmed that the Tet- 
Off system allowed conditional reporter gene expression in these cells, it was 
important to determine whether we could achieve conditional MLL-ENL 
expression using this system. Conditional expression of the full-length MLL-ENL 
protein was achieved following transient co-transfection of 293T cells with the Tet- 
Off system. Importantly, conditional MLL-ENL expression was also achieved 
following co-transduction of NIH3T3 cells. Therefore, although the viral genome of 
the conditional MLL-ENL retroviral construct is large, the virus is packaged 
effectively and it can integrate into the genome of target cells. The finding that 
MLL-ENL expression is regulatable by tTA following integration of the virus into 
the genome of target cells, suggests that the promoters and enhancers of 
endogenous genes which flank the integration site do not interfere with the tTA 
regulated minimal CMV promoter within the TRE. This finding implies that we 
would be able to turn off MLL-ENL expression in cells immortalised with the 
conditional MLL-ENL expression construct.
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Chapter 4 Analysis of the transforming capacity of MLL-ENL and 
MLL-AF4.
Previous studies have demonstrated that many MLL-fusion proteins including 
MLL-ENL and MLL-AF9 are leukaemogenic (Corral et al., 1996; Lavau et al., 
1997). However, the leukaemogenic potential of the MLL-AF4 fusion protein, the 
product of the most prevalent chromosomal translocation in infant ALL, has not 
been assessed. Previous retroviral transduction studies have employed murine adult 
bone marrow as the source of haematopoietic progenitors for transduction with 
MLL fusion genes (Lavau et al., 1997; Lavau et al., 2000a; Lavau et al., 2000b; 
DiMartino et al., 2002; So and Cleary, 2002; So and Cleary, 2003). Since the 
translocation that generates the MLL-fusion gene is postulated to occur in utero 
(Eguchi et al., 2003), HPCs isolated from the livers of El 2 mouse foetuses may be 
a more appropriate target population for retroviral transduction. MLL-fusion genes 
may immortalise foetal HPCs and induce leukaemogenesis in mice which may 
more accurately mimic the disease in patients.
Purified populations of haematopoietic stem cells (HSCs), common myeloid 
progenitors (CMPs) and granulocyte-monocyte progenitors (GMPs) isolated from 
adult bone marrow are all susceptible to immortalisation by MLL-ENL (Cozzio et 
al., 2003). The foetal equivalent of these three progenitor populations is present 
within the lin" c-Kit+ population of E14 foetal liver (Traver et al., 2001). We 
isolated the c-Kit+ Ter-119' progenitor population from E l2 foetal liver for 
retroviral transduction since E l2 foetal liver contains 8-fold higher percentages of 
c-Kit+ Ter-119' cells than E l4 foetal liver (data not shown). Negative selection 
against the erythrocyte marker Ter-119 was performed since the majority of 
haematopoietic cells in the foetal liver are erythroid and MLL-ENL is unable to 
immortalise the megakaryocyte-erythroid progenitor (MEP) (Cozzio et al., 2003).
4.1 MLL-ENL promotes the serial replating of foetal progenitors in 
methylcellulose.
In order to investigate whether MLL-ENL is capable of immortalising foetal HPCs, 
c-Kit+ Ter-119' cells were transduced with MLL-ENL expressing retroviral 
constructs following overnight stimulation with stem cell factor (SCF), interleukin- 
6 (IL-6) and IL-3. Cells were co-transduced with the conditional MLL-ENL 
expression construct pREV-TRE-MLL-ENL (pREV-TRE-M/E) or a control empty 
vector (pREV-TRE) and the inducer pMSCV-tTA-IRES-EGFP (pMSCV-tTA). 
Cells were also transduced with the conditional MLL-ENL expression construct in 
the absence of pMSCV-tTA. This condition was included because a low level of 
constitutive CD2 expression was observed in the absence of tTA binding to the 
TRE (section 3.2), hence it is possible that low levels of constitutive MLL-ENL 
expression would be sufficient to immortalise HPCs. As a positive control, cells 
were transduced with the constitutive MLL-ENL expression construct pMSCV- 
MLL-ENL (pMSCV-M/E). Following two rounds of transduction the cells were 
cultured in methylcellulose (M3434) supplemented with GM-CSF and serial 
replating assays were performed. Immortalised cells possess the ability to self- 
renew and can therefore replate in methylcellulose indefinitely. However, non­
immortalised cells progressively lose their self-renewal ability and terminally 
differentiate. Hygromycin was added to the first round of plating to select for cells 
transduced with pREV-TRE-M/E and G418 was used to select for cells transduced 
with pMSCV-M/E. After 6-10 days the colonies were counted, harvested and 
replated into a second round in the absence of selection.
Several of the primary colonies formed from pMSCV-M/E transduced cells were 
very large, round and compact (data not shown). In contrast, cells co-transduced 
with the empty pREV-TRE vector and pMSCV-tTA formed smaller granulocyte- 
macrophage (CFU-GM) colonies which were compact and of a non-uniform shape. 
Although a difference in colony morphology was observed, the total number of 
colonies formed and the total number of cells harvested was not significantly 
different between pMSCV-M/E and empty vector transduced cells in either the 
primary or secondary rounds of the assay (Figure 4.1 A and B). However, more 
colonies were formed from cells transduced with pMSCV-M/E than the empty 
vector in the third round of replating (Figure 4.1 A). The vast majority of the tertiary
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Figure 4.1 The constitutive MLL-ENL expression construct can immortalise 
foetal HPCs. E12 c-Kit+ Ter-119'HPCs were co-transduced with the conditional 
MLL-ENL expression construct pREV-TRE-M/E (or the empty vector pREV- 
TRE) and the inducer pMSCV-tTA. Cells were also transduced with the 
constitutive MLL-ENL expression construct pMSCV-M/E. The transduced cells 
were cultured in methylcellulose under conditions that promoted myeloid 
development and serial replating assays were performed. Colonies were counted 
every 6-10 days and cells were harvested and replated into a subsequent round 
under the same conditions. The graphs show A) the number of colonies formed 
and B) the number of cells harvested (per 104 cells plated) in each round of the 
assay from cells transduced with pREV-TRE-M/E and pMSCV-tTA (black 
squares), pREV-TRE-M/E alone (blue triangles), pMSCV-M/E (red diamonds) 
and pREV-TRE and pMSCV-tTA (green circles). The mean and SD of duplicate 
cultures are shown in A. C) The morphology of colonies formed in the third 
round of the assay shown in A and B. Original magnification x 40.
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pMSCV-M/E colonies were large and round. Some of them were surrounded by a 
halo of differentiating cells while others were more compact (Figure 4.1C). The 
pMSCV-M/E colonies replated consistently with the same frequency and 
morphology into subsequent rounds and a stable cell line was established in liquid 
culture supplemented with SCF, IL-6 and IL-3. In contrast, cells transduced with 
the empty vector formed progressively smaller colonies (Figure 4.1C) and 
exhausted their proliferative capacity by the fifth round of replating.
The conditional MLL-ENL expression construct pREV-TRE-M/E failed to 
immortalise foetal HPCs either alone or in combination with the inducer tTA. 
Several of the primary colonies formed from pREV-TRE-M/E and pMSCV-tTA 
co-transduced cells possessed a similar morphology to the primary colonies formed 
from pMSCV-M/E transduced cells (data not shown). However, in contrast to the 
cells transduced with pMSCV-M/E, the cells co-transduced with pREV-TRE-M/E 
and pMSCV-tTA were not immortalised since they ceased proliferating by the fifth 
round of replating (Figure 4.1 A) and a cell line could not be established in liquid 
culture. The conditional MLL-ENL expression construct failed to immortalise 
foetal HPCs in more than 20 experiments.
4.2 The conditional MLL-ENL expression construct does not induce unlimited 
self-renewal of foetal progenitors in methylcellulose.
The inability of pREV-TRE-M/E to immortalise HPCs might be explained by its 
low viral titre. The pREV-TRE-M/E construct routinely produced viral titres of 2 x 
105 ip/mL (infectious particles / mL), approximately 10-fold lower than that of 
pMSCV-M/E as measured by hygromycin or G418 resistance following 
transduction of NIH3T3 cells (section 2.5), data not shown. The way in which the 
co-transduction with pMSCV-tTA was performed reduced the titre of pREV-TRE- 
M/E further. The two viral supernatants were mixed in a 1:1 ratio, therefore the titre 
of each virus was effectively halved. In order to avoid this, the effect of performing 
a single transduction with pREV-TRE-M/E followed by a co-transduction with 
pREV-TRE-M/E and pMSCV-tTA, 24 hours later, was investigated. The effect of 
seeding twice the number of cells for transduction was also examined. This strategy 
yielded promising results. Although the total number of colonies formed was 
similar for all the constructs examined (Figure 4.2A), it is apparent that the cells co-
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Figure 4.2 The conditional MLL-ENL expression construct causes a 
transient enhancement of self-renewal in foetal HPCs. E12 c-Kit+ Ter-119‘ 
HPCs were co-transduced with the conditional MLL-ENL expression construct 
pREV-TRE-M/E (or the empty vector pREV-TRE) and the inducer pMSCV-tTA. 
Cells were also transduced with the constitutive MLL-ENL expression construct 
pMSCV-M/E. The transduced cells were cultured in methylcellulose under 
conditions that promoted myeloid development and serial replating assays were 
performed. The effect of plating twice the number of pREV-TRE-M/E and 
pMSCV-tTA transduced cells was investigated. The graphs show A) the number 
of colonies formed and B) the number of cells harvested (per 104 cells plated) in 
each round of the assay from cells transduced with pREV-TRE-M/E and 
pMSCV-tTA (12 x 104 cells) (black squares), pREV-TRE-M/E and pMSCV-tTA 
(6 x 104 cells) (blue triangles), pMSCV-M/E (red diamonds) and pREV-TRE and 
pMSCV-tTA (green circles). The mean and SD of duplicate cultures are shown in 
A. C) The morphology of colonies formed in the sixth round of the assay shown 
in A and B. Original magnification x 40.
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transduced with pREV-TRE-M/E and pMSCV-tTA formed much larger colonies, 
as shown by the larger number of cells harvested from each plate (Figure 4.2B). 
This effect was only observed when more cells were plated. Between the third and 
seventh rounds of the assay the colonies formed from pREV-TRE-M/E and 
pMSCV-tTA co-transduced cells were of a CFU-GM phenotype. They were very 
large and contained dense centres with more mature cells around the periphery 
(Figure 4.2C). However, the large CFU-GM colonies were not of the ‘immortalised 
phenotype’ observed in previous assays with pMSCV-M/E. They were not as 
circular or as compact and were mostly of a non-uniform shape. These cells were 
not immortalised since they ceased replating in methylcellulose after the ninth 
round and failed to grow in liquid culture. Cells transduced with the empty vector 
did not form large CFU-GM colonies, only sparse or small clustered colonies were 
observed (Figure 4.2C). Interestingly, the positive control pMSCV-M/E, failed to 
immortalise in this experiment.
Various strategies were employed to further improve the co-transduction procedure. 
A pMSCV-tTA construct was made that contained the neomycin resistance gene 
(Figure 2.1). This enabled dual selection to be performed (hygromycin selection for 
pREV-TRE-M/E and G418 selection for pMSCV-tTA) which ensured that all 
colony-forming cells were successfully co-transduced. In addition, attempts were 
made to increase the viral titre by concentrating the viral supernatants by • 
centrifugation (section 2.7). This technique did not work for pREV-TRE-M/E. 
However, it was possible to concentrate the pMSCV-tTA virus. This was beneficial 
since co-transduction could then be performed without diluting the pREV-TRE- 
M/E virus (the concentrated pMSCV-tTA viral pellet was resuspended in neat 
pREV-TRE-M/E virus). Despite these improvements to the co-transduction 
procedure, it was not possible to generate a conditional immortalised cell line from 
foetal liver. Therefore, a new conditional MLL-ENL expression construct that was 
capable of generating higher titre virus was made by sub-cloning TRE-MLL-ENL 
downstream of PGK-neo in pMSCV-neo (Figure 2.2). pMSCV-TRE-M/E routinely 
gave viral titres of 2 x 106 ip / mL which was comparable to that of the constitutive 
MLL-ENL construct pMSCV-M/E. Unfortunately co-transduction of foetal HPCs 
with the new conditional MLL-ENL construct and pMSCV-tTA did not yield an 
immortalised cell line.
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4.3 MLL-ENL immortalised cells are capable of long-term growth in vitro.
Two immortalised cell lines (FL-ME1 and FL-ME2) were generated from HPCs 
transduced with the constitutive MLL-ENL expression construct pMSCV-M/E in 
two independent experiments. The cell lines were generated by placing cells 
harvested from the fourth round of the methylcellulose replating assay in liquid 
culture supplemented with SCF, IL-6 and IL-3. Both FL-ME1 and FL-ME2 
proliferated rapidly while cells co-transduced with the empty vector pREV-TRE 
and pMSCV-tTA grew more slowly and stopped proliferating after two weeks in 
liquid culture (Figure 4.3A). The growth kinetics of cells transduced with the 
conditional MLL-ENL expression construct either alone or in combination with 
tTA mirrored that of the empty vector transduced cells (data not shown).
The presence of the intact 6 kb MLL-ENL provirus was confirmed in both FL-ME1 
and FL-ME2 by Southern blotting using an N-terminal MLL cDNA fragment as a 
probe (Figure 4.3B). A 12 kb band corresponding to an endogenous MLL fragment 
was also detected using this probe as expected. MLL-ENL protein expression could 
not be detected in FL-ME1 or FL-ME2 by Western blot analysis using either anti- 
FLAG or anti-MLL (clone 4.1) antibodies. Therefore, MLL-ENL transcript 
expression was examined by RT-PCR analysis using primers that flank the MLL- 
ENL breakpoint. The expected 846 bp product was amplified from total RNA 
isolated from FL-ME2 but not from FL-ME1 (Figure 4.3C). It has been previously 
reported that the level of MLL-ENL transcript expression in immortalised cell lines 
is so low that it can only be detected by performing RT-PCR on poly (A) RNA 
(Lavau et al., 1997). Therefore, it may be necessary to isolate poly (A) RNA from 
FL-ME1 and repeat this analysis. It may also be necessary to use primers which 
generate a shorter product than 846 bp.
4.4 Characterisation of MLL-ENL immortalised cell lines.
The morphology of FL-ME1 and FL-ME2 was examined by cytospin preparation 
followed by May Grunwald Giemsa (MGG) staining. Both lines were composed 
predominantly of myeloblasts. However, some cells were at a more advanced stage 
of myeloid differentiation since they possessed a more segmented nucleus (Figure 
4.4A). Analysis of cell surface antigen expression by flow cytometry confirmed that 
these cell lines were myeloid (Figure 4.4B). Both lines expressed high levels of the
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Figure 4.3 Stable cell lines can be established in liquid culture from MLL- 
ENL transduced foetal HPCs. Cells harvested from the fourth round of two 
independent methylcellulose assays were placed in liquid culture supplemented 
with SCF, IL-3 and IL-6. A) The graph shows the log of the fold accumulation in 
cell number of FL-ME1 (black squares) and FL-ME2 (red diamonds) which were 
derived from pMSCV-M/E transduced cells. The fold accumulation of cells 
transduced with the empty vector pREV-TRE and pMSCV-tTA (green circles and 
blue triangles) is also shown. B) Southern blot analysis of genomic DNA isolated 
from FL-ME1 (lane 1) and FL-ME2 (lane 2) showing integration of the MLL- 
ENL provirus. Untransduced E l2 c-Kit+ Ter-119' cells were used as a negative 
control (lane 3). The indicated N-terminal MLL cDNA fragment probe was used 
to detect the 6 kb proviral band following EcoRI digestion o f genomic DNA. The 
probe detects a fragment o f the endogenous MLL gene (top arrow) and the MLL- 
ENL provirus (bottom arrow). E indicates EcoRI. C) Reverse-transcription (RT)- 
PCR analysis of total RNA isolated from the cell lines demonstrating expression 
of the MLL-ENL transcript. The pCSARQ2 template was used as a positive 
control (pos cont). Negative control reactions were performed in the absence of 
reverse transcriptase (RT).
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Figure 4.4 Characterisation of MLL-ENL cell lines derived from foetal 
HPCs. A) The cellular morphology of the cell lines was assessed by cytospin 
preparation followed by May Grunwald Giemsa (MGG) staining. Original 
magnification x 400. B) Flow cytometric analysis of cell surface antigen 
expression by the cell lines. Thick red lines represent the expression profile of the 
indicated antigen and thin black lines represent the appropriate isotype control. C) 
Growth factor requirements of FL-ME1. The graph shows the absorbance from 
MTS assays performed following culture with the indicated cytokines for 48 
hours. Identical results were obtained for FL-ME2. The mean and SD of triplicate 
absorbance readings are shown.
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macrophage marker Mac-1 and intermediate levels of the granulocyte marker Gr-1. 
Gr-1 is expressed on monocytes and granulocytes. It is up regulated as granulocyte 
progenitors differentiate into mature granulocytes and down regulated as monocytes 
differentiate into macrophages (Lagasse and Weissman, 1996). Both lines 
expressed very low levels of the progenitor marker c-Kit and were negative for the 
B cell marker B220 and the erythrocyte marker Ter-119 (data not shown). The only 
antigen that was differentially expressed between the two cell lines was CD43 
which was expressed at higher levels on FL-ME2 than FL-ME1 (Figure 4.4B). 
CD43 is a marker of more primitive progenitors and is expressed on both myeloid 
and B cell precursors. This apparent difference in immunophenotype may be 
attributed to slight differences in the stage of lineage commitment that the 
progenitors were at when they became immortalised in the two experiments.
The cytokine requirements of the two cell lines were examined by seeding the cells 
in various combinations of cytokines and measuring cellular viability 48 hours later 
using an MTS assay. FL-ME1 and FL-ME2 possessed identical growth factor 
requirements. Both lines were growth factor dependent and required IL-3 for 
maximal proliferation (Figure 4.4C). Therefore SCF and IL-6 were omitted from 
the medium and the cells were maintained in just IL-3 for more than 3 months.
4.5 MLL-AF4 promotes the proliferation or cell to cell adhesion of foetal HPCs 
in methylcellulose.
In order to determine whether MLL-AF4 is able to immortalise foetal 
haematopoietic progenitor cells, E l2 c-Kit+ Ter-119' cells were transduced with a 
retroviral MLL-AF4 expression construct. Cells were transduced with the 
constitutive MLL-AF4 expression construct pMSCV-MLL-AF4 (pMSCV-M/A) or 
the control empty vector (pMSCV-neo) following overnight stimulation in SCF, IL- 
6 and IL-3. Following two rounds of transduction the cells were cultured in 
methylcellulose that supported B cell development (M3231 supplemented with 
SCF, IL-7 andfms-like tyrosine kinase-3 ligand [Flt-3 ligand]). These conditions 
were used because the MLL-AF4 translocation is predominantly associated with 
lymphoid leukaemias and a previous study used these conditions to generate MLL- 
ENL immortalised B cell lines (Zeisig et al., 2003a). In some experiments, the
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transduced cells were also plated in methylcellulose that supported myeloid 
development (M3434 supplemented with GM-CSF).
Flow cytometric analysis of cells harvested from the primary methylcellulose 
plating demonstrated that pMSCV-M/A and pMSCV-neo transduced cells failed to 
generate B cells (data not shown). This may have been because IL-3 can inhibit B 
cell commitment (Hirayama et al, 1994). Therefore, in subsequent experiments 
cells were transduced in the presence of SCF, IL-7 and Flt-3 ligand and then plated 
in M3231 methylcellulose supplemented with the same cytokines. Transduced cells 
were not selected since the PGK promoter and the neomycin gene were removed 
from the pMSCV-M/A construct (Figure 2.2). The neomycin resistance gene and its 
promoter were removed since the MLL-AF4 cDNA is 7.6 kb. A retrovirus encoding 
both the MLL-AF4 and the neomycin gene would not be packaged effectively since 
the size of the viral RNA would exceed the upper packaging constraint limit of 10 
kb.
Although there was no difference in the number or the morphology of colonies 
formed from pMSCV-M/A and pMSCV-neo transduced cells grown in myeloid 
conditions (data not shown), a difference in colony morphology was observed when 
the transduced cells were grown in B cell conditions. More primary B cell colonies 
were formed from cells transduced with pMSCV-M/A than pMSCV-neo (Figure 
4.5A). However, it is apparent from the number of cells harvested that the primary 
and secondary colonies formed from pMSCV-neo transduced cells were much 
larger than the colonies formed from pMSCV-M/A transduced cells (Figure 4.5B). 
The primary and secondary colonies formed from pMSCV-neo transduced cells 
were very large, dense and non-uniform in shape. In contrast, the colonies formed 
from pMSCV-M/A transduced cells were generally smaller, more circular and 
possessed a more compact centre (data not shown). However, by the third round of 
replating, many of the colonies formed from pMSCV-M/A transduced cells were 
much larger than the colonies formed from pMSCV-neo transduced cells (Figure 
4.5C). The former were large, round and compact whereas the latter were smaller 
and more diffuse. Although the colonies formed from pMSCV-M/A and pMSCV- 
neo transduced cells were vastly different in terms of their size, the total number of 
cells harvested was not significantly different (Figure 4.5B) and their
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Figure 4.5 MLL-AF4 promotes the proliferation or cell to cell adhesion of 
foetal HPCs. E l2 c-Kit+ Ter-119‘ HPCs were transduced with the constitutive 
MLL-AF4 expression construct pMSCV-M/A or the empty vector pMSCV-neo. 
Transduced cells were cultured in methylcellulose under conditions that promoted 
B cell development and serial replating assays were performed. The graphs show 
A) the number of colonies formed and B) the number of cells harvested in each 
round of the assay from cells transduced with pMSCV-M/A (black squares) and 
pMSCV-neo (red diamonds) per 104 cells plated. The mean and SD of duplicate 
cultures are shown in A. C) The morphology of colonies formed in the third round 
of the assay shown in A and B. Original magnification x 40.
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immunophenotype was identical (Figure 4.6). Both pMSCV-M/A and pMSCV-neo 
transduced cells expressed high levels of the B cell markers B220, CD 19 and BP-1. 
They also expressed the progenitor marker c-Kit and were negative for the myeloid 
marker Mac-1 (Figure 4.6). This cell surface antigen expression profile is consistent 
with that of a pre-B cell phenotype (Hardy and Hayakawa, 2001).
The large round colonies formed from pMSCV-M/A transduced cells replated into 
subsequent rounds with the same morphology (Figure 4.5A). However, attempts at 
generating stable cell lines from pMSCV-M/A transduced cells in liquid culture 
failed which suggests that the cells were not immortalised. Surprisingly, cells 
transduced with pMSCV-neo did not exhaust their proliferative capacity and also 
continued to form diffuse colonies of a similar size in subsequent replatings.
The observation that cells transduced with pMSCY-M/A formed larger colonies 
than cells transduced with the empty vector implies that MLL-AF4 may increase 
the proliferative capacity of B cell progenitors. However, the total number of cells 
harvested from the colonies formed from pMSCV-M/A and pMSCV-neo 
transduced cells was not significantly different. It is possible that the cells in the 
middle of the large dense MLL-AF4 colonies were exhausted of growth factors and 
subsequently died. Therefore, the number of cells harvested from the MLL-AF4 
colonies was under-represented. Alternatively, it is possible that instead of 
conferring an increased proliferative capacity to progenitors, MLL-AF4 may alter 
the expression of cell surface adhesion molecules such that the cells aggregate to 
form more compact, larger colonies. This result was only observed in 1 out of 4 
experiments hence further experiments are required to reproduce this data and 
validate this hypothesis.
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Figure 4.6 MLL-AF4 does not alter the differentiation of foetal HPCs. Cells 
transduced with the MLL-AF4 expression construct (pMSCV-M/A) and the empty 
vector (pMSCV-neo) were harvested from the fourth round of the methylcellulose 
serial replating assay and their cell surface antigen expression was analysed by 
flow cytometry. Thick red lines represent the expression profile of the indicated 
antigen and thin black lines represent the appropriate isotype control.
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Discussion
The constitutive MLL-ENL expression construct pMSCV-M/E was able to 
immortalise c-Kit+ Ter-119' foetal HPCs. The immortalised cells were capable of 
growth in liquid culture and two IL-3-dependent myeloid cell lines (FL-ME1 and 
FL-ME2) were established. Surprisingly, cells co-transduced with the empty-vector 
pREV-TRE and the inducer pMSCV-tTA did not exhaust their proliferative 
capacity until the fifth round of replating. Therefore, foetal HPCs have a greater 
capacity for self-renewal than that previously reported for HPCs isolated from bone 
marrow (Lavau et al., 1997). This is probably due to the increased percentage of 
HSCs in foetal liver compared to bone marrow (Morrison et al., 1995).
The immunophenotype of MLL-ENL immortalised cells derived from foetal liver 
(Mac-lhlgh, Gr-llow and c-Kit") more closely resembled the leukaemic cells isolated 
from MLL-ENL translocator mice (Mac-1+, Gr-1+, c-Kit') (Forster et al., 2003) than 
MLL-ENL immortalised cells derived from adult bone marrow (Mac-lhlgh, Gr-L, c- 
£itiow-int) (Lavau et ai ? 1 997). MLL-ENL translocator mice were generated by Cre- 
loxP mediated interchromosomal recombination (section 1.13). The MLL-ENL 
translocation could be detected in the bone marrow of some of these mice as early 
as 12 days after birth. Hence, the translocation possibly occurred in a cell of foetal 
origin. Leukaemia development following the de novo creation of the MLL-ENL 
translocation accurately mimics what occurs in patients since the translocation 
occurs specifically in haematopoietic cells and is likely to be a low frequency event. 
The fact that MLL-ENL cell lines derived from foetal HPCs are more similar to the 
leukaemic translocator mouse cells than MLL-ENL cell lines derived from adult 
HPCs suggests that retroviral transduction of foetal HPCs, rather than bone marrow 
HPCs, may more closely mimic the disease in patients.
The conditional MLL-ENL expression construct pREV-TRE-M/E consistently 
failed to immortalise foetal HPCs either alone, or in combination with the inducer 
pMSCV-tTA. A transient increase in self-renewal was observed in one experiment. 
However, the cells did not replate indefinitely in methylcellulose and they failed to 
grow in liquid culture. It is likely that successful co-transduction of the target cell 
capable of immortalisation with two retroviral constructs was a rare event. Various 
strategies were employed to increase the co-transduction efficiency. These included
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the generation of a pMSCV-tTA expression construct with a selectable marker to 
enable dual selection, concentration of the pMSCV-tTA virus, and generation of a 
new conditional MLL-ENL expression construct which produced higher titres of 
retrovirus. However, all of these approaches were unsuccessful in generating a 
conditional immortalised cell line derived from foetal HPCs. The fact that the 
constitutive MLL-ENL construct pMSCV-M/E yielded immortalised cell lines in 
only 2 out of 6 experiments suggested that the target cell susceptible to 
immortalisation by MLL-ENL was not present in sufficiently high numbers within 
the c-Kit+ Ter-119' population to give reproducible results. c-Kit is highly 
expressed on HSCs, CMPs and GMPs in E l4 foetal liver (Traver et al., 2001). 
However, c-Kit is also expressed on common lymphoid progenitors (CLPs) and 
megakaryocyte-erythroid progenitors (MEPs) (Traver et al., 2001). MLL-ENL is 
not able to immortalise the adult MEP or CLP (Cozzio et al., 2003), therefore the 
MEPs and CLPs present within the c-Kit+ Ter-119' population of El 2 foetal liver 
may be diluting the populations of progenitors that are susceptible to 
immortalisation by MLL-ENL. It is possible that a population of foetal HPCs 
further enriched in HSCs may give more reproducible results. This is described in 
more detail in chapter 5.
Preliminary experiments suggest that MLL-AF4 promotes the proliferation or cell 
to cell adhesion of foetal B cell progenitors. HPCs transduced with an MLL-AF4 
expression construct formed much larger colonies than cells transduced with an 
empty vector. However, the total number of cells harvested was not significantly 
different and both the MLL-AF4 and empty vector transduced cells exhibited an 
identical pre-B cell immunophenotype. The pre-B cell phenotype of the MLL-AF4 
transduced cells was surprising since leukaemic blasts isolated from patients with 
MLL-AF4 translocations usually have a pro-B cell phenotype (Eguchi et al., 2003). 
The pro-B cell leukaemic blasts also frequently express myeloid antigens. MLL- 
AF4 transduced cells lacked expression of the myeloid antigen Mac-1 and did not 
generate stable cell lines in liquid culture. Further experiments need to be 
performed in order to determine if these results are reproducible. It will be 
important to include a positive control for immortalisation given the inconsistency 
in generating myeloid MLL-ENL immortalised cell lines from c-Kit+ Ter-119’ 
HPCs. As with MLL-ENL, it may be important to obtain a purer population of stem
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cells for transduction. The frequent co-expression of myeloid antigens by pro-B cell 
leukaemic blasts isolated from patients harbouring 1 lq23 translocations suggests 
that a stem cell or a cell with bipotent B cell / monocytic differentiation capacity is 
the target for transformation.
Since the t(4; 11) translocation is one of the most prevalent translocations in infant 
ALL and the majority of MLL fusion proteins studied to date are oncogenic, it 
would be very surprising if MLL-AF4 lacked oncogenic potential. However, it is 
possible that MLL-AF4 is not oncogenic by itself and that secondary genetic events 
are required for immortalisation. MLL-AF4 may confer a pre-leukaemic phenotype 
to B cell progenitors by enhancing their proliferative capacity and creating an 
expanded pool of B cells in which secondary mutations can occur. Recent studies 
suggest that Flt-3 gene mutations are secondary genetic events which collaborate 
with MLL fusion proteins to induce leukaemia. Point mutations in the activation 
loop of the tyrosine kinase domain of Flt-3 were found in 18% of infant ALL 
patients with MLL-rearrangements (Taketani et al., 2004). Furthermore, over­
expression of a constitutively active mutant Flt-3 receptor bearing an internal 
tandem duplication (Flt3-ITD) co-operated with MLL-ENL and MLL-SEPT6 to 
accelerate leukaemogenesis (Ono et al., 2005). It will be interesting to examine 
whether a constitutively active Flt-3 receptor can co-operate with MLL-AF4 to 
immortalise HPCs.
An alternative hypothesis is that the reciprocal translocation product AF4-MLL 
confers oncogenic activity. This hypothesis is supported by the fact that AF4-MLL 
can transform murine embryonic fibroblasts yet MLL-AF4 cannot (Bursen et al., 
2004). The hypothesis is controversial since the AF4-MLL fusion gene is not 
expressed in all t(4;l 1) patients (Downing et al., 1994). One theory is that AF4- 
MLL may operate by way of a “hit and run mechanism” such that AF4-MLL is 
expressed at disease onset but expression is lost as subsequent mutations occur 
(Bursen et al., 2004). It will be interesting to examine whether AF4-MLL is able to 
immortalise HPCs and if MLL-AF4 can co-operate with AF4-MLL to induce 
leukaemia.
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Another possibility is that MLL-AF4 is oncogenic in human HPCs but not in 
murine HPCs. This may be due to differences in the transcriptional regulation of 
haematopoiesis between mice and humans. Interestingly, it has recently been 
reported that a dominant negative mutant CEBPa protein induces a differentiation 
block in human but not murine myeloid progenitors (Schwieger et al., 2004). 
Differences in the transcriptional regulation of the CEBPa gene, or CEBPa target 
genes, between mouse and human progenitors may explain these results. There is 
evidence to suggest that some genes might be differentially regulated in human and 
murine haematopoietic cells. For example, the CD34 gene is highly expressed by 
the vast majority of human HSCs (Baum et al., 1992), yet murine HSCs do not 
express significant levels of this gene (Osawa et al., 1996). Instead, CD34 is up- 
regulated at a slightly later stage in murine haematopoiesis (Okuno et al., 2002). It 
is possible therefore, that murine and human HSCs possess slightly different 
transcriptional programmes and that the murine HSC transcriptional programme 
may not facilitate immortalisation by MLL-AF4. There may also be differences in 
the transcriptional programme of murine and human B cell progenitors. This is 
because the signalling pathways governing B cell differentiation are more complex 
in humans than those in mice. Mice are dependent on IL-7 for B cell development 
since IL-7 receptor deficient mice lack B cells (Miller et al., 2002). However, other 
signalling pathways exist in humans that promote B cell development since 
individuals which lack expression of the IL-7 receptor possess normal numbers of 
B cells (Puel et al., 1998). The differences in cytokine requirements of human and 
murine B cell progenitors may ultimately result in different transcriptional 
programmes in these cells which may affect their susceptibility to immortalisation 
by MLL-AF4.
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Chapter 5 Establishment of conditional MLL-ENL immortalised 
cell lines.
Retroviral transduction of El 2 c-Kit+ Ter-119" HPCs with the constitutive MLL- 
ENL expression construct pMSCV-M/E yielded immortalised cell lines in 2 out of 
6 experiments. However co-transduction of this HPC population with the 
conditional MLL-ENL expression construct pREV-TRE-M/E or pMSCV-TRE-M/E 
(which generated higher titre retrovirus) and the inducer pMSCV-tTA failed to 
immortalise. We hypothesised that the c-Kit+ Ter-119" population may not contain 
the target cell, which is susceptible to immortalisation by MLL-ENL, at a high 
frequency. Therefore, a population of HPCs further enriched in HSCs was isolated. 
Since all long term reconstituting foetal HSCs are Mac-1+, c-Kit+ and Sca-1+ 
(Morrison et al., 1995), the Sca-1+ c-Kit+ HPC population from E l2 foetal liver was 
purified by fluorescence activated cell sorting (FACS). The ability of MLL-ENL to 
immortalise this enriched population of foetal HSCs was studied and compared to 
the ability of MLL-ENL to immortalise unsorted adult HPCs isolated from bone 
marrow of 5-fluorouracil (5-FU) treated mice.
5.1 The conditional MLL-ENL expression construct can immortalise HPCs 
isolated from bone marrow but not foetal liver.
The ability of MLL-ENL to immortalise El 2 Sca-1+ c-Kit+ foetal HPCs or unsorted 
adult HPCs isolated from the bone marrow of 5-FU treated mice was compared in 
the same experiment. 5-FU depletes the bone marrow of cycling cells thus 
enriching it in non-cycling progenitors. Cells were transduced on two consecutive 
days as described in section 4.1 with the constitutive MLL-ENL expression 
construct pMSCV-M/E or the empty vector pMSCV-neo. In addition, co­
transductions were performed with the conditional MLL-ENL construct pMSCV- 
TRE-M/E and the inducer pMSCV-tTA. Concentrated pMSCV-tTA virus was used 
for each co-transduction. After two rounds of transduction the cells were plated in 
methylcellulose (M3434 supplemented with GM-SCF) with G418 selection.
The constitutive MLL-ENL expression construct pMSCV-M/E was able to 
immortalise E12 Sca-1+ c-Kit+ HPCs (Figure 5.1 A). Several of the primary colonies
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Figure 5.1 The conditional MLL-ENL expression construct can immortalise 
unsorted adult HPCs but not Sca-1+ c-Kit+ foetal HPCs. A) Sca-1+ c-Kit+ HPCs 
isolated from E l2 foetal liver or B) unsorted HPCs isolated from the bone marrow 
of 5-FU treated mice were co-transduced with the conditional MLL-ENL 
expression construct pMSCV-TRE-M/E and pMSCV-tTA. Cells were also 
transduced with the constitutive MLL-ENL expression construct pMSCV-M/E or 
the empty vector pMSCV-neo. The transduced cells were cultured in 
methylcellulose under conditions that promoted myeloid development and serial 
replating assays were performed. The graphs show the number of colonies formed 
per 104 cells plated in each round of the assay following transduction with pMSCV- 
TRE-M/E and pMSCV-tTA (black squares), pMSCV-M/E (red diamonds) and 
pMSCV-neo (green circles). The mean and SD of duplicate cultures are shown in 
A. C) The morphology of colonies formed in the third round of the assays shown in 
A and B (original magnification x 40).
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formed from pMSCV-M/E transduced cells were very large, round and compact, 
similar to the immortalised colonies observed in previous assays using c-Kit+ Ter- 
119' HPCs. By the third round virtually all of the colonies were of this phenotype 
(Figure 5.1C). In contrast, the tertiary colonies formed from empty vector or 
pMSCV-TRE-M/E and pMSCV-tTA co-transduced cells were much smaller and 
less compact. Cells transduced with pMSCV-M/E were able to replate into the fifth 
and subsequent rounds of the methylcellulose assay (Figure 5.1 A) and a stable cell 
line was established in liquid culture supplemented with SCF, IL-6 and IL-3. 
However, cells transduced with pMSCV-neo or co-transduced with pMSCV-TRE- 
M/E and pMSCV-tTA ceased replating by the fifth round (Figure 5.1 A).
The conditional MLL-ENL expression construct pMSCV-TRE-M/E immortalised 
adult unsorted HPCs in the presence of the inducer pMSCV-tTA (Figure 5. IB). In 
contrast to the assays using foetal HPCs, the morphology of the primary colonies 
formed from adult HPCs was similar for all of the constructs examined. Many 
colonies were large, dense CFU-GM (colony-forming-unit granulocyte- 
macrophage) or CFU-GEMM (colony-forming-unit granulocyte-erythrocyte- 
macrophage-megakaryocyte) of round or non-uniform shape. The secondary 
colonies possessed a similar morphology to the primary colonies but by the third 
plating, cells transduced with pMSCV-M/E or pMSCV-neo formed only sparse 
macrophage or small granulocyte colonies (Figure 5.1C). The majority of the 
colonies formed from pMSCV-TRE-M/E and pMSCV-tTA co-transduced cells 
were of a similar morphology. However, one of the colonies formed from pMSCV- 
TRE-M/E and pMSCV-tTA co-transduced cells was large, round and dense (Figure 
5.1C). This colony replated into the fourth and subsequent rounds of the 
methylcellulose assay and a stable cell line was established in liquid culture. Cells 
transduced with either the empty vector or the constitutive construct pMSCV-M/E 
exhausted their proliferative capacity by the fourth round of replating (Figure 5. IB).
5.2 The constitutive and conditional MLL-ENL expression constructs do not 
immortalise the same purified populations of adult HPCs.
In previous experiments, the constitutive MLL-ENL expression construct pMSCV- 
M/E immortalised c-Kit+ Ter-119’ foetal HPCs (2/6 experiments) and Sca-1+ c-Kit+ 
foetal HPCs (1/1 experiment) while the conditional MLL-ENL expression construct
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pMSCV-TRE-M/E, either alone or in combination with pMSCV-tTA, did not 
(Figures 4.1 and 5.1 A). However, the conditional MLL-ENL expression construct 
in combination with tTA, was able to immortalise unsorted adult HPCs (5/5 
experiments) but the constitutive construct was not (Figure 5.IB). The ability of 
these constructs to immortalise purified populations of adult HPCs was examined 
by isolating lin" and c-Kit+ populations from the bone marrow of 5-FU treated mice 
by magnetic activated cell sorting (MACS). Transductions were performed as 
described in section 5.1.
The constitutive MLL-ENL expression construct pMSCV-M/E was able to 
immortalise c-Kit+ adult HPCs (Figure 5.2A). Many of the tertiary colonies formed 
from pMSCV-M/E transduced cells were of the immortalised phenotype (Figure 
5.2C). These colonies replated into subsequent rounds and a stable cell line was 
established in liquid culture. However, immortalisation was not observed using the 
conditional MLL-ENL expression construct either alone or in combination tTA 
(Figure 5.2A).
The conditional MLL-ENL expression construct pMSCV-TRE-M/E in combination 
with the inducer tTA was able to immortalise lin' adult HPCs (Figure 5.2B). Many 
of the tertiary colonies formed from pMSCV-TRE-M/E and pMSCV-tTA co- 
transduced cells were of the immortalised phenotype (Figure 5.2C). These colonies 
replated into subsequent rounds and a stable cell line was established in liquid 
culture. However, immortalisation was not observed using the constitutive MLL- 
ENL expression construct (Figure 5.2B). The ability of the conditional construct to 
immortalise lin' HPCs in the absence of tTA expression was not addressed in this 
experiment due to the low numbers of lin' sorted cells obtained. In summary, the 
constitutive MLL-ENL expression construct was able to immortalise c-Kit+ HPCs 
bit not lin' HPCs and the conditional MLL-ENL expression construct in 
combination with tTA, was able to immortalise lin' HPCs but not c-Kit+ HPCs. The 
reason why the conditional and constitutive constructs failed to immortalise the 
same purified population of progenitors is not clear.
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Figure 5.2 The conditional and constitutive MLL-ENL expression constructs 
do not immortalise the same population of purified adult HPCs. A) c-Kit+ or 
B) lin" HPCs isolated from the bone marrow of 5-FU treated mice were co- 
transduced with the conditional MLL-ENL expression construct pMSCV-TRE- 
M/E and the inducer pMSCV-tTA. Cells were also transduced with the 
constitutive MLL-ENL expression construct pMSCV-M/E or the empty vector 
pMSCV-neo. c-Kit+ HPCs were also transduced with the conditional construct in 
the absence of pMSCV-tTA. The transduced cells were cultured in 
methylcellulose under conditions that promoted myeloid development and serial 
replating assays were performed. The graphs show the number of colonies formed 
per 104 cells plated in each round of the assay following transduction with 
pMSCV-TRE-M/E and pMSCV-tTA (black squares), pMSCV-TRE-M/E alone 
(blue triangles), pMSCV-M/E (red diamonds) or pMSCV-neo (green circles). The 
mean and SD of duplicate cultures are shown in A. C) The morphology of 
colonies formed in the third round of the assays shown in A and B (original 
magnification x 40).
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5.3 Continued MLL-ENL expression is required to maintain the immortalised 
phenotype in vitro.
In order to determine if cells immortalised by MLL-ENL require continued MLL- 
ENL expression to form colonies in methylcellulose, cells were harvested from the 
fourth round of the methylcellulose assay and an equivalent number of cells were 
re-plated with or without the addition of dox. Cells immortalised with the 
conditional MLL-ENL expression constructs pMSCV-TRE-M/E and pMSCV-tTA 
formed large round and compact colonies in the absence of dox, which were 
composed of myeloblasts (Figure 5.3A-D). However, in the presence of dox the 
cells did not generate colonies but instead formed extremely small clusters (Figure 
5.3A-C). These were mostly composed of terminally differentiated macrophages 
and granulocytes (Figure 5.3D). Cells immortalised with the constitutive MLL-ENL 
expression construct pMSCV-M/E formed a similar number of colonies in the 
presence or absence of dox (Figure 5.3A-B). Although the colonies were slightly 
smaller in the presence of dox, they were still of the immortalised phenotype (large, 
round and compact) and were composed of myeloblasts (Figure 5.3C-D).
Therefore, continued MLL-ENL expression is required for colony formation and to 
maintain the phenotype of the immortalised cells.
5.4 Generation and characterisation of conditional MLL-ENL immortalised 
cell lines.
Five conditional cell lines were generated from HPCs co-transduced with pMSCV- 
TRE-M/E and pMSCV-tTA in five independent experiments. However, only three 
(TRE-ME2, TRE-ME3 and TRE-ME6) were characterised in detail. The 
constitutive cell line (c-MEl) was generated from HPCs transduced with pMSCV- 
M/E. TRE-ME2 and TRE-ME6 were derived from unsorted bone marrow, TRE- 
ME3 was derived from lin' bone marrow and c-MEl was derived from c-Kit+ bone 
marrow. All were generated using unconcentrated MLL-ENL virus apart from 
TRE-ME6 in which both the pMSCV-TRE-M/E and the pMSCV-tTA virus were 
concentrated.
All of the cell lines proliferated rapidly in liquid culture, with c-MEl showing the 
highest rate of proliferation (Figure 5.4A). TRE-ME3 proliferated at a slower rate 
that the other cell lines at first (Figure 5.4A). However, after a few months in liquid
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Figure 5.3 MLL-ENL is required to maintain as well as initiate 
immortalisation of HPCs. Cells transduced with either the conditional MLL- 
ENL expression construct (pMSCV-TRE-M/E) and the inducer pMSCV-tTA or 
the constitutive MLL-ENL expression construct (pMSCV-M/E) were harvested 
from the fourth round of the methylcellulose assay and replated into a subsequent 
round with or without the addition of dox. A) The number of colonies formed per 
104 cells plated after 7 days is shown. The plot shows the mean and SD of 
duplicate cultures. B) INT stains of the fifth round methylcellulose cultures after 
culture in the presence or absence of dox for 7 days. C) Typical morphology of 
the colonies (original magnification, x 40) and D) typical morphology of the cells 
(original magnification, x 400) harvested from the fifth round of the assay after 
culture in the presence or absence of dox for 7 days. Cells were visualised by 
cytospin preparation followed by May-Grunwald-Giemsa staining.
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Figure 5.4 Generation of MLL-ENL immortalised cell lines. Immortalised cell 
lines were generated by placing cells harvested from the third round of the 
methylcellulose re-plating assay in liquid culture supplemented with SCF, IL-6 and 
IL-3. A) The graph shows the log of the fold accumulation in cell number of TRE - 
ME2 (red circles), TRE-ME3 (blue diamonds), TRE-ME6 (green squares) and c- 
ME1 (black triangles). B) Southern blot analysis of genomic DNA isolated from 
the cell lines showing integration of the MLL-ENL provirus. Untransduced bone 
marrow was used as a negative control. The indicated N-terminal MLL cDNA 
fragment was used as a probe to detect the 6-kilobase proviral band following 
EcoRl digestion of genomic DNA. The probe detects a fragment of the endogenous 
MLL gene (top arrow) and the MLL-ENL provirus (bottom arrow). E indicates 
EcoRI. C) Reverse-transcription (RT)-PCR analysis of total RNA isolated from the 
cell lines demonstrating expression of the MLL-ENL transcript. Untransduced 
bone marrow (BM) was used as a negative control. Negative control reactions 
were performed in the absence of reverse transcriptase (RT).
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culture its rate of proliferation increased to match that of TRE-ME2 (data not 
shown). Intact MLL-ENL provirus was detected in each cell line by Southern 
blotting (Figure 5.4B) and expression of the MLL-ENL transcript was confirmed in 
each cell line by RT-PCR using primers that span the MLL-ENL breakpoint (Figure 
5.4C). As previously reported for cells immortalised by MLL-ENL (Lavau et al., 
1997), MLL-ENL protein expression could not be detected in these cell lines by 
Western blot analysis using anti-MLL, anti-myc or anti-flag antibodies.
The cytokine requirements of the conditional cell lines were very similar to that of 
the constitutive line. All the lines were growth factor dependent since the 
immortalised cells died within 48 hours of growth factor withdrawal (data not 
shown). Each line was able to survive and proliferate in IL-3 alone and a synergistic 
response was observed when IL-3 was combined with SCF (Figure 5.5A). TRE- 
ME2, TRE-ME6 and the constitutive cell line proliferated well in GM-CSF. 
However, TRE-ME3 did not respond as well as the other lines to GM-CSF (Figure 
5.5A). Since TRE-ME3 expressed a pattern of surface markers reminiscent of a 
more immature progenitor (Gr-lmt, Mac-110, F4/8010 and c-Kit+) (Figure 5.5B), it 
could be that these cells fail to respond because they are blocked at a stage of 
differentiation prior to developing the ability to signal through the GM-CSF 
receptor. The surface marker expression profile of the other cell lines is consistent 
with that of a more mature myeloid progenitor (Figure 5.5B). The 
immunophenotype of c-MEl most closely resembled that of TRE-ME2. However, 
c-MEl expressed lower levels of Gr-1 and F4/80 than TRE-ME2. Hence, the cell 
surface marker expression profile of c-MEl is consistent with that of a slightly 
more immature myeloid progenitor than TRE-ME2. TRE-ME6 expressed lower 
levels of Gr-1 and c-Kit and higher levels of Mac-1 and F4/80 than any of the other 
cell lines (Figure 5.5B). This data suggests that TRE-ME6 is further engaged along 
the myeloid differentiation pathway than the other cell lines.
5.5 MLL-ENL immortalised cell lines cease proliferating upon loss of MLL- 
ENL expression.
In order to establish if MLL-ENL expression could be regulated by dox in the 
conditional cell lines a Q-PCR strategy was developed to measure the levels of 
MLL-ENL transcript expression in these cell lines (section 2.24). Culture of the
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Figure 5.5 Characterisation of MLL-ENL immortalised cell lines. A) The
graphs show the absorbance from MTS assays performed on the cell lines 
following culture with the indicated cytokines for 48 hours. Plots show the mean 
and SD of triplicate absorbance readings. B) Flow cytometric analysis of cell 
surface antigen expression of the cell lines. Thick red lines represent the 
expression profile of the indicated antigen and thin black lines represent the 
appropriate isotype control.
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conditional cell lines with dox for 24 hours resulted in a large decrease in MLL- 
ENL transcript expression, 93 fold, 482 fold and 705 fold for TRE-ME2, TRE-ME3 
and TRE-ME6, respectively (Figure 5.6A). As expected, treatment of the 
constitutive cell line with dox did not alter the level of MLL-ENL transcript 
expression.
The effect of losing MLL-ENL expression on the viability and phenotype of the 
MLL-ENL immortalised cell lines was examined by culturing the cells with or 
without the addition of dox. The conditional cell lines proliferated rapidly in the 
absence of dox. However, 10 days after the addition of dox, all of the conditional 
lines had ceased proliferating (Figure 5.6B). The constitutive cell line proliferated 
continuously in the presence of dox although the rate was slightly slower than that 
of cells maintained without dox (Figure 5.6B).
5.6 MLL-ENL immortalised cell lines terminally differentiate upon loss of 
MLL-ENL expression.
Both TRE-ME2 and TRE-ME6 terminally differentiated when MLL-ENL 
expression was turned off by the addition of dox. Four days after the addition of 
dox, TRE-ME2 expressed increased levels of Gr-1 and Mac-1 and decreased levels 
of c-Kit and F4/80 (Figure 5.7). These changes in cell surface marker expression 
are consistent with the differentiation of myeloid progenitors into neutrophils. By 8 
days all of the cells possessed a segmented nucleus, which is a characteristic of 
differentiating neutrophils (Figure 5.8). In contrast to TRE-ME2 which exhibited 
only neutrophil differentiation potential, TRE-ME6 was able to differentiate into 
both neutrophils and macrophages in response to dox. After culture of TRE-ME6 in 
dox for 4 days, the phenotypically uniform population split into a macrophage sub­
population (Mac-lhl, F4/80hl) and a neutrophil sub-population (Mac-1+, F4/8010) 
(Figure 5.7). The neutrophil population differentiated more quickly than the 
macrophage population and after culture in dox for 8 days the neutrophils had 
terminally differentiated and died, since only mature macrophages were observed 
(Figure 5.8).
In contrast to TRE-ME2 and TRE-ME6, TRE-ME3 did not terminally differentiate 
in response to dox. An increase in Gr-1 expression and a decrease in c-Kit
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Figure 5.6 MLL-ENL cell lines cease proliferating upon loss of MLL-ENL 
expression. A) The graph shows the relative level of MLL-ENL mRNA 
expression in TRE-ME2, TRE-ME3, TRE-ME6 and c-MEl following treatment 
with (red columns) or without dox (black columns) for 24 hours. Total RNA was 
used to make cDNA for Q-PCR analysis and data was normalised to GAPDH. The 
mean and SD of triplicate measurements are shown. B) The graphs show the log of 
the fold accumulation in cell number following maintenance of TRE-ME2 
(circles), TRE-ME3 (diamonds), TRE-ME6 (squares) and c-MEl (triangles) with 
(red lines) or without dox (black lines).
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Figure 5.8 MLL-ENL cell lines terminally differentiate upon loss of MLL- 
ENL expression. Morphology of the cells following culture with or without dox 
for 4 and 8 days (original magnification x 400). The morphology of TRE-ME3 
after 8 days with dox is not shown since there were no viable cells left in the 
culture.
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expression were observed after culture in dox for 4 days which is consistent with 
neutrophil differentiation (Figure 5.7). However, at this time-point the majority of 
the cells were still myeloblasts, very few cells possessed a segmented nucleus 
(Figure 5.8). This is probably because TRE-ME3 is more immature than the other 
conditional cell lines and would therefore take longer to differentiate. However, 
instead of terminally differentiating into neutrophils, the cells died. After 8 days in 
the presence of dox, no viable cells were left in the culture (data not shown). 
Therefore, it seems that TRE-ME3 is able to initiate but not complete the process of 
differentiation. As expected, the constitutive cell line did not differentiate in 
response to dox. Eight days after the addition of dox the cellular morphology was 
similar to that of cells maintained in the absence of dox (Figure 5.8).
5.7 MLL-ENL immortalised cells terminally differentiate in response to G- 
CSF.
MLL-ENL immortalised cell lines derived from adult bone marrow retain the 
ability to undergo terminal differentiation in the presence of G-CSF (Lavau et al., 
1997). Therefore, the G-SCF responsiveness of the cell lines that I had generated 
was examined. Since TRE-ME6 differentiated into both neutrophils and 
macrophages in response to dox, their response to M-CSF was also examined. 
TRE-ME2, TRE-ME6 and c-MEl were able to terminally differentiate into 
neutrophils in response to G-CSF. Within 4 days there was an increase in Gr-1 
expression and a decrease in c-Kit expression (Figure 5.9). TRE-ME2 and c-MEl 
expressed increased levels of Mac-1 after 4 days of G-CSF treatment. This is 
consistent with the differentiation of myeloid blasts into myelomonocytic cells 
(Lagasse and Weissman, 1996). However, the level of Mac-1 expressed by TRE- 
ME6 decreased after 4 days of G-CSF treatment (Figure 5.9). This is consistent 
with the fact that TRE-ME6 is further engaged along the myeloid differentiation 
pathway that the other cell lines (Figure 5.5) and that Mac-1 expression normally 
decreases at late stages of neutrophil differentiation (Lagasse and Weissman, 1996). 
By 4 days TRE-ME6 had completely differentiated into neutrophils whereas c-MEl 
and TRE-ME2 took another 4 days to reach a similar stage of differentiation 
(Figure 5.10). In contrast to the other cell lines, TRE-ME3 died within 48 hours 
when cultured in G-CSF (data not shown), which is consistent with its inability to 
terminally differentiate into neutrophils in response to dox.
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Figure 5.9 MLL-ENL cell lines differentiate in response to G-CSF. Flow 
cytometric analysis of cell surface antigen expression following culture of the cell 
lines in either G-CSF or M-CSF. The cells treated with G-CSF were analysed after 
4 days and the cells treated with M-CSF were analysed after 3 days. Shaded plots 
represent expression of the indicated antigen following culture with SCF, IL6 and 
IL-3. Thick black lines represent expression of the antigen following culture in 
either G-CSF or M-CSF.
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Figure 5.10 MLL-ENL cell lines differentiate in response to G-CSF.
Morphology of the cell lines and a representative clone of TRE-ME6 following 
culture with the indicated cytokines (original magnification x 400).
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TRE-ME6 was the only cell line able to differentiate into macrophages in response 
to M-CSF. After 4 days the cells expressed increased levels of Mac-1, Gr-1 and 
F4/80 (Figure 5.9) and possessed a large and vacuolar cytoplasm (Figure 5.10). The 
TRE-ME6 cell line was cloned in order to determine whether it was comprised of 
different unipotent clones capable of differentiation into either neutrophils or 
macrophages, or whether it was truly bipotent. All five of the clones derived from 
this cell line were able to differentiate into neutrophils in response to G-CSF and 
macrophages in response to M-CSF (see example in Figure 5.10). Southern blotting 
analysis using a neomycin probe to detect 5’ end fragments revealed that all of the 
clones possessed the same single retroviral integration site as the parental TRE- 
ME6 cell line (Figure 5.11A-B). Therefore, TRE-ME6 is monoclonal and bi-potent. 
Analysis of the retroviral integration sites of the other cell lines revealed that TRE- 
ME2 and TRE-ME3 were also monoclonal (Figure 5.1 IB). Further experiments are 
required in order to determine if c-MEl is monoclonal. The end fragment obtained 
upon BamHl digestion of genomic DNA isolated from c-MEl was greater than 11 
kb which did not transfer as well as the shorter end fragments obtained for the other 
cell lines.
In contrast to TRE-ME6, the other cell lines did not differentiate in response to M- 
CSF. TRE-ME2, TRE-ME3 and c-MEl ceased proliferating and died following 
culture in M-CSF (data not shown). The inability of these cell lines to respond to 
M-CSF and the inability of TRE-ME3 to respond to G-CSF or GM-CSF cannot be 
explained by a lack of expression of the appropriate growth factor receptors since 
all of the lines expressed the receptors for M-CSF, G-CSF and GM-CSF (Figure 
5.12). However, it is possible that the absolute levels of expression of these growth 
factor receptors vary between the cell lines and that this variation may account for 
the different cytokine responses observed. A more quantitative analysis such as Q- 
PCR should reveal if this is the case.
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Figure 5.11 The conditional MLL-ENL cell lines are monoclonal. A) Southern 
blot analysis of genomic DNA isolated from 5 TRE-ME6 clones in lanes 2-6 
respectively. Untransduced bone marrow was used as a negative control (lane 1). 
B) Southern blot analysis of genomic DNA isolated from the parental TRE-ME6 
cell line (lane 1), TRE-ME2 (lane 2), TRE-ME3(A) (lane 3) and TRE-ME3(B) 
(lane 4). TRE-ME3(A) is the TRE-ME3 cell line analysed in this chapter. TRE- 
ME3(B) will be described in chapter 6. Genomic DNA was digested with BamHI 
which cuts just after the neomycin gene within the provirus. By probing the blot 
with a neomycin cDNA fragment, retroviral integration sites can be identified 
based on the proximity of the 5’LTR to the nearest endogenous BamHI site. 
Different integration sites would give rise to bands of different sizes. A single band 
suggests that the cell line has one integration and is therefore monoclonal. The 
arrows indicate the proviral integration sites.
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Figure 5.12 Expression of growth factor receptors by the MLL-ENL cell lines.
The figure shows the expression of the granulocyte-macrophage colony- 
stimulating factor receptor (GM-CSFR) (upper panel), granulocyte-colony- 
stimulating factor receptor (G-CSFR) (middle panel) and macrophage-colony- 
stimulating factor receptor (M-CSFR) (lower panel) by each cell line. Transcript 
expression was analysed by RT-PCR using primers specific for each receptor. 
Negative control reactions were performed in the absence of reverse transcriptase 
(RT).
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Discussion
We hypothesised that the c-Kit+ Ter-119' progenitor population from E l2 foetal 
liver may not be the best source of HPCs to generate MLL-ENL immortalised cell 
lines since the immortalisation observed using the constitutive MLL-ENL 
expression construct was not reproducible. Immortalisation was only observed in 2 
out of 6 experiments using the constitutive MLL-ENL expression construct and was 
never observed using the conditional MLL-ENL expression construct.
A current hypothesis is that the target cell susceptible to transformation by 
chromosomal translocations is an HSC (section 1.6). However, MLL-ENL is also 
able to transform the CMP and GMP (Cozzio et al., 2003). HSCs, CMPs and GMPs 
are present within the c-Kit+ Ter-119' population isolated from E l2 foetal liver. 
However, foetal CMPs are more biased to differentiate into MEPs than GMPs 
(Nicolini et al., 1999; Traver et al., 2001). Comparison of differential counts of 
colony types derived from single foetal CMPs (Traver et al., 2001) and adult CMPs 
(Akashi et al., 2000) revealed that megakaryocyte-erythroid production from the 
foetal CMP was approximately two-fold greater than that from the adult CMP 
(Traver et al., 2001). The authors hypothesised that this was due to the critical role 
of the foetal CMP in generating sufficient numbers of erythrocytes to oxygenate the 
rapidly expanding tissues of the embryo (Traver et al., 2001). Since the GMP rather 
than the MEP is a target of MLL-ENL transformation (Cozzio et al., 2003), a purer 
population of foetal HSCs was isolated for retroviral transduction. The ability of 
MLL-ENL to immortalise foetal HSCs and unsorted adult HPCs was directly 
compared. The constitutive MLL-ENL expression construct successfully 
immortalised the HSC enriched population of El 2 Sca-1+ c-Kit+ progenitors but the 
conditional MLL-ENL expression did not. In contrast, the conditional MLL-ENL 
expression construct in combination with the inducer tTA, successfully 
immortalised unsorted adult HPCs from 5-FU treated mice but the constitutive 
MLL-ENL expression construct did not.
Further experiments revealed that the constitutive and conditional constructs 
consistently failed to immortalise the same purified population of progenitors. The 
constitutive construct immortalised foetal and adult c-Kit+ HPCs whereas the 
conditional construct immortalised unsorted and lin' adult HPCs from 5-FU treated
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mice. A potential explanation for this observation is that the level of MLL-ENL 
expression required to initiate immortalisation may differ between populations of 
progenitors. It is possible that high levels of MLL-ENL expression are required to 
immortalise progenitor populations that are enriched in HSCs such as c-Kit+ Ter- 
119' or Sca-1+ c-Kit+ foetal HPCs and adult c-Kit+ HPCs. Lower levels of MLL- 
ENL expression may not facilitate immortalisation of these populations. If the LTR 
of pMSCV is capable of driving higher levels of MLL-ENL expression than the 
TRE, this hypothesis might explain the results. Indeed, quantitative analysis 
revealed that the constitutive cell line (c-MEl) which was derived from adult c-Kit+ 
HPCs, expressed higher levels of the MLL-ENL transcript than all three conditional 
cell lines which were derived from adult lin" and unsorted HPCs. Therefore, it is 
possible that low levels of MLL-ENL can immortalise more mature populations of 
HPCs such as those found in the lin' and unsorted populations from adult bone 
marrow. Higher levels of MLL-ENL expression may be deleterious to these more 
mature populations. In accordance with this, it has been reported that high levels of 
MLL-fusion protein expression are incompatible with the survival of some cell 
types (Caslini et al., 2000; Ayton and Cleary, 2001) (section 1.13).
Cells immortalised by MLL-ENL failed to self-renew in methylcellulose upon loss 
of MLL-ENL expression suggesting that continued MLL-ENL expression is 
required to maintain the immortalised phenotype in vitro. Furthermore, conditional 
myeloid cell lines were generated which either terminally differentiated or died 
upon switching off MLL-ENL expression by addition of dox. This result is 
consistent with previous studies in which haematopoietic progenitor cells were 
immortalised with an oestrogen-regulated conditional MLL-ENL fusion protein 
(Ayton and Cleary, 2003; Zeisig et al., 2004). In the latter study immortalised 
myeloid cell lines were generated which were dependent on tamoxifen for their 
continued proliferation and survival and underwent terminal neutrophil 
differentiation following the withdrawal of tamoxifen. Two out of the three 
conditional cell lines I generated (TRE-ME2 and TRE-ME6), terminally 
differentiated into neutrophils upon loss of MLL-ENL expression. TRE-ME6 was 
bipotent, since it also exhibited macrophage differentiation potential in response to 
dox and clones were capable of neutrophil or macrophage differentiation in 
response to G-CSF or M-CSF, respectively. The bipotent nature of this cell line
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suggests that the differentiation block imposed by MLL-ENL occurred prior to 
commitment to either the granulocyte or monocyte lineage, at the level of, or 
upstream of, the GMP. In contrast, TRE-ME2 and the constitutive cell line (c-MEl) 
were capable of neutrophil differentiation in response to G-CSF but lacked the 
ability to respond to M-CSF even though they expressed the M-CSF receptor. This 
might suggest that the differentiation block imposed by MLL-ENL in these cell 
lines is downstream of the GMP, after commitment to the granulocyte lineage. 
However, TRE-ME2 and c-MEl possessed a more immature immunophenotype 
than TRE-ME6. It is possible that the differentiation block occurred prior to 
neutrophil commitment in TRE-ME2 and c-MEl and that MLL-ENL may suppress 
macrophage differentiation to a greater extent in these cell lines. Interestingly, the 
third conditional cell line (TRE-ME3) lacked the ability to respond to both G-CSF 
and M-CSF and failed to complete differentiation upon loss of MLL-ENL 
expression. The phenotype of this cell line is consistent with that of a more 
immature myeloid progenitor than the other cell lines. It is possible that this cell 
line fails to undergo cytokine induced differentiation because MLL-ENL suppresses 
factors required for both neutrophil and macrophage differentiation. Hence, the 
more immature the progenitor immortalised by MLL-ENL, the stronger the 
differentiation block imposed. However, TRE-ME3 also failed to differentiate upon 
loss of MLL-ENL expression. Therefore, it is possible that this cell line has 
acquired other genetic changes such that it cannot differentiate and instead 
undergoes cell death upon loss of MLL-ENL expression. The fact that TRE-ME3 
proliferated more slowly than the other cell lines at first but matched the rate of 
proliferation of the other cell lines after a few months in culture suggests that it may 
have acquired secondary mutations.
Immortalised MLL-ENL cell lines generated by retroviral transduction of purified 
populations of HSCs, CMPs and GMPs were found to be blocked at an identical 
stage of myelomonocytic development and induced AML in mice with identical 
latencies and phenotype (Cozzio et al., 2003). The authors of this study state that 
the differentiation block imposed by MLL-ENL in these cells occurs at the 
unipotent monocytic progenitor stage. However, the present experiments and 
previous studies (Lavau et al., 1997) show that MLL-ENL immortalised cells retain 
neutrophil differentiation capacity which would be incompatible with a block at the
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level of the unipotent monocytic progenitor stage. Interestingly, the cell lines that I 
have generated do not possess identical immunophenotypes which suggests that 
MLL-ENL can arrest the differentiation of cells at different stages of myeloid 
development. I have also demonstrated that MLL-ENL can immortalise progenitors 
which retain both neutrophil and macrophage differentiation potential. Therefore, 
the differentiation arrest imposed by MLL-ENL can occur prior to lineage 
commitment.
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Chapter 6 Identification of targets of MLL-ENL.
It has been previously suggested that Hoxa7, Hoxa9 and Meis-1 are targets of 
MLL-ENL (Zeisig et al., 2004). However, it is not known if other members of the 
Hoxa cluster such as Hoxa4, Hoxa5 and HoxalO, which are frequently over­
expressed in patients with 1 lq23 translocations (Armstrong et al., 2002; Debemardi 
et al., 2003; Rozovskaia et al., 2003), are also targets of MLL-ENL. A current 
hypothesis is that MLL-fusion proteins immortalise HPCs by aberrantly 
maintaining the expression of genes regulated by wild-type MLL. Since several 
members of the Hoxa, Hoxb and Hoxc gene clusters are targets of wild-type MLL 
(Yu et al., 1995; Hess et al., 1997; Yagi et al., 1998; Yu et al., 1998; Ernst et al., 
2004b), we analysed the expression profile of all 39 murine Hox genes and the Meis 
and Pbx Hox co-factors in the constitutive (c-MEl) and conditional (TRE-ME2, 
TRE-ME3 and TRE-ME6) MLL-ENL immortalised cell lines by Quantitative-PCR. 
Global gene expression profiling of the cell lines was also performed by Affymetrix 
microarray analysis in order to identify other non-Hox targets of MLL-ENL.
6.1 MLL-ENL immortalised cell lines express a specific pattern of Hoxa genes.
In a collaboration with Prof. Terry Lappin (Queen’s University, Belfast), we 
analysed the global Hox gene expression profile of the MLL-ENL immortalised cell 
lines by Q-PCR. The murine Hox genes were cloned and standard curves were 
generated for 38 of the 39 genes and for the Hox co-factors Meis-1 and Pbx-1.
These curves were used to convert Q-PCR data, which had been normalised to 18S 
ribosomal RNA expression, into Hox gene copy number (work of D. Grier, G. 
McGonigle, A. Thompson and T. Lappin, Queen’s University, Belfast). The 
expression levels of each Hox gene could then be compared with other Hox genes 
expressed by the same cell line and with Hox gene expression in other cell lines 
(Horton et al., 2005).
All of the MLL-ENL immortalised cell lines expressed a broadly similar pattern of 
Hoxa cluster genes (Figure 6.1) (Horton et al, 2005). TRE-ME2 and c-MEl 
expressed similar levels of the Hoxa cluster genes while TRE-ME3 and TRE-ME6 
expressed slightly lower levels. The 5’ Hoxa genes (excluding HoxalS which was
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Figure 6.1 MLL-ENL cell lines express a Hoxa code. The graphs show the 
number of copies of each Hoxa gene per 25 ng total RNA following culture of 
each line in the presence (red columns) or absence (black columns) of dox for 48 
hours. The mean and SD of triplicate measurements are shown.
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not expressed) were more highly expressed than the 3’ Hoxa genes in all of the 
lines examined. The Hoxa4-Hoxal 1 genes were always expressed at significant 
levels and Hoxa9 was consistently the most highly expressed Hox gene (Figure 
6 . 1).
6.2 MLL-ENL immortalised cell lines express some Hoxb genes but do not 
express any Hoxc or Hoxd genes.
Hoxb3, Hoxb4 and Hoxbl3 were the only Hoxb cluster genes expressed in MLL- 
ENL immortalised cell lines (Figure 6.2). These genes were expressed at much 
lower levels than the 5’ Hoxa genes. The level of expression of the Hoxc and Hoxd 
cluster genes was not significant when compared to the level of expression of the 
Hoxa and Hoxb genes (Figure 6.3). Therefore, Hoxb5, Hoxb6, Hoxb8, Hoxc6, 
Hoxc8 and Hoxc9, which are regulated by wild-type MLL (Hanson et al., 1999; 
Ernst et al., 2004b), are not expressed in the MLL-ENL immortalised cell lines.
6.3 The 5’ Hoxa genes are potential targets of MLL-ENL.
The global Hox gene expression profile of each cell line was analysed after 
treatment with dox for 48 hours in order to determine if Hox gene expression was 
regulated by MLL-ENL. Dox caused a significant decrease in the expression (p < 
0.05 [two-tailed students t-test]) of Hoxa4, Hoxa7, Hoxa9, HoxalO and Hoxall in 
all of the conditional cell lines (Figure 6.1). A significant decrease was also 
observed in Hoxa5 and Hoxa6 expression in TRE-ME3 and TRE-ME6. In contrast, 
Hoxa gene expression was either unchanged or slightly increased following 
treatment of c-MEl with dox. This data suggests that the Hoxa4-all genes may be 
targets of MLL-ENL.
Dox caused an increase in the expression of Hoxb 3 and Hoxb4 in c-MEl, TRE- 
ME2 and TRE-ME3 and a decrease in Hoxb 13 expression in all of the lines 
examined (Figure 6.2). The fact that dox caused similar changes in the expression 
of these genes in c-MEl as in the conditional cell lines means that we were unable 
to establish whether these changes in expression were connected with the loss of 
MLL-ENL expression. It is known that dox alters the kinetics of the cell cycle. For 
example, c-MEl proliferates at a slightly slower rate when cultured in the presence 
of dox (Figure 5.6). There is also evidence that the expression of certain Hox genes
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Figure 6.2 MLL-ENL cell lines express some Hoxb genes. The graphs show the 
number of copies of each Hoxb gene per 25 ng total RNA following culture of each 
cell line in the presence (red columns) or absence (black columns) of dox for 48 
hours. The mean and SD of triplicate measurements are shown.
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changes during the cell cycle (McGonigle et al., 2005). Therefore, it is possible that 
the dox induced changes in Hoxb expression reflect the effect of dox on slowing the 
cell cycle.
The changes in Hoxa gene expression upon dox treatment suggest that MLL-ENL 
regulates the expression of multiple 5’ Hoxa cluster genes. However, there is an 
alternative explanation for these results. Hox gene expression normally decreases as 
myeloid cells differentiate from progenitors to terminally differentiated cells 
(Sauvageau et al., 1994; Pineault et al., 2002). The conditional cell lines 
differentiate upon loss of MLL-ENL expression (Figures 5.7 and 5.8), therefore 
early time-points were chosen in order to minimise differentiation associated 
changes in Hox gene expression. However, it cannot be excluded that the decreases 
observed in Hox gene expression in this experiment are due to the differentiation of 
immortalised cells upon loss of MLL-ENL expression rather than as a direct result 
of losing MLL-ENL expression. Therefore, the fact that TRE-ME2 and TRE-ME6 
differentiated into neutrophils in response to G-CSF was utilised in addressing 
whether the Hoxa4-all genes were targets of MLL-ENL.
6.4 The Hoxa4-all genes are targets of MLL-ENL.
The Hoxa gene expression profile of cells stimulated to differentiate with G-CSF 
(in the presence of MLL-ENL expression) was compared to that of cells, stimulated 
to differentiate with dox. TRE-ME2 and c-MEl were treated with or without dox or 
with G-CSF for 48 hours while TRE-ME6 was treated in the same way but 
analysed after 24 hours. At these time-points the amount of differentiation induced 
by dox or G-CSF in the conditional lines was comparable since the Gr-1 expression 
profiles were identical (Figure 6.4A). Strikingly, in both conditional cell lines,
Hoxa gene expression was much lower in cells treated with dox than in cells treated 
with G-CSF (Figure 6.4B). G-CSF treatment actually caused an increase in 
expression of the Hoxa4-all genes in c-MEl and TRE-ME2. In TRE-ME6, the 
only change in Hoxa gene expression caused by G-CSF was a decrease in the 
expression of Hoxa7, HoxalO and H oxall. Of these, only the decrease in Hoxall 
expression was of a similar magnitude to that caused by dox. Collectively, these 
data suggest that the decrease observed in expression of the Hoxa4-all genes upon
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Figure 6.4 MLL-ENL maintains the expression of multiple Hoxa genes. The
cell lines were cultured with or without dox or with G-CSF in order to compare 
their Hoxa gene expression profile by Q-PCR. A) Plots show the Gr-1 expression 
profile of c-MEl, TRE-ME2 and TRE-ME6 following culture with either dox 
(grey line) or G-CSF (thick black line). Cells were harvested at a time-point at 
which the amount of differentiation induced by dox or G-CSF was comparable. 
C-MEl and TRE-ME2 were analysed after 48 hours and TRE-ME6 was analysed 
after 24 hours. B) The graphs show the number of copies of each Hoxa gene per 
25 ng total RNA following culture of the cell lines in SCF, IL-6, IL-3 without dox 
(black columns), with dox (red columns), or with G-CSF (white columns). The 
means and SD of triplicate measurements are shown.
136
loss of MLL-ENL expression is not a secondary result of differentiation, but rather 
that expression of the Hoxa4-all genes is directly maintained by MLL-ENL.
6.5 Meis-2 is expressed instead of Meis-1 in the conditional cell lines.
The global Hox gene expression profiling included analysis of the Meis-1 and Pbx- 
1 Hox co-factors but did not include analysis of the other members of the Meis and 
Pbx gene families. Therefore, I compared the expression levels of the Meis and Pbx 
genes in the MLL-ENL cell lines using commercially available pre-designed 
Taqman probe and primer sets. Surprisingly, the Hox co-factor Meis-1 was only 
expressed in c-MEl and was completely absent in all of the conditional cell lines 
(Figures 6.1, 6.4B and 6.5). Previous studies have shown that Meis-1 co-operates 
with Hoxa9 and Hoxa7 to induce AML in murine models (Nakamura et al., 1996a) 
and Meis-1 has been suggested to be a direct or indirect target of MLL-ENL (Zeisig 
et al., 2004). Analysis of the other Meis family members revealed that the 
conditional cell lines expressed high levels of Meis-2 whereas it was expressed at 
very low levels by c-MEl (Figure 6.5). Meis-2 was expressed by all of the cell 
lines, although c-MEl expressed slightly lower levels than the conditional cell 
lines. Pbx-1 was only expressed by TRE-ME2 and all of the lines expressed similar 
levels of Pbx-2 and Pbx-3. The expression of Flt-3 was also analysed since this 
gene has been previously identified as a target of MLL-ENL (Zeisig et al., 2004) 
and more recently Meis-1 (Wang et al., 2005). Surprisingly, Flt-3 expression was 
not detected in any of the cell lines (data not shown).
6.6 Pbx-3 is a target of MLL-ENL.
In order to determine whether the Hox co-factors were regulated by MLL-ENL, 
their expression was analysed following treatment of the cell lines with dox or G- 
CSF for the same amount of time as that in the previous analysis of Hoxa gene 
expression (Figure 6.4). Dox had no significant effect on Meis-2 expression (Figure 
6.5). Although Meis-3 expression decreased in the conditional cell lines in response 
to dox, G-CSF caused similar if not greater decreases. These changes are therefore 
likely to be due to differentiation of the cells. Dox caused an increase in the 
expression of Pbx-2 in all of the cell lines, whereas expression was unchanged by 
G-CSF. Since dox caused a similar change in Pbx-2 expression in c-MEl as in the 
conditional cell lines, we were unable to determine if this gene was regulated by
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Figure 6.5 MLL-ENL maintains the expression of Pbx-3 but not other Hox co­
factors. The graphs show the relative level of expression of the Meis and Pbx Hox 
co-factor genes following culture of the cell lines in SCF, IL-6 and IL-3 without 
dox (black columns), with dox (red columns) or with G-CSF (white columns). 
Cells were analysed at time-points identical to that used in the analysis of Hoxa 
gene expression (see Figure 6.4). TRE-ME3 was not analysed after culture in G- 
CSF since the cells died. Q-PCR was performed using commercially available pre­
designed Taqman probe and primer sets and data was normalised to 18S ribosomal 
RNA. The mean and SD of quadruplicate measurements are shown.
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MLL-ENL. Dox caused a decrease in Pbx-3 expression in all of the conditional cell 
lines. However, Pbx-3 expression increased in c-MEl in response to dox and was 
unchanged in all of the cell lines in response to G-CSF. Hence, the decrease in Pbx- 
3 expression upon loss of MLL-ENL expression is not a secondary result of 
differentiation, but rather Pbx-3 expression is directly maintained by MLL-ENL.
6.7 Global gene expression profiling.
Prior to performing the Affymetrix microarray analysis, the MLL-ENL cell lines 
were re-established in liquid culture from freezes of the cells harvested from the 
methylcellulose replating assays. This was done because the MLL-ENL cell lines 
had been cultured for many months and some may have acquired mutations. All of 
the cell lines exhibited identical phenotypes and differentiation potentials as the 
previous cell line established from the same methylcellulose replating assay apart 
from TRE-ME3. Whereas the previous TRE-ME3 cell line (TRE-ME3A) failed to 
terminally differentiate upon loss of MLL-ENL expression (section 5.6), the newly 
established TRE-ME3 cell line (TRE-ME3B) terminally differentiated into 
neutrophils upon loss of MLL-ENL expression with similar kinetics to TRE-ME2 
(data not shown). Southern blot analysis revealed that TRE-ME3A and TRE-ME3B 
were composed of different clones (Figure 5.1 IB). Therefore, it seems that the 
immortalised cells grew as an oligoclonal line in methylcellulose and that the 
different clones out-competed each other upon establishment of cell lines in liquid 
culture.
It was important to measure changes in global gene expression at early time-points 
in order to minimise differentiation associated changes in gene expression and 
increase the chances of identifying primary targets of MLL-ENL. In order to 
determine a suitable time-point for the experiment, the expression of the MLL-ENL 
target genes Hoxa7 and Hoxa9 were analysed by Q-PCR using commercially 
available probe and primer sets. Hox gene expression was analysed following 
treatment of the MLL-ENL cell lines with or without dox for 24 and 48 hours. 
TRE-ME6 was only analysed after 24 hours since this cell line differentiates more 
rapidly than the others upon loss of MLL-ENL expression. Although a significant 
decrease in Hox gene expression was observed after 24 hours in TRE-ME2 and 
TRE-ME3(B) following dox treatment (p < 0.07 [ two-tailed students t-test]), the
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decrease was not as significant as that observed after 48 hours (p < 1.4 x 10'5 [two- 
tailed students t-test], Figure 6.6). Therefore, we decided to analyse the gene 
expression profiles of TRE-ME2, TRE-ME3(B) and c-MEl after 48 hours and 
TRE-ME6 after 24 hours treatment with or without dox.
6.8 Identification of MLL-ENL target genes.
RNA was prepared from each cell line following treatment with or without dox and 
hybridised to Affymetrix murine 430 2.0 oligonucleotide microarrays representing 
more than 39,000 transcripts based on the mouse UniGene cluster (build 107). The 
three conditional cell lines were grouped as replicates and pairwise comparisons of 
these samples treated with and without dox were performed to identify 
differentially expressed genes. The data was filtered by selecting for genes which 
were present and whose expression level changed more than 1.3-fold upon 
treatment with dox (section 2.25). A Welch t-test was then used to identify genes 
which were changed significantly in the conditional cell lines upon dox treatment. 
The expression of the genes which were changed significantly in the conditional 
cell lines upon dox treatment was then examined in the constitutive cell line. This 
comparison was made in order to discriminate between changes in gene expression 
connected with loss of MLL-ENL expression versus changes in gene expression 
due to non-specific effects of dox. Fifty-seven percent of the genes which were 
changed in the conditional cell lines showed a concordant change in expression in 
the constitutive cell line upon dox treatment (Tables A.l and A.2). Since only one 
constitutive cell line was analysed and replicates were not performed, it was not 
possible to determine whether the concordant changes in gene expression in the 
constitutive cell line were reproducible. Therefore, genes such as Ikraklbp and 
Sap30 (Table A.l), which have been previously identified as up-regulated in patient 
samples with 1 lq23 translocations, should be analysed in more detail by Q-PCR. 
Genes which did not show a concordant change in expression in the constitutive 
cell line upon dox treatment are potentially targets of MLL-ENL or its downstream 
effectors and are the focus of the remainder of this chapter.
6.9 Genes down-regulated following loss of MLL-ENL expression.
In total, 30 genes were down-regulated in the three conditional cell lines upon loss 
of MLL-ENL expression (Table 6.1). These included the transcription factors
140
A 24 hours
Hoxa7 Hoxa9
B  -  dox 
■ + dox
P 2.5
4
3.5
3 '
2.5 
2
1.5
1  ■
1
0.5
TRE-ME6 c-MEi
0
0  - dox 
□ + dox
TRE-ME2 TRE-ME3 TRE-ME6 c-MEl
B
co
'< /)
to
0i _
Q.
X0
2.5
2
I 1-50 11 
0
£  0.5 0 
0 q: o-
48 hours
Hoxa7
o - dox 
■ + dox
l i
5
4.5 
4
3.5 
3
2.5 
2
1.5 
1
0.5
0
Hoxa9
b - dox 
b + dox
l
TRE-ME2 TRE-ME3 C-ME1 TRE-ME2 TRE-ME3 C-ME1
Figure 6.6 Identification of a suitable time-point for global gene expression 
profiling. The graphs show the relative level of Hoxa7 and Hoxa9 expression 
following culture of each cell line with (red columns) or without (black columns) 
dox for A) 24 or B) 48 hours. Q-PCR was performed using commercially 
available pre-designed Taqman probe and primer sets and data was normalised to 
18S ribosomal RNA. TRE-ME6 was not analysed after 48 hours since this cell 
line differentiates more rapidly than the other conditional cell lines upon loss of 
MLL-ENL expression. The mean and SD of quadruplicate measurements are 
shown.
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Hoxa9 and Sdccag33. The differential expression of Hoxa9 confirmed the Q-PCR 
analysis (Figure 6.4B) and validated the experiment. Sdccag33 (also known as 
Mtshl) is the murine orthologue of the Drosophila Teashirt (Tsh) gene. Like the 
HOM-C proteins of Drosophila, Tsh is a transcription factor which determines 
segment identity during development (Alexandre et al., 1996). Interestingly, the 
Tsh and HOM-C transcription factors share some common target genes (Alexandre 
et al., 1996). Therefore, it will be interesting to determine if Mtshl and the Hoxa 
proteins share common targets in haematopoietic cells and whether these genes co­
operate to induce leukaemogenesis.
Other genes involved in transcription that were down-regulated upon loss of MLL- 
ENL expression include Elp3 and Mettl2. Elp3 is a component of the yeast 
Elongator complex which possesses histone acetyltransferase activity (Winkler et 
al., 2002). Elongator associates with RNA polymerase II and promotes 
transcriptional elongation by acetylating histones and thereby maintaining an open 
chromatin structure. Mettl2 may also promote transcriptional initiation or 
elongation if it possesses histone methyltransferase activity.
The Aldehyde dehydrogenase 1, family member L2 (Aldhll2) gene showed the 
greatest fold decrease upon loss of MLL-ENL expression (Table 6.1). Aldehyde 
dehydrogenase is an enzyme that oxidises intracellular aldehydes and is thought to 
confer resistance to cyclophosphamide (Magni et al., 1996). Interestingly, Aldhl 
has been previously identified as a direct target of Hoxa9 in myeloid cell lines 
(Dorsam et al., 2004). The Pim-1 oncogene is also a target of Hoxa9 (Dorsam et al., 
2004). We found that the close family member Pim-2 was down-regulated upon 
loss of MLL-ENL expression. Pim-2 confers protection from apoptosis in response 
to growth factor withdrawal (Fox et al., 2003) and it is over-expressed in several 
types of cancer in humans including leukaemias (Amson et al., 1989). Hence, Pim- 
2 is an attractive candidate target gene to explore in more detail. Other interesting 
target genes include M tssl which is an actin-binding protein that regulates the actin 
cytoskeleton (Gonzalez-Quevedo et al., 2005) and also plays a role in transcription. 
It is a member of the Sonic Hedgehog signalling pathway that potentiates Gli- 
dependent transcription during development and carcinogenesis (Callahan et al., 
2004).
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Table 6.1 Genes down-regulated upon loss of MLL-ENL expression.
Gene P-value
Relative expression (RE)
ProductAverage
RE
TRE-
ME2
TRE-
ME3
TRE-
ME6 c-MEl
Aldhl 12 0.0142 0.24 0.12 0.20 0.40 1.59 Aldehyde dehydrogenase 1 family, member L2
Magil 0.0102 0.32 0.29 0.43 0.24 1.69 Membrane associated guanylate kinase interacting protein-like 1
Higl 0.0268 0.40 0.23 0.29 0.69 0.83 Hypoxia induced gene 1
Sdccag33 0.00614 0.46 I 0.45 0.30 0.63 0.97 Serologically defined colon cancer antigen 33
4921530L18Rik 0.0115 0.53 0.43 0.43 0.72 0.87 Unknown EST
Hoxa9 0.0291 0.55 0.67 0.41 0.56 1.08 Homeobox transcription factor
Mtssl 0.0424 0.55 0.40 0.42 0.83 0.94 Metastasis suppressor 1
5730405O12Rik 0.0256 0.58 0.50 0.65 0.58 1.75 Unclassifiable
4833442J19Rik 0.0487 0.58 0.60 0.63 0.50 1.19 Hypothetical protein LOC320204
Senp8 0.0381 0.6 0.73 0.5 0.57 1 SUMO / senthrin specific protease 8
A sfla 0.0132 0.61 0.63 0.56 0.63 0.86 Anti-silencing function 1 homolog A (S.cerevisiae)
1700037C18Rik 0.0253 0.61 0.68 0.52
Elp3 0.0487 0.65 0.54 0.68
HelB 0.00842 0.65 0.57 0.56
Pim2 0.0207 0.65 0.66 0.55
Anp32b 0.0345 0.66 0.49 0.65
Amotll 0.0482 0.68 0.7 0.68
Ierepo4 0.045 0.70 0.78 0.56
9530078B04Rik 0.0399 0.70 0.85 0.56
Taokl 0.0409 0.71 0.76 0.53
2510005D08Rik 0.00429 0.71 0.79 0.63
Cdc27 0.0453 0.73 0.61 0.78
4933432P15Rik 0.0311 0.73 0.63 0.72
Ap3s2 0.0212 0.74 0.65 0.91
Timm8a 0.0237 0.74 0.80 0.76
0.64 1.01 Hypothetical protein LOC73261
0.73 0.92 Elongation protein 3 homolog (S.cerevisiae)
0.81 0.88 Helicase (DNA) B
0.74 1.65 Proviral integration site 2
0.85 1.25 Acidic nuclear phosphoprotein 32, family member B
0.67 1.49 Angiomotin-like 1
0.75 1.18 Immediate early response, erythropoietin 4
0.70 6.07 Unclassifiable
0.83 1.20 Thousand and one amino acid protein kinase 1
0.71 1.25 Hypothetical protein LOC68043
0.80 1.44 Cell division cycle 27 homolog (S.cerevisiae)
0.84 0.86 Similar to GRAF gene
0.67 1.79 Adaptor related protein complex 3, sigma 2 subunit
0.65 1.14 Translocase of inner mitochondrial membrane 8 homolog a (yeast)
Paipl 0.0293 0.75 0.79 0.69 0.76 1.18 Polyadenylate binding protein-interacting protein 1
A730091E23Rik 0.0463 0.75 0.71 0.59 0.95 1.23 Unknown EST
Mettl2 0.0461 0.75 0.93 0.66 0.67 1.03 Methyltransferase-like2
Algl2 0.00618 0.77 0.77 0.75 0.78 0.88 Asparagine-linked glycosylation 12 homolog (yeast a-l,6-mannosyltransferase)
Nomol 0.0233 0.77 0.73 0.81 0.76 1.14 Nodal modulator 1
Relative Expression is the level of gene expression in the presence of dox relative to that in the absence of dox. Genes in red are over­
expressed in patients with 1 lq23 translocations compared to other leukaemias (Armstrong et al., 2002, Ross et al., 2004, Andersson et al., 
2005, Kohlmann et al., 2005).
Several genes required for cell cycle progression were down-regulated upon loss of 
MLL-ENL expression (Table 6.2). These included Anp32b, a Cdc27 homologue, an 
Asfl homologue and Hel(B). Anp32b (also known as Pal31), is a nuclear 
phosphoprotein required for S phase progression (Sun et al., 2001). Cdc27 is a 
component of the yeast DNA polymerase 8 complex. It is essential for DNA 
replication since it recruits proliferating cell nuclear antigen (PCNA) to the 
polymerase complex (Bermudez et al., 2002). Asfl is essential for cell cycle 
progression in yeast since it assembles chromatin following DNA replication (Tyler 
et al., 1999) and Hel(B) is required to unwind DNA prior to replication (Matsumoto 
et al., 1995).
Table 6.2 Classification of genes down-regulated upon loss of MLL-ENL 
expression according to function.
Function Gene
Pim2
Cell signalling Magil
Taokl
Anp32b
Cell cycle
Asfl a 
Cdc27 
HelB
Cytoskeleton regulation Mtssl
Protein targeting / 
transport
Ap3s2
Senp8
Timm8a
Elp3
Transcription regulation
Hoxa9
Mettl2
Sdccag33
Translation regulation Paipl
6.10 Genes up-regulated following loss of MLL-ENL expression.
Thirty-six genes were up-regulated in the three conditional cell lines upon loss of 
MLL-ENL expression (Table 6.3). These included several genes whose products
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Table 6.3 Genes up-regulated upon loss of MLL-ENL expression.
I J  1  Ml 1 11 A
Relative Expression (RE)
Gene r-vaiue Average
RE
TRE-
ME2
TRE-
ME3
TRE-
ME6 c-MEl
Product
Camp 0.0407 14.46 25.00 12.5 5.88 1.04 Cathelicidin antimicrobial peptide
Pgiyrp 0.0298 10.53 20.00 9.09 2.50 0.85 Peptidogylcan recognition protein
Ngp 0.00694 6.00 5.88 9.09 3.03 0.50 Neutrophil granule protein
CeacamlO 0.013 5.49 7.14 5.88 3.45 0.09 CEA-related cell adhesion molecule 10
Praml 0.0288 3.54 2.94 4.35 3.33 0.68 PML-RARa regulated adaptor molecule 1 (PRAM-1) protein
1190003K14Rik 0.0193 2.76 4.35 1.67 2.27 0.46 Unclassified
Ddb2 0.00158 2.41 2.27 2.63 2.33 0.63 Damage specific DNA binding protein 2
Prkd2 0.014 2.25 2.5 1.30 2.94 0.71 Protein kinase D2
Ceacaml 0.0384 2.12 2.94 1.82 1.61 0.41 CEA-related cell adhesion molecule 1
A130086G1 IRik 0.047 2.03 1.75 2.38 1.96 1.11 Unknown EST
Hook2 0.042 1.92 2.17 2.13 1.45 0.14 Hook homolog 2 (Drosophila)
Wdr37 0.0282 1.84 1.72 2.17
Cnn2 0.0376 1.79 2.13 1.69
Cybasc3 0.0187 1.78 1.41 2.08
Mtl 0.0125 1.70 1.35 1.61
Arhgapl9 0.012 1.58 1.59 1.64
1190002H09Rik 0.0188 1.58 1.56 1.61
Nfatcl 0.0362 1.54 1.37 1.18
6230416A05Rik 0.037 1.54 1.75 1.45
Map4k2 0.0236 1.53 1.69 1.35
C030046I01Rik 0.0483 1.52 1.67 1.22
Bri3bp 0.0293 1.49 1.96 1.19
Apg71 0.0422 1.45 ! 1.82 1.19
Fln29 0.0452 1.43 1.52 1.33
Actn4 0.0152 1.42 1.64
1
1.27
1.64
1.56
0.28
0.49
WD repeat domain 37 
Calponin 2
1.85 0.95 Cytochrome b, ascorbate dependent 3
2.13 0.39 Metallothionein 1
1.52 0.38 Rho GTPase activating protein 19
1.56 0.39 Hypothetical protein LOC68857
2.08 0.56 Nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1
1.41 0.45 Hypothetical protein LOC76137
1.54 0.37 Mitogen activated protein kinase kinase kinase kinase 2
1.67 0.81 Hypothetical protein LOCI09284
1.33 1.11 Bri 3 binding protein
1.33 0.16 Autophagy 7-like (S.cerevisiae)
1.45 0.66 FLN29 gene product
1.35 0.23 Actinin alpha 4
Aatk 0.0159 1.41 1.39 1.33 1.52 0.89 Apoptosis-associated tyrosine kinase
A630020E03Rik 0.0339 1.40 1.27 1.39 1.54 0.49 Unknown EST
Inpp5f 0.00896 1.37 1.35 1.3 1.47 0.72 Inositol polyphosphate-5-phosphatase F
Ypel5 0.0339 1.37 1.39 1.61 1.11 0.62 Yippee-like 5 (Drosophila)
Atrx 0.0234 1.35 1.49 1.37 1.19 0.29
Alpha thalassemia / mental retardation 
syndrome X linked homolog (human)
Gygl 0.0256 1.33 1.16 1.56 1.27 0.48 Glycogenin 1
D19Wsul2e 0.0168 1.33 1.32 1.39 1.27 0.67 Similar to human KIAA1815 protein
Slc25a30 0.0417 1.33 1.64 1.06 1.28 0.99 Solute family carrier 25, member 30
Crlf3 0.047 1.32 1.35 1.27 1.33 0.62 Cytokine receptor-like factor 3
Sri 0.012 1.31 1.28 1.27 1.39 0.49 Sorcin
Relative Expression is the level of gene expression in the presence of dox relative to that in the absence of dox. Genes in red are over­
expressed in patients with 1 lq23 translocations compared to other leukaemias (Armstrong et al., 2002, Ross et al., 2004, Andersson et al., 
2005, Kohlmann et al., 2005).
are involved in myeloid cell differentiation and function such as the secondary 
granule protein Ngp, Pram-1 which is required for mature neutrophil function 
(Clemens et al., 2004) and Camp and Pglyrp which are involved in the recognition 
and destruction of pathogens (Table 6.4). The differential expression of such genes 
was expected since the cells differentiate upon loss of MLL-ENL expression.
The genes Nfatcl and Atrx, whose products are involved in transcriptional 
regulation, were also up-regulated following loss of MLL-ENL expression. Nfatcl 
is a transcription factor which regulates the expression of cytokine genes in 
activated T lymphocytes (Zhou et al., 2002) and Atrx is a SWI / SNF chromatin 
remodelling protein which is mutated in X-linked mental retardation syndromes 
(Park et al., 2004). Interestingly, inactivating mutations of Atrx are found in 
patients with acquired alpha thalassemia associated with myelodysplastic syndrome 
(Steensma et al., 2005). Therefore, it is feasible that transcriptional repression of 
this gene by MLL-ENL contributes to leukaemogenesis.
Other genes that were up-regulated following loss of MLL-ENL expression include 
Actn4 and Cnn2, whose products are both actin binding proteins. Previous studies 
have suggested that Actn4 is a tumour suppressor since it is mutated in some human 
lung carcinomas and over-expression of the wild type gene inhibits tumour cell 
growth in vivo (Menez et al., 2004). Furthermore, over-expression of Actn4 in 
malignant neuroblastoma cells results in decreased anchorage independent growth 
and loss of tumorigenecity in vivo (Nikolopoulos et al., 2000). Cnn2 (also known as 
h2 calponin) is another actin binding protein which is thought to inhibit 
proliferation by inhibiting cytokinesis in smooth muscle cells (Hossain et al., 2003).
Of particular interest was the fact that several genes whose products are required for 
apoptosis such as Aatk, Ddb2 and Bri3 binding protein were up-regulated following 
loss of MLL-ENL expression. Aatk is required for growth arrest and apoptosis of 
terminally differentiated myeloid cells (Gaozza et al., 1997). Ddb2 is a tumour 
suppressor which is mutated in patients with Xeroderma pigmentosam group E. 
Patients with this disease are susceptible to UV light-induced skin cancers (Itoh et 
al, 2001), since Ddb2 is required to induce p53 mediated apoptosis in response to 
UV irradiation (Itoh et al., 2004). Bri3 is required for apoptosis in response to
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tumour necrosis factor (TNF) (Wu et al., 2003). Thus, it is likely that the function 
of Bri3 binding protein will be to regulate this process. It will be interesting to 
determine whether the repression of these genes by MLL-ENL contributes to 
leukaemogenesis.
Table 6.4 Classification of genes up-regulated upon loss of MLL-ENL 
expression according to function.
Function Gene
Arhgapl9
Cell signalling
Inpp5f
Map4k2
Prdk2
Cytoskeleton regulation
Actn4
Cnn2
Camp
Ceacaml
Myeloid immune 
function
CecamlO
Crlf3
Ngp
Pglyrp
Praml
DNA repair and 
apoptosis
Aatk
Bri3bp
Ddb2
Transcription regulation
Atrx
Nfatcl
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Discussion
Global Hox gene expression profiling of MLL-ENL immortalised cell lines 
revealed that these cells expressed a Hoxa code which consisted of Hoxa4, Hoxa5, 
Hoxa6, Hoxa7, Hoxa9, Hoxa 10 and Hoxa 11. Interestingly, the absolute levels of 
Hoxa gene expression broadly correlated with the rate of proliferation of each 
conditional cell line. For example, TRE-ME2 proliferated at a faster rate than TRE- 
ME3 or TRE-ME6 and expressed the highest levels of Hoxa genes. Furthermore, 
TRE-ME3 proliferated at a slower rate than TRE-ME2 and TRE-ME6 and 
expressed the lowest overall level of Hoxa genes. The absolute levels of Hoxa gene 
expression in the conditional cell lines increased over time (compare Figures 6.1 
and 6.4B). However, a similar increase in Hoxa gene expression was not observed 
for the constitutive cell line. It is possible that Hox genes confer a selection 
advantage to the cells, such that over time, the cells express higher levels of these 
genes. This selection advantage may not be as strong for the constitutive cell line 
since this line expresses Meis-1 which has been shown to provide a clonal selection 
advantage to myeloid cells immortalised by Hoxa9 (Wang et al., 2005).
Expression of Hoxa5, Hoxa7, Hoxa9, Hoxa 10 and Hoxa 11 in MLL-ENL 
immortalised cell lines has been previously reported (Ayton and Cleary, 2003; So et 
al., 2003b). However, Hoxa gene expression is not restricted to MLL-ENL cell 
lines, since some Hoxa genes are also expressed by myeloid cell lines immortalised 
by E2A-HLF (So et al., 2004). Therefore, it is possible that these cells express 
particular Hoxa genes because of a differentiation block imposed by MLL-ENL and 
that this depends on the Hox gene expression of the original immortalised myeloid 
progenitors. In order to distinguish between this explanation and the possibility that 
MLL-ENL was directly responsible for maintaining Hox gene expression in these 
lines, Hox gene expression was analysed following treatment of the MLL-ENL cell 
lines with dox and with G-CSF. A significant decrease in Hoxa gene expression 
was observed upon loss of MLL-ENL expression. This was not a secondary result 
of differentiation, since treatment of cells at an identical stage of differentiation 
induced by G-CSF, did not result in an equivalent decrease in expression.
Therefore, MLL-ENL directly maintains the expression of the Hoxa4-all genes. 
This result is supported by the finding that MLL-FKBP and MLL-AF10 bind to 
regulatory regions of the Hoxa7 and Hoxa9 promoters in transformed cells (Martin
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et al., 2003; Okada et al., 2005). The increase in Hoxa gene expression in TRE- 
ME2 and c-MEl in response to G-CSF was not expected since HOX gene 
expression normally decreases as myeloid cells differentiate (Sauvageau et al.,
1994; Pineault et al., 2002). These results suggest that MLL-ENL can maintain 
Hoxa gene expression even when the cells are differentiating. Further analysis of 
Hoxa gene expression at later stages of G-CSF induced differentiation in these cells 
is required to confirm this hypothesis.
Like MLL-ENL immortalised cell lines, Hoxa9 immortalised cell lines 
continuously proliferate in response to GM-CSF but terminally differentiate in 
response to G-CSF (Calvo et al., 2000). The authors suggest that Hoxa9 might 
block GM-CSF induced differentiation by suppressing the expression of 
transcription factors essential for GM-CSF signalling such as STAT5 (Calvo et al., 
2000). MLL-ENL immortalised cells might retain the ability to differentiate in 
response to G-CSF if factors required for G-CSF signalling, such as STAT3 
(Shimozaki et al., 1997), are not altered by the over-expression of Hoxa genes. 
Alternatively, G-CSF signalling may overcome the differentiation block imposed 
by Hoxa proteins by modulating the expression of genes required by the Hox 
proteins to exert their effect.
The Hox code expressed in MLL-ENL immortalised cell lines is very similar to that 
expressed in bone marrow cells from leukaemic MLL-AF9 knock-in mice (Kumar 
et al., 2004). Bone marrow cells from MLL-AF9 knock-in leukaemic mice 
expressed higher levels of Hoxa5, Hoxa6, Hoxa7, Hoxa9, HoxalO and Meis-1 than 
cells from wild-type or pre-leukaemic mice. Given the strong homology between 
AF9 and ENL, it is easy to envisage that MLL-AF9 and MLL-ENL de-regulate a 
common set of target genes. These murine models recapitulate the HOX gene 
deregulation observed in patients with MLL translocations. Gene expression 
profiling of patient material revealed that HOXA4, HOXA5, HOXA9, HOXA 10 and 
MEIS-1 were over-expressed in both myeloid and lymphoid leukaemias with MLL- 
rearrangements (Armstrong et al., 2002; Debemardi et al., 2003; Ross et al., 2004; 
Kohlmann et al., 2005).
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Wild type MLL maintains the expression of multiple Hox genes during 
embryogenesis including Hoxa7, Hoxa9 and Hoxa 10 (Yu et a l , 1995; Hess et al., 
1997; Yagi et al., 1998; Yu et al., 1998; Ernst et al., 2004b). Since these genes are 
also targets of the MLL-ENL fusion protein, a current hypothesis is that MLL- 
fusion proteins immortalise cells by aberrantly maintaining the expression of these 
genes. However, several members of the Hoxb and Hoxc gene clusters which are 
regulated by wild-type MLL during embryogenesis such as Hoxb5, Hoxb6, Hoxb8 
and Hoxc8, were not expressed in MLL-ENL immortalised cell lines. HoxbS,
Hoxb4 and Hoxb 13 were expressed in MLL-ENL cell lines but significant levels of 
expression of members of the Hoxc or Hoxd clusters were not detected. Recent 
studies suggest that Hoxb3 and Hoxb4 are also regulated by wild-type MLL (Ernst 
et al., 2004b). However, it was not possible to determine if these genes were 
regulated by MLL-ENL since dox induced similar changes in expression of these 
genes in both the constitutive and conditional cell lines.
It has been suggested that Meis-1 is a target of MLL-ENL (Zeisig et al., 2004). 
Although Meis-1 expression is not regulated by wild-type MLL (Ernst et al., 
2004b), it is possible that it is regulated by MLL-ENL since the ENL moiety may 
confer a change in the DNA binding and transactivation specificity of MLL. The 
MLL-ENL fusion protein may thus be able to regulate the expression of genes 
which are not regulated by wild-type MLL. Alternatively, it is possible that Meis-1 
is an indirect target of MLL-ENL or it is up-regulated as a secondary event in 
leukaemogenesis. Our data are consistent with the latter possibility since although 
Meis-1 was expressed in the constitutive cell line, it was not expressed in any of the 
conditional MLL-ENL cell lines. A potential mechanism which might explain why 
Meis-1 was expressed in the constitutive cell line but not the conditional cell lines is 
that tTA may sequester transcription factors that are required for Meis-1 expression 
away from the Meis-1 promoter.
Interestingly, the conditional MLL-ENL cell lines expressed Meis-2 instead of 
Meis-1. The Meis family consists of three members Meis-1, Meis-2 and Meis-3. 
Meis-2 and Meis-3 share strong homology with Meis-1, 77.2% and 69.9% 
respectively. Their homology is even greater within the homeodomain (96.8% 
identity among the three proteins) (Nakamura et al., 1996b). Although Meis-2
154
expression in MLL-ENL cell lines has not been previously reported, this gene is 
expressed in some murine (Nakamura et al., 1996b) and human myeloid leukaemias 
(Andersson et al., 2005). Interestingly, Meis-2 and Meis-3 were expressed in the 
absence of Meis-1 in the BXH-2 leukaemic cell lines (Nakamura et al., 1996b). 
Meis-2 is also expressed in the absence of Meis-1 in WEHI-3B cells.
The Pbx and Meis Hox co-factors can form heterotrimeric DNA binding complexes 
with Hox proteins and are thought to increase the specificity and affinity with 
which Hox proteins bind to their target DNA sequences (Shen et al, 1996; Shen et 
al., 1997; Shen et al., 1999). Pbx-3 was the only Hox co-factor whose expression 
was maintained by MLL-ENL. This finding is consistent with that of a previous 
study in which Pbx-3 expression decreased upon loss of MLL-ENL function in 
myeloid immortalised cell lines (Zeisig et al., 2004). Interestingly, PBX-3 is over­
expressed in patients with MLZ-translocations when compared to other AML or 
ALL patients (Andersson et al., 2005). It has been reported that in the presence of 
Pbx-3, Hoxa9 can interact with either Meis-1 or Meis-2 on target enhancers and 
that over-expression of Hoxa9, Meis-1 or Meis-2 alone can block G-CSF induced 
differentiation of 32Dcl3 cells (Fujino et al., 2001). Hence, Meis-2 shares some of 
the functions of Meis-1 in myeloid progenitors. A more recent study demonstrated 
that Meis-1 required its Pbx interaction motif, DNA binding domain and a novel 
transcriptional activation domain in the C terminus to accelerate leukaemogenesis 
induced by Hoxa9 over-expression (Huang et al., 2005; Wang et al., 2005). Since 
the C-terminal transactivation domain of Meis-1 is highly conserved between Meis- 
1, Meis-2 and Meis-3, we hypothesise that Meis-2 can substitute for Meis-1 in the 
conditional MLL-ENL cell lines. MEIS-1 is frequently over-expressed in patients 
with MLL- translocations (Armstrong et al., 2002; Ferrando et al., 2003;
Rozovskaia et al., 2003; Ross et al., 2004; Kohlmann et al., 2005). However, it is 
not over-expressed in all patient samples (Drabkin et al., 2002). Therefore, it will 
be interesting to examine if MEIS-2 is expressed instead of MEIS-1 in these 
patients.
Conflicting studies have been published on the requirement for individual Hox 
genes in MLL-fusion protein mediated leukaemogenesis. It has been shown that 
MLL-ENL is not able to immortalise HPCs isolated from Hoxa9~/~ or HoxaTf~ mice.
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Hoxa 7 and Hoxa9 deficient mice display reduced numbers of committed 
progenitors (So and Cleary, 2003). However, Hoxa9'A progenitors were susceptible 
to immortalisation by MLL-ENL since co-transduction of these progenitors with 
MLL-ENL and Hoxa9 yielded immortalised cell lines (Ayton and Cleary, 2003). 
This study clearly demonstrated that Hoxa7 and Hoxa9 were required by MLL- 
ENL to immortalise HPCs. However, the same group demonstrated that MLL- 
GAS7 could immortalise Hoxa9'/' or HoxaT ' HPCs although with reduced 
efficiency (So et al., 2004). Furthermore, the authors report that MLL-ENL was 
able to promote the in vitro self-renewal of Hoxa9'/~ or HoxaTA HPCs. This result is 
not in agreement with the conclusion of their previous study (Ayton and Cleary, 
2003). The authors suggest that these contrasting results may be attributable to 
different methods of HPC isolation in the two studies.
A separate study analysed the ability of the knock-in MLL-AF9 mutation to 
promote leukaemogenesis of Hoxa9 deficient mice. MLL-AF9+/VHoxa9'/' mice 
developed AML with the same penetrance and latency as MLL-AF9+/VHoxa9+/+ 
mice (Kumar et al., 2004). However, the leukaemias of the /fcwcaP-deficient mice 
were of a more immature phenotype than those of the Hoxa9 wild-type mice. 
Therefore, although Hoxa9 is not essential for MLL-AF9 induced leukaemogenesis, 
it does play a role in determining the phenotype of the leukaemia.
Individually Hoxa7 and Hoxa9 are dispensable for leukaemogenesis mediated by 
certain MLL-fusion proteins. It is possible that other members of the 5’ Hoxa 
cluster such as Hoxa5, Hoxa6 or Hoxa 10 may compensate for the lack of Hoxa7 or 
Hoxa9 expression in these models. In support of this hypothesis, a recent study 
demonstrated that transduction of MLL'1' embryoid bodies with Hoxa9, Hoxa 10 or 
Hoxb4 was able to completely rescue haematopoietic colony formation (Ernst et al., 
2004b). Hence, these Hox genes share a common function in promoting 
haematopoietic development. Since redundancy among certain Hox genes exists, it 
is likely that therapeutic strategies designed to treat MLL-rearranged leukaemias 
which target individual HOX  genes will not be efficacious. The identification of 
HOXA target genes and other genes regulated by MLL-ENL will probably represent 
a better therapeutic avenue.
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Global gene expression profiling was performed using Affymetrix microarray 
analysis in order to identify other targets of MLL-ENL. The number of genes 
down-regulated upon loss of MLL-ENL expression was similar to the number of 
genes up-regulated upon loss of MLL-ENL expression. This suggests that MLL- 
ENL can repress the expression of some genes while activating or maintaining the 
expression of others. Although previous studies have shown than MLL-ENL can 
transactivate certain promoters in vitro, including that of Hoxa7 (Schreiner et al.,
1999), it remains to be determined as to whether the genes up-regulated upon loss 
of MLL-ENL expression are directly repressed by MLL-ENL. The fact that the 
transcriptional repression domain of MLL is retained in MLL fusion proteins 
(Zeleznik-Le et al., 1994) and the fact that ENL interacts with the transcriptional 
repressor human polycomb 3 (hPc3) (Garcia-Cuellar et al., 2001) lends support to 
the hypothesis that MLL-ENL can repress the transcription of some of its target 
genes.
The microarray results will be confirmed by Q-PCR analysis of individual target 
genes. In addition, we will separate the class of genes whose change in expression 
is associated with differentiation by comparing the changes in gene expression of 
cells stimulated to differentiate with dox to that of cells stimulated to differentiate 
with G-CSF. Of the genes down-regulated upon loss of MLL-ENL expression, 
those involved in signalling pathways, the cell cycle and transcriptional regulation 
are probably the most interesting MLL-ENL candidate target genes. Pim-2 is of 
particular interest because of its ability to promote the growth and survival of 
haematopoietic cells in response to a variety of apoptotic stimuli (Fox et al., 2003). 
Pim-1, Pim-2 and Pim-3 were first identified as frequent sites of retroviral insertion 
in lymphomas which developed following infection with the Murine Moloney 
Leukaemia virus (Breuer et a l, 1989; Mikkers et a l, 2002). Subsequently, it has 
been shown that Pim-2 and c-myc co-operate to induce lymphomas in transgenic 
mice (Allen et a l,  1997). Interestingly, a previous study demonstrated that c-myc 
also co-operated with MLL-ENL to transform haematopoietic progenitors and that 
MLL-ENL was unable to transform cells that lacked c-myc (Schreiner et a l, 2001).
Of known Hox target genes onlyAldhl, which is a target of Hoxa9, was identified 
in this study. Interestingly, HSCs and LSCs exhibit a high level of Aldhl activity
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and this activity has been utilised in the isolation of these stem cell populations 
(Pearce et al., 2005). Aldhl confers resistance to cyclophosphamide (an alkylating 
agent commonly used in chemotherapeutic regimens) in haematopoietic cells 
(Magni et al., 1996). Hence, the direct activation of Aldhl by Hoxa9 may contribute 
to a mechanism which explains the correlation between Hoxa9 over-expression and 
poor prognosis in AML patients (Golub et al., 1999).
Several of the genes up-regulated upon loss of MLL-ENL expression, i.e. genes 
which are repressed by MLL-ENL, are mediators of apoptosis. Therefore, MLL- 
ENL may contribute to leukaemogenesis by blocking apoptosis. Indeed, MLL-AF9, 
MLL-ELL and MLL-ENL can block GADD34 induced apoptosis in response to 
gamma irradiation (Adler et al., 1999). The mechanism underlying the protection 
from GADD34 induced apoptosis remains unclear. However, these fusion proteins 
have been shown to impair the transcriptional activity of p53 in response to DNA 
damage by reducing p53 acetylation by p300 (Wiederschain et al., 2005). It is 
possible that MLL-ENL inhibits the function of p53 not only by disrupting its 
acetylation, but also by repressing the transcription of genes such as Ddb2 which 
may be required to elicit its apoptotic response (Itoh et al., 2004).
Very few of the genes identified in this study are differentially expressed in patients 
with 1 lq23 translocations. Apart from the HOXA and PBX-3 genes, only MT-1 and 
ACTN4 are differentially expressed in patients with A/LL-rearrangements 
(Armstrong et al., 2002; Andersson et al., 2005). Both MT-1 and ACTN4 are over- 
expressed in patients with 11 q23 translocations. However, we found that these 
genes were up-regulated upon loss of MLL-ENL expression, indicating that their 
expression was suppressed by MLL-ENL. Several of the genes which were 
concordantly changed in both the constitutive and conditional cell lines upon the 
addition of dox are differentially expressed in patients. Both SAP 30 and IRAKI BP 
are up-regulated in patients with A/LL-rearrangements (Andersson et al., 2005). 
Accordingly, we found that these genes were down-regulated upon loss of MLL- 
ENL expression. Many of the published data sets obtained from patient samples 
include only the top 100 differentially expressed genes. Therefore, a more detailed 
analysis of the patient data may reveal a higher correlation between the genes 
differentially expressed in this study and in patients. However, it is possible that
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some targets of the MLL-fusion proteins will not be identified from the analysis of 
patient material since leukaemic cells often contain multiple genetic aberrations 
which can result in varied and complex gene expression profiles.
Comparison of the genes identified in this study with those identified in a previous 
study of conditional MLL-ENL expression in primary haematopoietic progenitor 
cells (Zeisig et al., 2004) revealed that Hoxa9, Pbx-3 and Cnn2 were the only 
differentially expressed genes common to both studies. The Flt-3, Ptprc, Lmo2, 
AdamlO, Meis-1 and S100a4 genes have been previously identified as targets of 
MLL-ENL (Zeisig et al., 2004) and are over-expressed in patients with 1 lq23 
translocations (Armstrong et al., 2002; Yeoh et al., 2002; Andersson et al., 2005). 
However, these genes were not identified as targets of MLL-ENL in this study. Fit- 
3 and Meis-1 were not expressed by the conditional cell lines. Meis-1 was 
expressed by the constitutive cell line but this cell line did not express Flt-3. This 
result was surprising since it has been reported that Meis-1 activates the expression 
of Flt-3 in Hoxa9 transformed cells (Wang et al., 2005). It is possible that the level 
of Meis-1 expressed by the constitutive cell line is not sufficient to activate the 
expression of Flt-3. Although the expression of Ptprc and Lmo2 decreased in all 
three conditional MLL-ENL cell lines upon loss of MLL-ENL expression, the fold 
changes did not reach statistical significance (data not shown). S100a4 was not 
expressed by any of the lines and AdamlO was not concordantly changed in each 
conditional cell line. For example, the expression of AdamlO was unchanged in 
TRE-ME2, decreased in TRE-ME3 and increased in TRE-ME6 upon loss of MLL- 
ENL expression (data not shown). Hence, it is unlikely that AdamlO is a target of 
MLL-ENL.
In the previous study of conditional MLL-ENL expression in primary HPCs, MLL- 
ENL was fused to the hormone binding domain of the oestrogen receptor such that 
MLL-ENL was activated upon the addition of tamoxifen (Zeisig et al, 2004). 
Immortalised myeloid cell lines were generated which were dependent on 
tamoxifen for their continued proliferation and survival. A potential caveat of this 
study is that differentially expressed genes were identified based on the analysis of 
only one cell line following treatment with or without tamoxifen and the effect that 
tamoxifen itself has on gene expression was not taken into account. Our experiment
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was more stringent since three different cell lines were used to identify 
differentially expressed genes. Although the first 27aa of MLL was missing in the 
MLL-ENL cDNA that we used, our construct contained the entire ENL sequence 
that is found in MLL-ENL translocations in patients. In contrast, the previous study 
employed a truncated MLL-ENL cDNA encoding only the last 129 amino acids of 
ENL (aa 430-559 of ENL), which encompasses a conserved transactivation domain. 
Deletion mutagenesis studies revealed that this C-terminal domain of ENL was 
sufficient to transform haematopoietic progenitor cells when fused to MLL but the 
leukaemogenic potential of the truncated MLL-ENL fusion protein was not 
assessed (Slany et al., 1998). A more recent study demonstrated that the N-terminus 
of ENL (amino acids 1 - 120) encodes a conserved YEATS domain which also 
confers transactivation properties to ENL and is required for histone binding (Zeisig 
et al., 2005). Only the first five amino acids of ENL are missing in the full-length 
MLL-ENL fusion protein hence the YEATS domain is retained in the translocation. 
However, the YEATS domain is not retained in the truncated MLL-ENL fusion 
protein utilised by Zeisig et al. Since YEATS domain proteins are involved in 
histone modification in yeast (Bittner et al., 2004; Zhang et al., 2004), it is possible 
that the YEATS domain of ENL plays a role in chromatin remodelling and 
potentially in regulating target gene expression.
The Affymetrix analysis allowed us to identify genes regulated by MLL-ENL. 
These targets will allow us to delineate the molecular pathways de-regulated by 
expression of MLL-ENL and ascertain how MLL-ENL contributes to 
leukaemogenesis. Future work includes analysis of the role that the candidate MLL- 
ENL target genes play in leukaemogenesis. For the genes which were down- 
regulated following loss of MLL-ENL expression such as Hoxa9 and Pim-2, this 
can be achieved by knocking down their expression in MLL-ENL immortalised cell 
lines by small-interfering RNA (siRNA). In contrast, investigation into the role of 
genes which were up-regulated following loss of MLL-ENL expression such as 
Atrx and Ddb2, will probably involve over-expressing these genes in the MLL-ENL 
immortalised cell lines. Ultimately, these target genes may provide exciting 
possibilities for the design of new leukaemia therapies.
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Chapter 7 Establishment of a conditional model of MLL-ENL 
leukaemia in vivo.
Previous studies have shown that MLL-ENL immortalised cell lines can induce 
leukaemia with relatively short latency and high penetrance in vivo (Lavau et al., 
1997; Ayton and Cleary, 2003; Cozzio et al., 2003). However, not all immortalised 
cell lines are leukaemogenic. For example, progenitors immortalised by Hoxa9 give 
rise to AML infrequently and only after an extremely long latency. The latency of 
Hoxa9 induced AML is dramatically shortened by the co-expression of Meis-1 
(Kroon et al., 1998; Wang et al., 2005). Interestingly, progenitors immortalised by 
Hoxa9 and Meis-1 do not induce leukaemia in vivo if the immortalised cells were 
derived from progenitors cultured in GM-CSF (Calvo et al., 2001). Since Hoxa9 
and Meis-1 are thought to be key regulators of MLL-ENL mediated immortalisation 
(Zeisig et al., 2004), it was important to determine whether the conditional MLL- 
ENL cell lines that we generated which lack Meis-1 expression are leukaemogenic. 
If these cells could induce leukaemia in vivo, this would provide us with the 
opportunity to analyse whether continued MLL-ENL expression is required to 
maintain leukaemogenesis. Although it is known that MLL-ENL is required to 
maintain the phenotype of the immortalised cells in vitro, it is not known if 
continued expression is required to maintain the leukaemia in vivo. This is an 
important point to address since the immortalised cells generated in vitro may 
acquire secondary mutations following transfer into mice. These secondary 
mutations may be able to substitute for MLL-ENL expression. If this is the case the 
leukaemic cells may no longer be dependent on continued expression of the fusion 
protein and therapies designed to target MLL-ENL expression in humans may not 
be efficacious.
7.1 Transplantation of MLL-ENL immortalised cell lines into NOD/SCID mice 
induces AML.
All of the MLL-ENL immortalised cell lines were transferred into NOD/SCID mice 
in order to assess their leukaemogenic potential. The NOD/SCID strain was used 
since these mice are immunodeficient and are therefore unlikely to reject the donor 
immortalised cells which are from a C57B1/6 background. All of the cell lines, with
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the exception of TRE-ME6, induced leukaemia in recipient mice. Recipients of the 
constitutive cell line (c-MEl) developed AML with a shorter latency (80 ± 9 days, 
n = 5) than recipients of the conditional cell lines (Figure 7.1). Of the conditional 
cell lines, TRE-ME3 induced AML with a slightly shorter latency (118 ± 19 days, n 
= 5) than TRE-ME2 (132 ± 34 days, n = 9). None of the recipients of TRE-ME6 
succumbed to AML within an observation period of over 300 days (Figure 7.1).
The leukaemic mice displayed minimal to extensive leukaemic infiltration of the 
liver and kidney (Figure 7.2). The leukaemic cells were also present in the lymph 
nodes and thymus in some cases. Analysis of the haematopoietic organs of 
leukaemic mice by flow cytometry revealed that all of the leukaemias were derived 
from donor cells. The donor and host cells could be distinguished since the 
haematopoietic cells of the C57B1/6 mice express CD45.2, whereas the 
haematopoietic cells of the NOD/SCID mice express CD45.1. The surface marker 
expression profile and morphology of the bone marrow and spleen from a 
representative c-MEl recipient is shown in Figure 7.3. Both the bone marrow and 
spleen were composed almost exclusively of donor cells which expressed Mac-1, 
Gr-1 and intermediate levels of c-Kit (Figure 7.3 A). This expression profile was 
very similar to that of the original c-MEl cell line prior to transfer (Figure 5.5B). 
Morphological analysis revealed that the majority of the leukaemic cells in the 
spleen were myeloblasts while the bone marrow contained a mixture of myeloblasts 
and more differentiated myeloid cells (Figure 7.3B). The fact that differentiated 
myeloid cells were present in the bone marrow and that these were donor derived 
proves that c-MEl does possess some differentiation capacity in vivo. This data is 
consistent with the leukaemia being classified as a myeloid leukaemia with 
maturation according to the Bethesda mouse leukaemia classification guidelines 
(Kogan et al., 2002).
The conditional MLL-ENL cells could be distinguished from host cells based on 
their expression of EGFP, since tTA expression is linked via an IRES to EGFP. An 
analysis of the spleen and bone marrow of a representative TRE-ME2 recipient is 
shown in Figure 7.4. In this mouse, half of the cells in the bone marrow expressed 
EGFP and were therefore donor derived, whereas the majority of splenocytes (75%) 
were donor derived (Figure 7.4). In contrast to the parental TRE-ME2 cell line
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Figure 7.1 Leukaemogenicity of the MLL-ENL cell lines. 106 TRE-ME2 (red 
diamonds), TRE-ME3(A) (blue diamonds), TRE-ME6 (green diamonds) and c- 
ME1 (black diamonds) immortalised cells were injected intraperitoneally into 
NOD/SCID mice. The mice were sacrificed when they began to show signs of 
illness (section 2.11).
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Figure 7.2 Leukaemic infiltration of the liver and kidney. 106 immortalised 
cells were injected into NOD/SCID mice which were sacrificed when they began 
to show signs of ill health. A) The liver and B) kidney of moribund mice were 
fixed in formalin, sectioned and stained with hematoxylin and eosin. A healthy 
aged matched mouse served as a negative control. Original magnification x 40.
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Figure 7.3 C-M El is leukaemogenic in NOD/SCID mice. The leukaemogenic 
potential of the constitutive cell line was examined by transfer into NOD/SCID 
mice. Moribund mice were sacrificed and the spleen and bone marrow were lysed 
and analysed by A) flow cytometry and B) cytospin analysis followed by MGG 
staining. The plots show the expression of the Mac-1, Gr-1 and c-Kit cell surface 
antigens versus the CD45.2 antigen. CD45.2 is only expressed by donor cells. A 
healthy age-matched mouse served as a negative control.
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Figure 7.4 TRE-ME2 and TRE-ME3(A) are leukaemogenic in NOD/SCID 
mice. The leukaemogenic potential of TRE-ME2 and TRE-ME3(A) were 
examined by transfer into NOD/ SCID mice. Moribund mice were sacrificed and 
the spleen and bone marrow were analysed by flow cytometry. The plots show 
the expression of the Mac-1, Gr-1 and c-Kit cell surface antigens versus EGFP. 
EGFP is only expressed by donor cells. A healthy age-matched control mouse 
served as a negative control.
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which expressed uniformly high levels of Mac-1 (Figure 5.5B), the bone marrow 
and spleen of this TRE-ME2 recipient was composed of two populations of EGFP+ 
Mac-1+ cells, a population which expressed very high levels of Mac-1 and a 
population which expressed lower levels. By gating on the different populations, we 
found that the cells expressing lower levels of Mac-1 expressed c-Kit, while the 
cells expressing high levels of Mac-1 did not (data not shown). This probably 
reflects the different stages of differentiation of the cell line in vivo. Therefore, as 
observed with c-MEl, the TRE-ME2 cells can differentiate in vivo.
The flow cytometric and morphological analysis of the spleen from a representative 
TRE-ME3 recipient is shown in Figure 7.4. Virtually all of the splenocytes 
expressed EGFP and were therefore donor derived. Like the parental TRE-ME3(A) 
cell line (Figure 5.5B), the leukaemic cells expressed very low levels of Mac-1, 
higher levels of Gr-1 and intermediate levels of c-Kit (Figure 7.4).
7.2 Are secondary mutations required for MLL-ENL mediated 
leukaemogenesis?
In order to confirm that the mice had leukaemia, splenocytes were harvested from a 
primary recipient and transferred to a secondary recipient. Only HSCs and 
leukaemic cells have the capacity to home to the bone marrow and engraft a 
secondary recipient. Within 51 days, 3 out of 4 of the secondary TRE-ME3(A) 
recipients had succumbed to AML with a phenotype identical to that of the primary 
leukaemia (data not shown). The fourth mouse did not succumb to AML within an 
observation period of over 150 days. The reasons for this are unclear. The latency 
of AML development in the secondary recipients was generally much shorter than 
that of the primary recipients (Figure 7.5), which suggests that secondary mutations 
are required for MLL-ENL mediated leukaemogenesis. This must be confirmed by 
analysing larger numbers of mice and by performing secondary transfers with 
splenocytes harvested from primary recipients of the other immortalised cell lines.
7.3 Is continued MLL-ENL expression required to maintain AML in vivo? 
Having established that TRE-ME2 and TRE-ME3(A) are leukaemogenic, we 
wanted to examine whether leukaemic mice could be cured by administering dox. 
Since TRE-ME3(A) dies rather than terminally differentiating upon the addition of
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Figure 7.5 Development of leukaemia in prim ary and secondary recipients of 
TRE-ME3(A) immortalised cells. 106 TRE-ME3(A) immortalised cells were 
injected into NOD/SCID mice. Primary recipients (black diamonds) were 
sacrificed when they began to show signs of ill health. 2 x 106 or 107 splenocytes 
from a primary recipient were injected into secondary recipients (blue diamonds) 
which were sacrificed when they began to show signs of illness.
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dox in vitro, we performed preliminary experiments with TRE-ME2. Nine mice 
were injected with the TRE-ME2 cell line. The mice were monitored for leukaemia 
development by analysing the EGFP expression of peripheral blood cells at regular 
intervals post transfer. The mean time-frame from injection to the detection of 
EGFP positive cells in the peripheral blood was 97 ± 10 days (n = 7). Two mice 
died of leukaemia without prior detection of cells in the blood. This may have been 
because the immortalised cells were able to grow as solid masses in the 
intraperitoneal cavity of some of the mice. Therefore, it is likely that the mice died 
as a result of the solid tumour, before the leukaemia was fully established.
Two mice were administered dox as soon as EGFP+ cells were detected in the 
peripheral blood (from here on denoted as day 1). In the following analysis the 
number of EGFP+ cells is expressed as a percentage of the total number of Mac-1+ 
cells. One mouse (ME2 EB) had 0.9% EGFP+ cells and the other (ME2 EL) had 
1.28% EGFP+ cells in the blood on day 1 (Figure 7.6). The mice were injected with 
dox the day after the cells were detected (day 2) and then maintained on dox in the 
drinking water. Within 7 days of dox administration, the percentage of EGFP+ cells 
in the blood of ME2 EL had decreased to 0.71% and by day 24, it had decreased 
further to 0.27% (Figure 7.6). However, by day 38 the percentage of EGFP+ cells 
had increased to 1.35% and the mouse died 19 days later. Although the percentage 
of EGFP+ cells in the peripheral blood of ME2 EB increased initially with dox 
treatment, the percentage decreased with time and by day 24, the percentage of 
EGFP+ cells in the peripheral blood was half of that on day 7. However, by day 38 
the number of EGFP+ cells in the peripheral blood had increased significantly to 
66% and the mouse died 8 days later (Figure 7.6). Although dox did not cure the 
mice, it substantially hindered the progression of the leukaemia since mice which 
received dox survived for a lot longer (51 ± 8 days, n = 2) after the detection of 
EGFP+ cells in the peripheral blood than mice which did not receive dox (24 ± 4 
days, n = 3) (Figure 7.7).
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Figure 7.6 Reversing the leukaemia with dox. 106 TRE-ME2 immortalised cells 
were injected into NOD /SCID mice. Leukaemia development was followed by 
analysing the Mac-1 and EGFP expression of peripheral blood cells at regular 
intervals by flow cytometry. The day when EGFP positive cells were first detected 
in the peripheral blood of each mouse is denoted as day 1. Two mice (ME2 EB 
and ME2 EL) were administered dox on day 2 whereas ME2 DB was not given 
dox. Leukaemia progression was followed by analysing the percentage of Mac-1 
expressing cells that were EGFP positive at regular intervals by flow cytometry. A 
control mouse which did not receive TRE-ME2 cells served as a negative control.
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Figure 7.7 Dox hinders the progression of leukaemia. 106 TRE-ME2 
immortalised cells were injected into NOD/SCID mice. Leukaemia development 
was followed by analysing the EGFP expression of peripheral blood cells at 
regular intervals post transfer by flow cytometry. The day when EGFP+ cells 
were first detected in the peripheral blood is denoted as day 1. Dox was 
administered to two mice on day 2. The graph shows the survival of mice which 
were treated with (red diamonds) or without (black diamonds) dox following the 
detection of EGFP+ cells in the peripheral blood.
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Discussion
All of the MLL-ENL immortalised cell lines, with the exception of TRE-ME6, 
were leukaemogenic in NOD/SCID mice. Recipients of the constitutive cell line (c- 
ME1) developed AML with a latency similar to that previously reported for 
recipients of MLL-ENL immortalised cell lines (Lavau et al., 1997), whereas 
recipients of the conditional cell lines TRE-ME2 and TRE-ME3, developed AML 
with a slightly longer latency. TRE-ME6 did not induce AML over the observed 
time frame of 7 months. This may be because the differentiation impairment 
imposed by MLL-ENL is less severe in TRE-ME6 than the other cell lines. TRE- 
ME6 differentiated more rapidly in response to dox or G-CSF and it was the only 
line able to differentiate in response to M-CSF. TRE-ME6 also had a lower cloning 
efficiency in methylcellulose compared to the other cell lines (data not shown). This 
suggests that the self-renewal capability of TRE-ME6 was not as great as the other 
cell lines. Therefore, it may be necessary to transfer a larger number of cells in 
order to get a level of engraftment similar to that of the other conditional cell lines.
In vitro, c-MEl is composed almost exclusively of myeloblasts, very few 
neutrophils are observed. Similar observations in previous studies of MLL-ENL 
immortalised myeloid cell lines have led to the hypothesis that MLL-ENL causes a 
block in myeloid differentiation. However, MLL-ENL immortalised cells can be 
induced to differentiate in response to G-CSF. Furthermore, the leukaemic cells are 
able to differentiate in vivo, since the bone marrow of a leukaemic mouse, which 
was composed almost exclusively of donor c-MEl cells, consisted of a 
heterogeneous population of myeloblasts, myelocytes and neutrophils. Therefore, 
rather than causing an absolute differentiation block, MLL-ENL may suppress the 
differentiation of myeloid progenitors, which when combined with an enhanced 
proliferation, survival and self-renewal capacity ultimately results in 
leukaemogenesis.
The TRE-ME2 and TRE-ME3 conditional cell lines express Meis-2 rather than 
Meis-1, yet they are still capable of inducing leukaemia in vivo. This suggests that 
Meis-1 is not required for MLL-ENL induced leukaemogenesis. Although it has not 
been shown whether Meis-2 can accelerate Hoxa9 induced leukaemogenesis, it is 
possible that Meis-2 is able to compensate for the absence of Meis-1 expression in
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these cells. However, the latency of leukaemia induced by these cell lines is slightly 
longer than that of the constitutive cell line which expresses Meis-1. Therefore, 
although Meis-2 may be able to compensate for Meis-1, it may not be as efficient as 
Meis-1 at accelerating Hox induced leukaemogenesis.
Preliminary experiments revealed that secondary TRE-ME3(A) recipients 
developed AML with a shorter latency than that of primary recipients. This 
suggests that other genetic events occur which co-operate with MLL-ENL to induce 
AML. This hypothesis is supported by the multi-step model of MLL-AF9 
leukaemogenesis, which is based on the finding that MLL-AF9 knock-in mice 
develop a myeloproliferative disease prior to the onset of AML (Dobson et al., 
1999). The myeloproliferative disease commences during the prenatal phase which 
is followed by an increased self-renewal or survival capacity of myeloid progenitors 
in the post-natal phase and eventual AML development in the adult phase (Johnson 
et al., 2003). The long latency of AML development and the fact that it is preceded 
by a myeloproliferative disease suggests that secondary mutations are required for 
MLL-AF9 mediated leukaemogenesis.
Flt-3 gene mutations are possible candidates for co-operating secondary genetic 
events in MZZ-rearranged leukaemias. In paediatric lymphoid leukaemias, a 
correlation exists between MZZ-translocations and point mutations in the Flt3 gene 
(Taketani et al., 2004). Although internal tandem duplications of the 
juxtamembrane domain of the Flt3 gene (F/ri-ITDs) are frequently found in AML 
patients (Stirewalt and Radich, 2003), an association between F/r3-ITDs and 
duplications or double strand breaks in the MLL gene has been reported (Libura et 
al., 2003). Furthermore, a recent study demonstrated that Flt3-ITD co-operated with 
MLL-ENL to induce leukaemogenesis in mice, since co-expression of MLL-ENL 
and F//3-ITD dramatically shortened the latency of MLL-ENL induced AML from 
92 days to just 17 days (Ono et al., 2005).
Although most cancers are the result of multiple genetic lesions, the inactivation of 
only one genetic lesion can induce tumour regression (Felsher and Bishop, 1999; 
Huettner et al., 2000). MYC transgenic mice, which were generated using the 
tetracycline regulatory system, died of T cell lymphomas or AML in the absence of
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dox (Felsher and Bishop, 1999). Treatment of moribund mice with dox resulted in 
sustained tumour regression as a result of tumour cell differentiation. Similarly, 
BCR-ABL transgenic mice were effectively cured of ALL as a result of BCR-ABL 
inactivation by tetracycline (Huettner et al., 2000). Therefore, in these models, Myc 
and BCR-ABL are required to initiate as well as maintain leukaemogenesis. We 
examined whether continued expression of MLL-ENL was required to maintain 
leukaemogenesis by using dox to turn off MLL-ENL expression in mice that 
showed early signs of leukaemia. Initially dox caused a decrease in the number of 
leukaemic cells in the blood. However, the effect was not sustained and the mice 
eventually died of AML, although with a longer latency than mice which did not 
receive dox. Therefore, dox has a transient effect on decreasing the leukaemic 
burden.
In order to confirm that dox hinders leukaemia progression, the experiment must be 
repeated using larger numbers of mice. Transfer of the cells by intravenous rather 
than intraperitoneal injection may better model the disease since the mice would no 
longer develop tumours in the intraperitoneal cavity. Importantly, dox should be 
administered to recipients of the constitutive cell line in order to assess whether the 
delay in leukaemia progression is specific to the conditional mice. Since dox 
decreases the proliferation rate of the constitutive immortalised cell line in vitro, it 
is possible that the observed delay in disease progression is due to the effect of dox 
on slowing the proliferation of the leukaemic cells. If this is the case we would 
expect to observe a similar delay in disease progression in recipients of the 
constitutive cell line. In order to assess whether the leukaemic cells from the 
conditional mice retain the ability to differentiate upon loss of MLL-ENL 
expression, a cell line will be established from the leukaemic cells and the ability of 
dox to induce differentiation will be examined in vitro.
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Chapter 8 Conclusions
In order to generate a conditional system of MLL-ENL expression in primary 
HPCs, the retroviral delivery of the Tet-Off system to target cells was optimised 
using two reporter constructs. Conditional reporter gene expression was achieved in 
both NIH3T3 cells and HPCs, although a low level of tTA independent reporter 
gene expression was observed. Subsequent experiments revealed that tTS was able 
to prevent tTA independent reporter gene expression and this was regulatable by 
dox. We concluded that MLL-ENL expression may be regulated by tTS if low 
levels of tTA independent MLL-ENL expression are sufficient to immortalise 
HPCs. Conditional MLL-ENL expression was achieved following co-transduction 
of NIH3T3 cells with the conditional MLL-ENL and tTA expression constructs. 
Therefore, experiments were undertaken to generate constitutive and conditional 
MLL-ENL immortalised cell lines derived from HPCs isolated from E l2 foetal 
liver.
The constitutive MLL-ENL expression construct immortalised c-Kit+ Ter-119' and 
Sca-1+ c-Kit+ foetal HPCs under myeloid conditions and immortalised myeloid cell 
lines were established in liquid culture. In contrast, the constitutive MLL-AF4 
expression construct did not immortalise c-Kit+ Ter-119' foetal HPCs under 
myeloid or lymphoid conditions. Although three immortalised cell lines were 
generated from foetal HPCs transduced with the constitutive MLL-ENL expression 
construct, the conditional MLL-ENL and tTA expression constructs did not 
immortalise these progenitors. However, the conditional MLL-ENL and tTA 
expression constructs were able to immortalise unsorted or lin' HPCs isolated from 
the bone marrow of 5-FU treated mice.
HPCs immortalised using the conditional MLL-ENL and tTA expression constructs 
failed to self-renew in methylcellulose upon loss of MLL-ENL expression. 
Furthermore, conditional immortalised myeloid cell lines either terminally 
differentiated into neutrophils and macrophages or died upon loss of MLL-ENL 
expression. Thus we concluded that continued MLL-ENL expression is required to 
maintain the immortalised phenotype in vitro. Three conditional immortalised cell 
lines and one constitutive cell line, which was derived from c-Kit+ bone marrow
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isolated from 5-FU treated mice, were characterised in detail. All of the cell lines 
possessed slightly different immunophenotypes suggesting that the pool of 
progenitors susceptible to transformation by MLL-ENL is heterogeneous. Clones of 
one of the conditional cell lines possessed neutrophil and macrophage 
differentiation potential in response to G-SCF and M-CSF, respectively. Hence, the 
differentiation block imposed by MLL-ENL can occur prior to commitment to the 
granulocyte and monocyte lineages.
Global Hox gene expression profiling revealed that MLL-ENL maintained the 
aberrant expression of multiple Hoxa genes and the Hox co-factor Pbx-3. In 
contrast to previous studies, we found that Meis-1 was not a critical mediator of 
MLL-ENL activity since Meis-1 was not expressed by any of the conditional cell 
lines. Meis-2 was expressed instead of Meis-1 in these cells, yet Meis-2 was not 
regulated by MLL-ENL. Hence, it is possible that MLL-ENL activity is mediated 
by multiple Hoxa proteins which synergise with Pbx-3 and the Meis Hox co-factors 
normally expressed in myeloid progenitors. Consequently, rather than targeting 
individual Hox genes, therapies which target the pathways regulated by multiple 
Hox genes, acting in concert, may be more efficacious.
The constitutive cell line and two out of the three conditional cell lines induced 
leukaemia in vivo. Preliminary experiments revealed that loss of MLL-ENL 
expression in vivo resulted in a transient decrease in the leukaemic burden. 
However, the effect was not sustained and the mice eventually died of AML. 
Secondary transfer experiments suggest that in addition to MLL-ENL, other 
mutations may be required to induce leukaemia in vivo. Further experiments are 
required in order to determine whether these secondary mutations are able to 
substitute for MLL-ENL expression and therefore whether therapies that target 
MLL-ENL expression will be efficacious.
Although the de-regulation of Hoxa gene expression may be central to MLL-ENL 
leukaemogenesis, these genes are de-regulated in the leukaemic cells of many AML 
patients which lack ML!-rearrangements. Therefore, MLL-ENL must confer other 
properties to the leukaemic cells which underlie the poor prognosis of leukaemias 
bearing this fusion protein. Global gene expression profiling revealed that MLL-
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ENL may confer a protection from apoptosis by activating the expression of Pim-2 
and repressing the expression of multiple mediators of apoptosis such as Ddb2, 
Aatk and Bri3bp. Furthermore, MLL-ENL may maintain or activate the expression 
of Aldhl which confers resistance to cytotoxic drugs. The aberrant expression of 
these genes by the leukaemic cells may contribute to the poor prognosis of t(l 1;19) 
leukaemias. Ultimately, these MLL-ENL target genes may offer new possibilities 
for leukaemia therapy.
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Figure A .l M LL-ENL Q-PCR probe and prim er optimisation. A probe and 
primer set was designed which spanned the MLL-ENL breakpoint in order to 
measure MLL-ENL transcript expression by Q-PCR. A) The optimal primer 
concentration and B) the optimal probe concentration were determined by 
amplifying the MLL-ENL break-point sequence from cDNA using various 
concentrations of forward primer (f), reverse primer (r) or probe. The optimum 
primer and probe concentrations were determined by plotting the cycle threshold 
(C,) value versus primer / probe concentration. The optimal primer combination 
was 900f/300r (900 nM forward primer and 300 nM reverse primer). This 
combination produced the lowest CT value and the highest reaction (Rn) value. 
The optimal probe concentration was 150 nM since this was the lowest 
concentration which did not affect the CT value.
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Figure A.2 Standard curve generation for MLL-ENL Q-PCR. The standard 
curve was generated by Q-PCR analysis of serially diluted cDNA (range 3.125 ng 
to 100 ng) prepared from total RNA isolated from TRE-ME2. The x-axis 
represents the cDNA concentration and the y-axis represents the CT value. The 
slope reflects the kinetics of the assay, the y intercept reflects the sensitivity of the 
assay and the correlation co-efficient R2 indicates the reproducibility of the assay 
at high and low cDNA concentrations.
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Figure A.3 Analysis of RNA integrity. The RNA integrity was analysed using 
the Agilent 2100 Bioanalyser according to the manufacturer’s instructions. A) A 
representative electropherogram showing the fluorescence intensity versus 
migration time. The ratio o f the area under the 28S and 18S ribosomal peaks is an 
indication o f the integrity o f the RNA. A high quality RNA sample typically has 
a ratio o f 28S:18S ribosomal peaks o f 2:1. A ratio between 1.5:1 and 2:1 is 
acceptable for Affymetrix analysis. The sample shown has a ratio o f 1.6:1. B) A 
representative densitometry plot for the same sample shown in A.
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Table A.l Genes down-regulated by dox in both the conditional and constitutive cell lines.
Gene P-value
Relative Expression
ProductAverage
RE
TRE-
ME2
TRE-
ME3
TRE-
ME6 c-MEl
3110057012Rik 0.0364 0.35 0.25 0.33 0.48 0.46 Hypothetical protein LOC269423
Selenbpl 0.0469 0.37 0.13 0.50 0.47 0.083 Selenium binding protein 1
2310016C08Rik 0.0218 0.46 0.26 0.72 0.41 0.35 Hypoxia-inducible protein 2
Eglnl 0.0196 0.48 0.30 0.55 0.60 0.32 EGL nine homolog 1 (C.elegans)
C030034I22Rik 0.0339 0.48 0.50 0.36 0.58 0.51 Hypothetical protein LOC77533
Gm446 0.0497 0.50 0.39 0.42 0.69 0.41 Gene model 446
A130078K24Rik 0.0287 0.50 0.35 0.60 0.55 0.30 Unknown EST
Ppprl3b 0.00567 0.50 0.45 0.37 0.68 0.62
Protein phosphatase 1, regulatory (inhibitor) 
subunit 3B
Bnip3 0.0474 0.51 0.26 0.56 0.71 0.38
Bcl2 / adenovirus E lb  19kDa-interacting 
protein 1, NIP3
Mnsl 0.028 0.51 0.56 0.38 0.59 0.41 Meiosis-specific nuclear structural protein 1
F10 0.0471 0.53 0.41 0.55 0.63 0.48 Coagulation factor X
AI314180 0.00966 0.54 0.47 0.57
Angl 0.0412 0.56 0.35 0.45
Ptdsr 0.00611 0.58 0.67 0.53
Tiparp 0.0444 0.59 0.48 0.48
Iraki bp 0.0196 0.59 0.65 0.59
Gpatc4 0.0148 0.59 0.57 0.68
Sap30 0.0474 0.60 0.47 0.53
Zfp259 0.00583 0.60 0.53 0.64
Fndc3a 0.0385 0.60 0.50 0.67
1700022C21Rik 0.0303 0.61 0.53 0.55
2410025L10Rik 0.0325 0.61 0.68 0.53
Frapl 0.0208 0.62 0.85 0.54
2310042L06Rik 0.0297 0.62 0.56 0.57
Btd 0.00293 0.63 0.58 0.57
0.58 0.34 Expressed sequence AI314180
0.89 0.07 Angiogenin, ribonuclease A family, member 1
0.55 0.21 Phosphatidylserine receptor
0.82 0.54
TCDD-inducible poly (ADP- ribose) 
polymerase
0.54 0.71
Interleukin-1 receptor-associated kinase 1 
binding protein 1
0.51 0.40 G patch domain containing 4
0.81 0.52 Sin3 associated polypeptide
0.64 0.35 Zinc finger protein 259
0.64 0.34 Fibronectin type III, domain containing 3a
0.74 0.11 Hypothetical protein LOC76416
0.63 0.34 Hypothetical protein LOC381668
0.48 0.64
FK506 binding protein 12-rapamycin 
associated protein 1
0.74 0.43 Hypothetical protein LOC76457
0.74 0.67 Biotinidase
LOC24442 0.0383 0.63 0.55 0.63
4833428M15Rik 0.0414 0.64 0.60 0.80
Pvr 0.0383 0.65 0.67 0.55
Gas2 0.05 0.66 0.69 0.53
Osgepll 0.0275 0.66 0.71 0.56
Ptpla 0.0254 0.67 0.67 0.72
4632427E13Rik 0.0395 0.67 0.75 0.63
Arid2 0.0213 0.67 0.81 0.67
9130401M01Rik 0.0497 0.67 0.61 0.63
Gtf2e2 0.015 0.68 0.65 0.62
261031 lI19Rik 0.026 0.68 0.68 0.64
Zfp68 0.0461 0.69 0.78 0.61
Cog8 0.0214 0.69 0.65 0.70
Cril 0.00858 0.69 0.70 0.56
0.71 0.65 Similar to hypothetical protein FLJ23749
0.52 0.06 Unclassifiable
0.74 0.16 Poliovirus receptor
0.77 0.60 Growth arrest specific 2
0.71 0.46 O-sialoglycoprotein endopeptidase-like 1
0.63 0.47
Protein tyrosine phosphatase-like (proline 
instead of catalytic arginine), member a
0.64 0.34 Unknown EST
0.53 0.50 AT rich interactive domain 2
0.77 0.61 Hypothetical protein LOC75758
0.78 0.27 General transcription factor II E, polypeptide 2 (p subunit)
0.72 0.74 Hypothetical protein LOC67180
0.69 0.34 Zinc finger protein 68
0.72 0.34 Component of oligomeric golgi complex 8
0.81 0.34 CREBBP / EP300 inhibitory protein 1
Gtf2h5 0.0357 0.69 0.88
D830048P04Rik 0.00166 0.70 0.68
Mtap 0.00197 0.70 0.68
Cdol 0.0195 0.70 0.63
2410019A14Rik 0.0237 0.71 0.78
Smpdl 0.0434 0.72 0.75
1600002K03Rik 0.0365 0.72 0.88
Dirc2 0.0391 0.73 0.72
Pexl2 0.0419 0.73 0.68
Tmem33 0.0476 0.73 0.65
Dhdh 0.0267 0.73 0.80
9030624B09Rik 0.00045 0.73 0.68
Vhlh 0.043 0.74 0.70
Agpat5 0.00735 0.74 0.69
0.64
0.76
0.72
0.74
0.67
0.72
0.69
0.75
0.67
0.71
0.72
0.73
0.84
0.75
0.55 0.70 General transcription factor IIH, 
polypeptide 5
0.66 0.49 Unknown EST
0.71 0.61 Methylthioadenosine phosphorylase
0.74 0.76 Cysteine dioxygenase 1, cytosolic
0.67 0.62 Hypothetical protein LOC69746
0.70 0.53 Sphingomyelin phosphodiesterase 1, acid lysosomal
0.59 0.51 Hypothetical protein LOC69770
0.73 0.4 Disrupted in renal carcinoma 2 (human)
0.84 0.60 Peroxisomal biogenesis factor 12
0.83 0.66 Transmembrane protein 33
0.66 0.79 Dihydrodiol dehydrogenase (dimeric)
0.77 0.61 Hypothetical protein LOC67726
0.69 0.41 Von Hippel-Lindau syndrome homologue
0.79 0.40 Lysophosphatidic acid acyltransferase, epsilon
Txndcl 0.0464 0.74 0.75 0.63
Armc6 0.0151 0.74 0.74 0.68
Lengl 0.0496 0.75 0.69 0.71
Snx5 0.0419 0.75 0.61 0.76
Adck5 0.0179 0.75 0.80 0.64
2610033H07Rik 0.0404 0.75 0.83 0.74
Rrbpl 0.0345 0.76 0.66 0.76
9030624B09Rik 0.00601 0.76 0.66 0.80
4631422C13Rik 0.0167 0.76 0.83 0.64
0610030G03Rik 0.0151 0.76 0.81 0.94
Scd2 0.0106 0.77 0.74 0.77
5830453E1 IRik 0.0197 0.77 0.71 0.85
Ikbkap 0.0482 0.77 0.67 0.77
0.85 0.36 Thioredoxin domain containing 1
0.80 0.60 Armadillo repeat containing 6
0.86 0.23 Leukocyte receptor cluster (LRC) member 1
0.87 0.56 Sorting nexin 5
0.81 0.60 aarF domain containing kinase 5
0.68 0.69 Hypothetical protein LOC75416
0.85 0.37 Ribosome binding protein 1
0.83 0.23 Hypothetical protein LOC67726
0.82 0.67 Hypothetical protein LOC70799
0.53 0.81 Hypothetical protein LOC68385
0.79 0.22 Stearoyl-coenzyme A desaturase 2
0.74 0.40 Hypothetical protein A730008H23
0.86 0.49
Inhibitor of kappa light polypeptide 
enhancer in B cells, kinase complex 
associated protein
Nfxl 0.0406 0.77 0.68 0.90 0.72 0.72 Nuclear transcription factor, X-box binding 1
Ncbp2 0.0479 0.77 0.83 0.71 0.76 0.55 Nuclear cap binding protein subunit 2
Relative Expression is the level of gene expression in the presence of dox relative to that in the absence of dox. Genes in red are over­
expressed in patients with 1 lq23 translocations compared to other leukaemias (Armstrong et al., 2002, Ross et al., 2004, Andersson et al ., 
2005, Kohlmann et al., 2005).
Table A.2 Genes up-regulated by dox in both the conditional and constitutive cell lines.
Gene P-value
Relative Expression
Product
Average
RE
TRE-
ME2
TRE-
ME3
TRE-
ME6 c-MEl
Snail 0.00574 2.07 1.61 2.86 1.75 1.32 Snail 3 homologue (Drosophila)
Rtn3 0.0203 1.99 2.94 1.33 1.69 2.38 Reticulon 3
0610008K04Rik
7.67E-
05 1.91 1.85 2.00 1.89 2.44 Hypothetical protein LOC66039
Wbscrl 0.0292 1.77 2.33 1.67 1.30 1.92 Williams-Beuren syndrome chromosome region 1
Adcy2 0.0407 1.63 1.92 1.82 1.15 3.85 Adenylate cyclase 2
Gpatc2 0.0341 1.52 1.75 1.25 1.56 3.03 G patch domain containing 2
Pscdl 0.0454 1.52 1.67 1.23 1.67 1.67
Pleckstrin homology, Sec7 and coiled-coil 
domains 1
Sfn 0.0408 1.43 1.56 1.45 1.27 1.33 Stratifin
D330012F22Rik 0.0043 1.42 1.28 1.45 1.52 1.25
Hypothetical phosphopantethiene 
attachment site containing protein
Dpi 0.0471 1.41 1.25 1.52 1.45 1.56 Deleted in polyposis 1
Cct4 0.0333 1.40 1.33 1.16 1.72 1.32 Chaperonin subunit 4 (delta)
Rab3d 0.0301 1.35 1.32 1.14 1.59 1.18 RAB3D, member RAS oncogene family
2310007D09Rik 0.0343 1.34 1.59 1.09 1.33 1.49 Hypothetical protein LOC71878
Relative Expression is the level of gene expression in the presence of dox relative to that in the absence of dox.
Table A.3 Affymetrix probe ID of genes down-regulated upon loss of MLL-
ENL expression.
Gene Probe ID Gene Probe ID
A ldhll2 1436119_at Anp32b 144609 l_at
Magi 1 1433983_at Amotll 1455247_at
H igl 1416481 _s_at Ierepo4 1446512_at
Sdccag33 1427233_at 9530078B04Rik 1433289_at
4921530L18Rik 1441720_at Taokl 1456975_at
Hoxa9 1455626_at 2510005D08Rik 1435270_x_at
M tssl 1451496_at Cdc27 1433848_at
5730405012Rik 1432843_at 4933432P15Rik 1435694_at
4833442J19Rik 1457915_at Ap3s2 1436525_at
Senp8 1437307_at Timm8a 1416346_at
A sfla 1459882_at Paipl 1441955_s_at
1700037C18Rik 1430188_at A730091E23Rik 1446519_at
Elp3 1443452_at Mettl2 . 1444716_at
HelB 1419235_s_at A lgl2 1427558_s_at
Pim2 1417216_at Nomol 1451170 s at
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Table A.4 Aflymetrix probe ID of the genes up-regulated upon loss of MLL
ENL expression.
Gene Probe ID Gene Probe ID
Camp 1419691_at 6230416A05Rik 1453732_at
Pglyrp 1449184_at Map4k2 1450244_a_at
Ngp 1418722_at C030046I01Rik 1433932_x_at
CeacamlO 1448573_a_at Bri3bp 144443 9_at
Praml 1444090_at Apg71 1446418_at
1190003K14Rik 1424509_at Fln29 1428346_at
Ddb2 1425706_a_at Actn4 144425 8_at
Prkd2 1434333_a_at Aatk 1416936_at
Ceacaml 1422123_s_at A630020E03Rik 1440196_at
A130086G1 IRik 1442805_at Inpp5f 1445884_at
Hook2 1419350_at Ypel5 1433593_at
Wdr37 1454823_at Atrx 1420947_at
Cnn2 145098 l_at Gygl 1459522_s_at
Cybasc3 1454895_at D19Wsul2e 1433702_at
Mtl 1451612_at Slc25a30 1420836_at
Arhgapl9 143491 l_s_at Crlf3 1460338_a_at
1190002H09Rik 1446486_at Sri 1450878_at
Nfatcl 1428479_at
224
Table A.5 Affymetrix probe ID of genes down-regulated by dox in both the
conditional and constitutive cell lines.
Gene Probe ID Gene Probe ID
3110057012Rik 1452477_at Gtf2e2 1448884_at
Selenbpl 1450699_at 261031 lI19Rik 1444289_at
2310016C08Rik 1421031 _a_at Zfp68 1417549_at
Eglnl 1423785_at Cog8 1451052_at
C030034I22Rik 1435909_at Cril 1448406_at
Gm446 1458718_at Gtf2h5 145295 5_at
A130078K24Rik 1444482_at D830048P04Rik 1442124_at
Ppprl3b 1436590_at Mtap 1424426_at
Bnip3 1422470_at Cdol 1448842_at
M nsl 1419402_at 2410019A14Rik 1454214_a_at
F10 1418993_s_at Smpdl 1447874_x_at
AI314180 1456255_at 1600002K03Rik 142909 l_at
Angl 1438936_s_at Dirc2 1454654_at
Ptdsr 1454109_a_at Pexl2 1416259_at
Tiparp 1452160_at Tmem33 1436028_at
Iraki bp 1431771_a_at Dhdh 1453487_at
Gpatc4 1449390_at 9030624B09Rik 1424253_at
Sap30 1417719_at Vhlh 1434708_at
Zfp259 1424465_at Agpat5 1453257_at
Fndc3a 1443863_at Txndcl 1437143_a_at
1700022C21Rik 1424999_at Armc6 1460397_at
225
2410025L10Rik 1428403_at Lengl 1425280_at
Frapl 1459625_at Snx5 1448791 at
2310042L06Rik 142826 l_at Adck5 1436753_at
Btd 1417987_at 2610033H07Rik 1423 991 at
LOC24442 1455665_at Rrbpl 1452767_at
4833428M15Rik 1431471 at 9030624B09Rik 1451283_at
Pvr 1450295_s_at 4631422C13Rik 144008 l_at
Gas2 1450112_a_at 0610030G03Rik 1452132_at
Osgepll 1435127_a_at Scd2 1415824 at
P tp la 1457434_s_at 5830453E1 IRik 1433685_a_at
4632427E13Rik 142933l_at Ikbkap 1451254_at
Arid2 1454990_at N fxl 1428248_at
9130401M01Rik 1452215_at Ncbp2 1423045_at
226
Table A.6 Affymetrix probe ID of genes up-regulated by dox in both the
conditional and constitutive cell lines.
Gene Probe ID
Snail 1456796_at
Rtn3 1443220_at
0610008K04Rik 1457717_at
W bscrl 1436637_at
Adcy2 1455462_at
Gpatc2 1457443_at
Pscdl 1418183_a_at
Sfn 1433748_at
D330012F22Rik 1444106_at
Dpi 1442128_at
Cct4 1430034_at
Rab3d 1418891_a_at
2310007D09Rik 1452924_at
227
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